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Abstract 
Lung transplantation has become a viable therapeutic option for patients with end-stage 
lung disease, however, despite improvements in surgical techniques and post-operative 
management long term survival is poor when compared to those of other solid organ 
transplants. The long term success is limited by the onset of obliterative bronchiolitis 
(08) and its clinical correlate bronchiolitis obliterans syndrome (80S). Obliterative 
bronchiolitis is a chronic pathology involving inflammation and airway fibrosis causing 
allograft dysfunction. It is thought to occur as a response to both immunological and 
non-immunological mechanisms, and there is increasing evidence to suggest that 
gastro-oesophageal reflux with subsequent aspiration is a contributing factor. 
lhe aims of this project were to investigate whether gastric aspiration is occurring in 
lung transplant recipients and whether it can predispose a patient to the development of 
chronic rejection (08/80S). This was investigated using the gastric protease pepsin as 
a biomarker for gastric aspiration in the bronchoalveolar lavage (8AL) of lung transplant 
recipients. In addition, to further understand the link between aspiration and the 
development of OB/BOS the effects of pepsin on mucus and cytokine production from 
primary bronchial epithelial cells from lung transplant patients and goblet cells were 
investigated. 
From cross-sectional analyses pepsin levels were found to be elevated in lung 
transplant recipients compared to normal and disease controls, with the highest levels 
been found in the acute rejection (grade ~A2) group (normal: median, 1.1, range 0-
2.3ng/ml vs. all transplant: median 8.3, range 0-51.7ng/ml, P =0.02). Further analysis 
involving a longitudinal cohort of patients also confirmed that pepsin was present in the 
BAL of lung transplant recipients. A cut off value for a 'high' pepsin level was 
Prospectively determined using a separate and 'clinically well' stable transplant control 
group (75th percentile pepsin level, 10.4ng/ml). These subjects were documented to be 
free from rejection, infection or any clinical problems commonly associated with 
transplantation. Patients with early elevated levels of 8AL pepsin (Le. above 10.4ng/ml 
ii 
at 3 months post-transplant) were estimated to develop BOS at 3.0 times the rate of 
those with low early BAL pepsin. This is the first longitudinal study of BAL pepsin in lung 
transplant recipients which shows a trend for decreased survival in patients with early 
elevated BAL pepsin levels (60% BOS free in those with high early BAL pepsin vs. 80% 
BOS free in those with low early BAL pepsin at 3 years post-transplant). This shows a 
need for further investigations with increased patient numbers to reach statistical 
significance and confirm these results. 
The effect of pepsin and gastric juice on bronchial epithelial and goblet cell cultures was 
also investigated. The viability of the cells was not affected with the addition of pepsin, 
however the addition of whole gastric juice did cause a significant reduction in epithelial 
cell viability. In addition, mucin production from goblet cells was significantly increased 
at 72h on addition of 50l-lg/ml pepsin at pH 7.4 (median values pH 7.4; 163.4l-1g/ml and 
pH 7.4 & pepsin; 448.9I-1g/ml, P=0.038) and at pH 7.0 (median values pH 7.0; 55.3I-1g/ml 
and pH 7.0 & pepsin; 327.2I-1g/ml, P=0.016). Previous investigations from our group 
have shown that interleukin-8 (IL-8) can stimulate the production of mucin from goblet 
cells in vitro, therefore media from epithelial and goblet cells stimulated with pepsin was 
measured for IL-8, however there was no significant increase in production from either 
cell type. This suggests that the increase in mucin production in cells stimulated with 
pepsin is not mediated through an IL-8 pathway, therefore other mechanisms should be 
investigated. 
This thesis supports the hypothesis that gastric aspiration may be an important injury in 
lung transplantation and that pepsin is a potentially useful biomarker that may be 
associated with chronic allograft damage. 
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Chapter 1 
Introduction 
1.1 Lung transplantation 
1.1.1 History of and indications for lung transplantation 
Lung transplantation has become a viable therapeutic option for a variety of end 
stage lung diseases, and since the first successful isolated unilateral lung 
transplant performed in 1983 by the Toronto Group (Toronto Lung Transplant 
Group 1986), the International Society for Heart and Lung Transplantation 
(ISHL T) has reported data on approximately 3200 heart-lung transplants and 
over 23000 lung transplants. The number of transplants performed each year 
peaked in 2005 with 2169 (Trulock et al. 2007). The number of single lung 
transplants has remained fairly constant since 1994; however, the number of 
bilateral transplants has been increasing each year, and exceeded the number of 
single transplants for the first time in 2002 (Trulock et al. 2005). This move 
towards bilateral transplants is likely to be due to better survival statistics when 
compared to unilateral transplantations for certain pre-transplant indications 
(Meyers et al. 1999; Hadjiliadis et al. 2002; Trulock et al. 2005). 
The majority of lung transplants are carried out for the following conditions; 
chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis 
(IPF), cystic fibrosis (CF) and o1-anti-trypsin deficiency emphysema. Figures 1.1 
1 
and 1.2 show the distribution of pre-transplant indications for single and bilateral 
transplants for the period of January 1996 to June 2006. 
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Figure 1.1. Main indications for single lung transplants over the period of 
January 1996 to June 2006. Alpha-1: anti-trypsin deficiency emphysema (8%), 
COPD: chronic obstructive pulmonary disease (52%), CF cystic fibrosis (2%), 
IPF: idiopathic pulmonary fibrosis (26%), PPH: primary pulmonary hypertension 
(1%) and Re-TX: re-transplantation (2%) *Others include: Sarcoidosis, 
Bronchiectasis, Congenital Heart Disease, Iymphangioleiomyomatosis and OB 
(non-ReTx). This figure has been modified from Trulock et al 2007. 
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Figure 1.2. Main indications for bilateral lung transplants over the period of 
January 1996 to June 2006. Alpha-1: anti-trypsin deficiency emphysema (9%), 
capo: chronic obstructive pulmonary disease (24%), CF: cystic fibrosis (29%), 
IPF: idiopathic pulmonary fibrosis (13%), PPH: primary pulmonary hypertension 
(6%) and Re-TX: re-transplantation (2%). *Others include: Sarcoidosis, 
Bronchiectasis, Congenital Heart Disease, Iymphangioleiomyomatosis and 08 
(non-ReTx) This figure has been modified from Trulock et a12007. 
4 
Experience gained over the last two decades shows that the 1 year survival rate 
has increased over this time period and figure 1.3 illustrates the survival rates for 
three different eras (1988-94, 1995-99 and 2000-06). The most recent era (2000-
06) has the best 1 year survival rate at approximately 80%, followed by 74% for 
1995-99 and finally 70% for 1988-94 (Trulock et al. 2007). This difference 
indicates improvements in surgical techniques, organ preservation and post 
operative management (Meyers et al. 1999; Moffatt et al. 2005), however, at 
around 5 years the difference in survival rate between the three eras becomes 
less marked, indicating that more research is required to further improve long 
term outcomes. 
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Figure 1.3 Survival rates by era for adult lung transplantations performed 
between January 1988 and June 2006. This figure has been modified from 
Trulock et al 2007. 
6 
1. 1.2 Acute and chronic rejection in lung transplantation 
Long term survival rates for lung transplant recipients are poor when compared 
to those of other solid organs. One of the major limitations to long term survival in 
lung transplantation is the onset of obliterative bronchiolitis (08). 08 is a chronic 
disease process involving the fibrosis of and cellular deposition in airways 
causing allograft dysfunction. The histological diagnosis of 08 requires tissue 
obtained from either transbronchial biopsies (T88) or from open lung biopsy and 
is graded according to internationally accepted criteria that was instituted by the 
Lung Rejection Study Group in 1990, and was revised in 1995 (Yousem et al. 
1990; Yousem et al. 1996). In this revised criteria as well as grading 08 it was 
put forward that the relative activity of the inflammatory infiltrate should be noted, 
and would be graded as either, a-Active or b-Inactive. The following definitions 
are taken from the revised criteria from Yousem et al (Yousem et al. 1996): 
Active: In addition to the fibrosis, there are intra-bronchiolar and/or peri-
bronchiolar submucosal and peri-bronchiolar mononuclear cell infiltrates usually 
associated with ongoing epithelial damage. 
Inactive: Dense fibrous scarring without cellular infiltrates; this represents 
old cicatricial change in the small airways with a lack of significant submucosal 
and peri-bronchiolar inflammatory infiltrates. 
Obliterative bronchiolitis is thought to represent an overall response to epithelial 
injury that results from multiple insults to the graft. The functional changes are 
thought to be due to submucosal scarring, which can lead to total obliteration of 
the airway (figure 1.4). 
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Normal small airway Remodelled airway 
Figure 1.4: Transbronchial biopsies of a normal and a remodelled airway 
showing complete obliteration. These biopsies were taken and processed at the 
Freeman Hospital, Newcastle, UK. 
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Histological diagnosis is, however, invasive and not always sensitive enough 
which may lead to under-diagnosis. This lack of sensitivity can be caused by 
sampling error, the inconsistent pattern of the disorder, or any other pathologies 
that might be present at the time of sampling. As 08 is difficult to define 
histologica"y a committee sponsored by the International Society for Heart and 
Lung Transplantation (ISHL T) proposed a clinical description of 08 in 1993, 
termed bronchiolitis obliterans syndrome (80S) (Cooper et al. 1993). 80S 
represents the functional manifestation of chronic rejection in lung allograft 
patients and is defined by a persistent decline in lung function measured by 
forced expiratory volume in 1 second (FEV1). A baseline FEV1 is measured (an 
average of the patient's two best post-transplant readings taken 3-6 weeks apart) 
and from this the status of BOS can be determined (table 1.1). 
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Status FEV1 Values (% of Post-transplant 
Baseline) 
BOS-O >80 
BOS-1 (mild) 66-80 
BOS-2 (moderate) 51-65 
BOS-3 (severe) S50 
Table 1.1. BOS classification using FEV1 values (Cooper et al. 1993). 
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Although this classification system has gained universal acceptance some 
limitations have been noted. The original system defines BOS as a 20% 
reduction in FEV 1, however, this may miss early and small but potentially 
important changes in lung function, and therefore in the updated diagnostic 
criteria an extra potential BOS stage (BOS O-p) was added to the system. This 
status is given with a decrease of 10-19% in baseline FEV1 (Estenne et al. 2002). 
Bronchiolitis obliterans syndrome is thought to be the functional manifestation of 
the pathophysiological changes that occur in OB. It is the most common chronic 
complication affecting the allograft itself. Figure 1.5 shows freedom from BOS in 
adult lung allograft recipients for follow-up between 1994 and 2006 taken from 
the international registry (Trulock et al. 2007). At 5 years post-transplant almost 
50% of recipients have developed BOS. 
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Figure 1.5 Freedom from bronchiolitis obliterans syndrome (80S) in adult lung 
allograft recipients for follow-up between 1994 and 2006. This figure has been 
taken from Trulock et al 2007. 
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The fibroblastic scarring process in OB involves the respiratory bronchioles. 
Mononuclear cell infiltration of all layers of the bronchiolar wall in the active 
phase of OB can lead to the smooth muscle layers being destroyed by extension 
of the fibrous tissue into the peri-bronchiolar interstitium. As well as fibrosis of the 
airways there can be epithelial damage and even loss with lymphocytic 
infiltration. Extensive fibrosis connected with destruction of the smooth muscle 
may lead to extrinsic compression of the lumen in a constrictive form of 
bronchiolitis obliterans (Stewart 1994). 
The origin of the fibroblasts responsible for this pathology is controversial, but 
these cells may originate from a variety of sources, including, in situ proliferation 
of resident fibroblasts or recruitment of circulating monocytes (Stewart 2004). 
There is also evidence to suggest that epithelial to mesenchymal transition 
(EMT) may be another source in this fibrotic response (Kalluri and Neilson 2003). 
This process involves epithelial cells becoming fibroblasts and can be described 
as a loss of epithelial markers and a gain of fibroblastic characteristics. An early 
marker of EMT is the expression of the human homologue of the fibroblast 
specific protein 1, S100A4. In addition, matrix-metallo proteases (MMP) 7,2 and 
9 are also associated with EMT and collagen type IV, a major component of the 
reticular basement membrane of airway epithelia, is a common substrate for 
these enzymes. Disruption of the reticular membrane by MMPs can cause 
damage, inflammation and further EMT, as epithelial cells rely on contact with the 
basement membrane to maintain their phenotype (Kalluri and Neilson 2003). 
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Ward et al have investigated the occurrence of EMT in lung transplantation using 
biopsies and primary bronchial epithelial cell cultures taken from lung transplant 
recipients. The group found epithelial expression of S100A4 in large airway 
biopsies and primary cultures, and also found that in the biopsies S 1 00A4 
expression was accompanied by staining for MMP-7, supporting the role of EMT 
in lung transplantation. In addition, the primary epithelial cells treated with TGF-~ 
(a prototypical driver of EMT) demonstrated increased MMP dependant invasion 
of collagen coated filters (Ward et al. 2005). 
Several risk factors for post-transplant OBIBOS have been identified from studies 
in individual centres, with one of the most important being acute rejection. A 
grading system for acute rejection was also included in the 1990 and revised 
1995 criteria from the Lung Rejection Study Group (Yousem et al. 1990; Yousem 
et al. 1996). It states that there are 5 grades (0-4) of acute rejection, summarised 
in table 1.2. 
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Grade Severity of Rejection 
AO No acute rejection; no mononuclear infiltration, haemorrhage or 
necrosis. 
A1 Minimal acute rejection; scattered, infrequent perivascular 
mononuclear infiltrates not obvious at low magnification (40 X). Blood 
vessels are cuffed by small, round and transformed lymphocytes. 
A2 Mild acute rejection; perivascular mononuclear infiltrates surrounding 
venuoles and arterioles are recognisable at low magnification. 
Presence of subendothelial mononuclear infiltrates, eosinophils and 
coexistent airway inflammation. 
A3 Moderate acute rejection; readily recognisable venuole and arteriole 
cuffing by dense perivascular mononuclear cell infiltrates. Eosinophils 
and occasional neutrophils are also common. By definition, there is 
extension of the inflammatory cell infiltrate including alveolar 
macrophages into perivascular and peri-bronchiolar alveolar septae 
and air spaces. 
A4 Severe acute rejection; diffuse perivascular, interstitial, and air space 
infiltrates of mononuclear cells and prominent alveolar pneumocyte 
damage. Grade A4 can be distinguished from post-transplant acute 
lung injury by the presence of perivascular and interstitial 
mononuclear cells, as they are not present in peri-operative lung 
injury. 
Table 1.2 A summary of the acute rejection grading system defined by the Lung 
Rejection Study Group (Yousem et al. 1990; Yousem et al. 1996). 
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In addition to these definitions, airway inflammation also has a grading system. 
The report states that the airway inflammation (lymphocytic 
bronchitis/bronchiolitis) should be listed as a 8 category and have 5 grades each 
being defined histologically (0-4, 4 being most severe) and also a 8X category, 
which represents an un-gradable biopsy, due to sampling errors, infection or 
other problems that may have occurred at the time of sampling. 
1. 1.3 Risk factors for lung transplant rejection 
In a review by Scott et al identifying risk factors and therapeutic strategies for 
80S, 13 of 15 centres studied reported a significant association with acute 
rejection (Scott et al. 2005). In the two centres that did not show a significant 
association, one involved only a small number of cases of 80S, and the other 
involved surveillance biopsies only, which may not be sensitive enough to pick up 
an association (Norgaard et al. 1998; Swanson et al. 2000). A group from the 
Papworth Hospital also observed that the number of acute rejection episodes 
occurring in the first six months post-transplantation had a significant effect on 
subsequent 80S, with those who experienced three or more episodes being 
more at risk than those only experiencing one or two (Sharples et al. 1996). 
These data show that acute rejection is the most common and consistent risk 
factor for 08/80S. 
Other immunological risk factors include lymphocytic bronchitis/bronchiolitis (Le. 
airway inflammation) and human leukocyte antigen (HLA) mismatching. Hussain 
16 
et al performed a retrospective study of lung transplant biopsies from patients 
surviving at least 90 days to investigate whether lymphocytic 
bronchitis/bronchiolitis (LBB), independent of perivascular rejection, influenced 
the development of OB/BOS (Husain et al. 1999). They showed that at 180 and 
365 days the B scores (defining airway inflammation/LBB) in BOS patients were 
more than twice that of patients with no BOS, indicating a possible association 
between LBB and BOS. Lymphocytic bronchiolitis is thought to be a specific and 
specialised manifestation of acute rejection. 
The association between OBIBOS and HLA mismatching is not as clear as the 
association between acute rejection and OB. A large multi-centre study of the 
effect of HLA mismatching on the outcome of lung transplantation did not show a 
significant difference in total HLA mismatches in patients with OB compared to 
those without (Quantz et al. 2000). However some other studies from single 
centres have reported a significant association between HLA mismatching and 
OB (Kroshus et al. 1997; Sundaresan et al. 1998), making it difficult to determine 
whether or not it is an important risk factor. 
Other non-immunological risk factors have been put forward, including 
cytomegalovirus infections, other respiratory infections (including respiratory 
syncytial virus (RSV), parainfluenza virus (PIV) and influenza A, donor 
characteristics (for example age, or whether the donor suffered traumatic brain 
injury), prolonged graft ischemia time and type of transplantation (Le. single or 
bilateral) (Hohfield et al. 1996; Boehler et al. 1998; Husain et al. 1999; Bowdish 
et al. 2004; Khalifah et al. 2004). 
17 
Gastro-oesophageal reflux (GOR) has also been implicated as a non-
immunological factor leading to lung allograft dysfunction (Palmer et al. 2000; 
Davis et al. 2003; Cantu et al. 2004). 
1.2 Gastro-oesophageal reflux 
Gastro-oesophageal reflux (GOR) is defined as the retrograde movement of 
gastric contents into the oesophagus and can cause symptoms such as 
heartburn. Chronic reflux (gastro-oesophageal reflux disease, GORD) can also 
cause metaplasia of the lower oesophagus, in which the squamous epithelium is 
replaced with a columnar epithelium (Barrett's oesophagus). Barrett's 
oesophagus has been associated with an increased risk of developing 
oesophageal carcinoma (Badreddine and Wang 2008). 
In addition, when the reflux of gastric content advances beyond the oesophagus 
to the larynx and pharynx (laryngopharyngeal reflux, LPR) further symptoms and 
pathologies can develop, some resulting from the aspiration of gastric contents 
into the lungs (Farrokhi and Vaezi 2007; Galmiche et al. 2008). 
GORD is considered a common problem. Using a questionnaire Locke et al 
investigated the prevalence of reflux in a population based study in the USA. 
They found, after adjusting for age and sex that approximately 40% suffered from 
at least one episode of heartburn, one of the key symptoms of GORD, over the 
year of the study. Furthermore, approximately 18% suffered from heartburn on a 
regular basis (at least one episode a week) (Locke et al. 1997). Sandler et al also 
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report that GORD is the fourth most prevalent gastrointestinal disease in the USA 
with approximately 19 million cases per year, and it is also the most expensive. 
The total annual direct cost in the USA was 9.3 billion dollars for 1998 (Sandler et 
al. 2002). 
1.2. 1 Diagnosis of gastro-oesophageal reflux 
There are several methods for diagnosing GORD, as outlined in the updated 
guidelines from DeVault et al. Firstly, in patients who present with un-
complicated symptoms such as heartburn that is relieved by antacids the 
guidelines state that it is appropriate to offer empirical therapy and also suggest 
that it is reasonable to assume a diagnosis of GORD in patients who respond to 
such therapy (DeVault and Castell 2005). 
For patients who do not respond to empirical therapy, or who are suspected of 
having more complicated disease (for example Barrett's oesophagus) endoscopy 
can be performed. Endoscopy allows visualisation of the oesophageal mucosa 
and allows biopsies to be taken. However, while endoscopy may confirm 
mucosal injury suggestive of GORD it does not provide evidence that the 
symptoms are actually related to reflux. In addition, many patients may suffer 
from symptoms of GORD but lack oesophagitis (inflammation of the 
oesophagus), therefore would be less likely to have endoscopic findings. 
19 
In patients who have persistent symptoms without evidence of mucosal damage 
ambulatory pH testing can be performed. This is the current 'gold standard' for 
the measurement of gastro-oesophageal reflux. Ambulatory pH monitoring allows 
the role of acid reflux to be studied in patients without any endoscopic findings 
over an extended period of time. Catheter based pH monitoring systems require 
a flexible catheter and a data logger to record the pH measurements. Typically, 
the catheter is inserted through the nose and the pH sensor is placed in the distal 
oesophagus, approximately 5cm above the lower oesophageal sphincter (LOS). 
Additionally, a second sensor can be included between 15 and 20cm above the 
LOS (figure 1.6,) (Tutu ian and Castell 2006). Normally ambulatory pH testing is 
performed over 24h, however there is data to suggest that 16h studies can 
provide accurate information and also improve patient tolerance (Dobhan and 
Castell 1992). 
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Figure 1.6 Ambulatory pH catheter placement, showing duel channel proximal 
and distal pH monitoring. LOS-lower oesophageal sphincter. This figure was 
modified from Tutuian and Castell 2006. 
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A positive result is one in which there is a sudden drop in intra-oesophageal pH 
to below pH 4.0. Once reflux has been established the number of and duration of 
episodes can help to quantify GOR. 
Although ambulatory pH monitoring is considered the gold standard and is used 
by many clinicians there are certain limitations to this method. pH monitoring only 
identifies reflux events with a pH of 4.0 or below, therefore providing limited 
information on non-acidic reflux. As some patients are on acid suppression 
th~rapy but still have symptoms of GOR non-acid reflux may be important in 
some cases and should therefore be monitored. 
This problem can be overcome through the use of combined multichannel 
intraluminal impedance and pH (Mil-pH) monitoring. Impedance is a measure of 
the total opposition to current flow between adjacent electrodes. Pairs of 
electrodes are placed on a catheter inside the oesophagus and when liquid is 
present in-between two electrodes there is a rapid drop in impedance, as the 
ionic content of the liquid improves the electrical conductivity between the 
electrodes. Once the liquid has passed away from the electrodes the impedance 
will return to baseline. The presence of gas in the oesophagus is recognised by 
an increase in impedance as there are no electrical charges to close the circuit 
when the two electrodes are suspended in a gas. 
With multichannel impedance (a series of electrodes placed along the catheter, 
(figure 1.7), the direction of movement can be determined; therefore swallowing 
(movement from proximal to distal) can be distinguished from reflux events (distal 
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to proximal movement). Combining multichannel impedance with conventional 
pH monitoring can provide a more comprehensive picture of what is happening in 
terms of reflux, for example the physical properties (Le. whether the refluxate is a 
liquid or a gas), the chemical properties (Le. acid or non-acid) and the direction of 
movement can be determined. 
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Figure 1.7 Combined multichannel intraluminal impedance and pH catheter. 
LOS-lower oesophageal sphincter. This figure was modified from Tutuian and 
Castell 2006. 
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1.2.2 Composition of gastric juice 
Gastric juice is a fluid secreted by the gastric mucosa and the cells responsible 
for the secretions are arranged in structures known as gastric pits (figure 1.8). 
Pits are made up of several gastric glands and are distributed throughout the 
mucosa. 
Gastric juice contains two major aggressors; hydrochloric acid and a group of 
proteolytic enzymes, pepsins. Hydrochloric acid is secreted by parietal cells 
located in the gastric pits and the pH of gastric juice is normally between 1 and 3. 
Gastric acid secretion can be stimulated by a variety of stimuli during both the 
cephalic and gastric phases of digestion. During the cephalic (head) phase the 
thought, taste, smell or sight of food, or swallowing can stimulate the release of 
acid through neural control, in which the vagus nerve stimulates acid secretion 
via muscarinic receptors and can also stimulate the release of gastrin (a 
hormone that increases gastric acid release) from G cells located in the antrum 
of the stomach. 
During the gastric phase, like the cephalic phase, acid secretion can be 
stimulated by a wide range of stimuli, including distension of the stomach and 
also the presence of chemical constituents of food. This again causes an 
increase in gastrin levels which in turn causes histamine release from endocrine 
cells in the fundus. Histamine has a powerful effect on acid secretion as it binds 
to histamine-2 (H2) receptors on parietal cells and stimulates them to produce 
acid. Acid production requires hydrogen ions that are secreted through a proton 
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pump (H+K+ -ATPase) that is present on the membrane of an active parietal cell 
(also called the secretory canaliculus). 
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Figure 1.8 Structure of the gastric pits located in the mucosa of the corpus and 
fundus of the stomach. 
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In addition to hydrochloric acid gastric juice also contains proteolytic enzymes, or 
pepsins. The name pepsin was first described by Schwann in 1836 (Schwann 
1836) and since then pepsin, or pepsin-like enzymes have been isolated from 
many species. Pepsins are endopeptidases that belong to the aspartate 
proteinase family and they have an active site consisting of a deep cleft 
containing two aspartic acid residues within hydrogen bonding distance of each 
other (Andreeva et al. 1977). They have a broad specificity; however they prefer 
peptide bonds between aromatic amino acids, particularly phenylalanine and 
tyrosine (Powers et al. 1977). 
Pepsins are secreted in a precursor form, pepsinogen, by chief cells. Under 
acidic conditions pepsinogen is rapidly converted to pepsin and the reaction can 
be autocatalytic. Pepsins are irreversibly denatured under alkali conditions, whilst 
pepsinogens can be resistant to denaturation up to pH 10 (Samloff 1971). 
Eight zones of proteolytic activity were identified by Etherington and Taylor in 
human gastric juice by agar gel electrophoresis (pepsins 1, 2, 3, 3a, 4, 5, 6 and 
7) (Etherington and Taylor 1969). Pepsin 3 is the most abundant of the pepsins 
found in gastric juice followed by pepsin 5. Pepsins 1-4 correspond to pepsin A 
and pepsins 5 and 6 to pepsin C (also known as gastricsin). Pepsin 7 
corresponds to a slow moving protease (SMP) described by Samloff and relates 
to pepsin B (Samloff 1971). 
The different pepsins vary in their pH optima and relative proteolytic activity 
depending on substrate type, pH, temperature and solute and substrate 
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concentration. They are active at acidic pH with optimal activity at approximately 
pH 2.0 (Foltman 1981). 
Two distinct groups of pepsinogens have been isolated, groups I and \I and 
according to Samloff et al they give rise to seven pepsinogens (PG1-7) (Samloff 
1971). Group I pepsinogens (PG1-5) produce pepsin A on activation and group \I 
(PG6 & 7) produce pepsin C. 
The conversion of pepsinogen to pepsin has been described in detail for porcine 
pepsinogen (James and Sielecki 1986). When activated by a decrease in pH to 5 
or below pepsinogen loses two peptides which make up the pro-enzyme 
segment of 44 amino acids found at the N-terminal of the protein. At a pH above 
5 electrostatic interactions between amino acids on the pro-enzyme segment and 
carboxyl groups on the enzyme stabilise the conformational shape of the protein. 
When the pH drops below 5 the carboxyl groups become protonated and the 
electrostatic interactions are broken, causing a conformational change which 
results in the hydrolysis of the peptide bond between leucine and isoleucine at 
positions 16 and 17, which takes place at the active site of the enzyme. This 
results in a pro-pepsin form and is further converted into active pepsin by other 
pro-pepsin or active pepsin molecules cleaving the peptide bond between leucine 
and isoleucine at positions 44 and 45 (figure 1.9) (Perlmann 1963; Dykes and 
Kay 1976). 
It is also possible for the gastric juice to contain bile acids that have been 
refluxed back into the stomach from the duodenum. Kauer et al performed a 
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study in which they assessed the concentration of bile aCids in the gastric 
refluxate of GORD patients and found that 86% showed at least trace amounts of 
bile during one or more collection of the gastric reflux ate (Kauer et al. 1997) 
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Figure 1.9. Pepsinogen activation. A-At pH levels above 5 electrostatic interactions between positively and negatively 
charged amino acids hold a cleft over the active site. B-At pH levels below 5 the negatively charged amino acids become 
protonated and lose their charge, breaking the interactions. This causes the cieft to fall into the active site of the enzyme, 
allowing part of the cleft to be cleaved (between amino acids 16 and 17). C- The active site is then partially freed, allowing 
more of the cieft (amino acids 17-44) to be cleaved off by either the enzyme itself or by other active pepsin molecules. 0-
This results in the active form of the enzyme. Model based on porcine pepsin (Perlmann 1963; Dykes and Kay 1976; 
James and Sielecki 1986). 
1.2.3 Current treatments for gastro-oesophageal reflux disease 
There are a variety of treatments available for patients with GORD. In patients 
with milder forms a lifestyle modification may be sufficient to reduce symptoms, 
for example, decreased fat intake and stopping smoking have been shown to 
reduce reflux (Becker et al. 1989; Waring et al. 1989). In addition, patients with 
milder GORD may choose to treat the problem themselves with antacids, anti-
refluxants (e.g. alginates) or over-the-counter acid suppressants (e.g. histamine 
2 receptor antagonists). 
Defects in oesophageal and gastric motility, including lower oesophageal 
incompetence and delayed gastric emptying play a substantial role in the 
pathogenesis of GORD and may therefore lead to more severe symptoms 
requiring additional treatment. The use of promotility agents or those which 
decrease lower oesophageal sphincter (LOS) relaxations may therefore be useful 
in selective patients. Dopamine receptor antagonists such as metoclopramide 
and domperidone have been used in the treatment of GORD on the basis that 
dopamine stimulates the sympathetic nervous system and acts to reduce LOS 
and gastric tone and inhibit antro-duodenal coordination (Tonini 1996), however 
there are a number of side effects associated with these types of drugs, 
particularly metoclopramide, including depression, drowsiness and involuntary 
diskinetic movements (Ganzini et al. 1993). 
Cisapride is a serotonin (5-HT 4) receptor agonist that has been shown to relieve 
symptoms of GORD by enhancing LOS tone, increasing oesophageal peristalsis 
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and also promoting gastric emptying (Tonini 1996). However as with the 
dopamine receptor antagonists there are side effects. In the case of cisapride the 
side effects are severe and can include fatal cardiac dysrhythmias which have 
therefore resulted in the product being withdrawn from the market (Chan-
Tompkins and Babinchak 1996). The unwanted effects produced by these 
products demonstrate that more research is required and as a result of this 
promotility agents are not ideal monotherapy for patients with GORD, however 
they may be useful when used together with acid suppression therapy. 
Acid suppression therapy can consist of histamine-2 receptor antagonists 
(H2RAs) and/or proton pump inhibitors (PPls). These therapeutic options have 
been developed over the last three decades and have led to a reduction of 
symptoms in the majority of patients. 
The introduction of H2RAs (including cimetidine, ranitidine, famotidine and 
nizatidine) made great advances in the ability of patients to control their 
symptoms of GORD, much more so than previously available options, such as 
antacids. 
H2RAs can relieve symptoms in approximately 60% of those treated, compared 
to 20% in placebo controls (DeVault and Castell 1995). All four of the H2RAs are 
equivalent in efficacy at comparable doses and the best results are seen when 
they are taken twice daily. In addition, H2RAs are more effective when given to a 
fasting patient, therefore are most effective when taken before bed on an empty 
stomach. Despite their effectiveness H2RAs are rarely used as maintenance 
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therapy as patients can become tolerant (Hatlebakk and Berstad 1996) and they 
are actually much less effective than PPls in controlling acid secretion (Katz and 
Tutuian 2001). 
There are five available proton pump inhibitors; omeprazole, lansoprazole, 
rebeprazole, pantoprazole and more recently, esomeprazole. Esomeprazole is 
an optical isomer of omeprazole that has a slower metabolic clearance and 
therefore may provide more effective control over acid secretion (Lind et al. 
2000). 
PPls are protonatable weak bases. The un-protonated form accumulates in the 
acidic space of the secretory canaliculus of the active parietal cell. Following 
accumulation these compounds undergo an acid-catalysed rearrangement which 
allows them to react with thiol groups on cysteine residues present on the alpha 
subunit of the proton pump (H+K+ -ATPase, figure 1.10) located on the apical 
membrane of the parietal cell, causing inhibition of acid production (Besancon et 
al. 1997). Acid production is restored when new H+K+-ATPase molecules are 
converted to their active form at the canalicular membrane. As mentioned 
previously, parietal cells are stimulated to produce acid by the sight, smell or 
taste of food and as PPls can only inhibit active pumps on the surface of the 
parietal cell they are most effective when taken just before a meal is consumed. 
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Figure 1.10 The proton pump (H+K+ -ATPase) of the parietal cell. The large 
mass of protein between transmembrane domains 4 and 5 contains ATP binding 
and phosphorylation sites involved in conformational transitions. * represents 
the site of a cysteine residue that is bound by proton pump inhibitors (e.g. 
omeprazole) (Pearson and Brownlee 2005). 
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Although PPls are the most effective medical therapy for controlling the 
symptoms of GORD there are a number of patients who require higher doses 
and some in which symptoms are not resolved despite these elevated levels 
(DeVault and Castell 2005). In addition, PPls can be expensive, especially for 
those that require maintenance/continuous therapy, therefore alternatives 
including surgery or endoscopic techniques may be required. 
Such patients may choose to undergo endoscopic techniques, as these are less 
invasive than open surgery. There are three main types of endoscopic treatment; 
radiofrequency application to the LOS, techniques designed to reduce reflux 
using endoscopic suturing devices and also techniques that require injecting the 
LOS. 
Radiofrequency application using the Stretta device (Curon Medical, USA) is 
designed to increase the reflux barrier of the LOS. It consists of a wire guided 
balloon tipped with a four needle catheter that can deliver radiofrequency energy 
to the gastro-oesophageal junction. When the balloon is inflated the four 
electrodes are placed into the oesophageal wall to make deep thermal lesions 
that result in fibrosis of the muscular sphincter (Schwartz and Smout 2007). One 
study has shown that radiofrequency application can reduce symptoms in 61 % of 
patients compared to 30% in a sham procedure, however PPI use was not 
reduced compared to sham and no reduction was seen in oesophageal acid 
exposure time. This suggests that a reduction in oesophageal sensitivity may be 
responsible for the reduction in symptoms (Corley et al. 2003). 
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Better results have been seen with endoscopic suturing, where two or three 
plications (folds) are made at or below the gastro-oesophageal junction. One 
study has shown a significant improvement in the number of patients off PPls 
after 3 months compared to sham and also in GORD symptoms. After 1 year 
41 % of patients experienced no or few symptoms, however 29% of patients were 
retreated within the year (Arts et al. 2005; Schwartz et al. 2007). 
The last main endoscopic technique involves the injection of a biopolymer into 
the LOS, on the basis that it will be incorporated into the muscle to augment the 
sphincter, creating a barrier against reflux. Early results showed that symptoms 
were decreased compared to sham procedures, but oesophageal acid exposure 
was not reduced (Deviere et al. 2005). In addition, one of the main biopolymers, 
Enteryx (Boston Scientific, USA), was recalled in 2005 after some serious 
adverse effects were reported, including renal failure, severe oesophageal 
stenosis and death. 
Despite the effectiveness of other treatments for GORD patients may still choose 
to undergo anti-reflux surgery. The Society of American Gastro-Enterological 
Surgeons (SAGES) recommend that surgical therapy should be considered in 
those who have failed medical management, have complicated GORD (e.g. 
Barrett's), atypical symptoms (e.g. asthma) or choose to have surgery for lifestyle 
considerations (e.g. age, expense of medications etc.) (Society of American 
Gastrointestinal Endoscopic 1998). 
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The most common form of anti-reflux surgery is Nissen fundoplication, in which 
the fundus of the stomach is wrapped all the way around the distal oesophagus 
(figure 1.11). This increases the pressure in the lower oesophagus and 
consequently reduces the occurrence of reflux. Since Dellemagne first described 
the laparoscopic fundoplication in 1991 patient interest in anti-reflux surgery has 
increased (Dallemagne et al. 1991). In 1990 4.4 anti-reflux procedures were 
performed per 100 000 adults, however in 1997 this had more than doubled to 
12.0 per 100 000 adults (Finlayson et al. 2003). 
Laparoscopic Nissen fundoplication (LNF) has showed some promising results in 
the treatment of GORD. It can provide symptom relief in up to 83-93% of patients 
(Hunter et al. 1996; Lafullarde et al. 2001; Khajanchee et al. 2002) and 
normalisation of oesophageal acid exposure time in 80-91 % (Hunter et al. 1996; 
Eubanks et al. 2000). In addition, LNF procedures have high patient satisfaction 
(96% satisfied (Bammer et al. 2001)) and show superior quality of life scores 
compared to those of patients treated with medical therapy (Fernando et al. 
2002). 
However, as with all surgeries there is a risk of intra-operative complications and 
also of developing post-operative symptoms. Pessaux et al investigated the 
morbidity of anti-reflux surgery in a review of 1470 patients operated on between 
1992 and 1996 from 20 different hospital centres (Pessaux et al. 2002). 2.1% of 
patients experienced intra-operative complications, including bleeding from short 
gastric vessels, gastric and oesophageal perforation, splenic lesion and 
pneumothorax. Early post-operative complications were seen in 2.9%, with 
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asymptomatic pneumothorax and pulmonary embolism being the most common. 
4.1 % of patients experienced other post-operative side effects, the most common 
including gas bloat (36 patients), diarrhoea (10 patients) and epigastric pain (6 
patients). In addition, 51.7% of patients experienced dysphagia (difficultly in 
swallowing) in the first 6 weeks; however this was reduced to 5.9% at 3 months. 
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Figure 1.11 Nissen fundoplication, in which the fundus is wrapped around the 
distal oesophagus (Grey 2007). 
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At 3 years 78 patients (5.3%) had recurrence of symptoms and objective 
evidence of reflux, consequently 60 patients were back on daily medical therapy 
and 18 patients underwent re-fundoplication. In total 35 patients were re-
fundoplicated. Incidence of dysphagia was further reduced to 0.35% a decrease 
from 5.9% at 3 months; however side effects were seen in 6.5%, an increase 
from 4.1 % at 3 months. 
This review of a large number of patients shows that anti-reflux surgery is a safe 
and effective treatment for GORD as the incidence of complications and side 
effects were relatively low. Another report suggests that the morbidity of anti-
reflux surgery can be reduced by adequate patient selection and attention to 
technical detail during the operation, therefore high-volume, specialist centres 
are linked with better surgical outcomes (Stein et al. 1996). 
1.2.4 Extra-oesophageal manifestations of gastro-oesophageal reflux 
In addition to gastro-oesophageal reflux and its associated symptoms (for 
example heartburn, 'typical GORD') some patients may suffer from extra-
oesophageal reflux, i.e. when the refluxate reaches the larynx/pharynx 
(laryngopharyngeal reflux, LPR). Symptoms of LPR can include laryngitis and 
chronic cough amongst others ('atypical reflux'). 
Symptoms of laryngitis can include hoarseness, sore throat, dysphagia and 
globus (the feeling of a lump in the throat). As many as 60% of chronic laryngitis 
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and difficult to treat sore throat cases are thought to be associated with acid 
reflux (Vaezi 2003). The most common mechanism for laryngeal damage caused 
by reflux is the direct contact of the refluxate with the laryngeal mucosa. Animal 
studies have shown that exposure of the laryngeal tissue to gastric contents 
results in inflammation, oedema, granularity and ulceration (Adhami et al. 2004). 
In addition, pepsin has been demonstrated in laryngeal biopsies (located in the 
interstitium and cytoplasm of laryngeal epithelial cells) in patients with ear, nose 
and throat (ENT) symptoms (Johnston et al. 2004). 
Extra-oesophageal reflux is also the most common cause of non-cardiac chest 
pain (NCCP). NCCP is defined as recurrent episodes of angina-like chest pain in 
patients who have a normal cardiac work up (Wong and Fass 2004). Locke et al 
have shown that NCCP is more commonly reported in patients who experience 
regular heartburn (at least once a week) compared to those who suffer from 
irregular heartburn (less than once a week) and those who have no symptoms of 
GORD (37%, 30% and 7.9% respectively) (Locke et al. 1997). In addition, using 
24h pH monitoring, Fass et al demonstrated that up to 60% of patients with 
NCCP had abnormal oesophageal acid exposure, suggesting a link between 
NCCP and GORD (Fass et al. 1998). 
As well as extra-oesophageal symptoms GORD has been associated with 
respiratory complications such as chronic cough. In a review by Morice and 
Kastelik GORD was found to be responsible for up to 41 % of chronic cough 
cases (Morice and Kastelik 2003). Reflux of gastric contents is thought to 
stimulate cough in two main ways; either indirectly, by stimulating an 
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oesophageal-bronchial cough reflex or, alternatively, reflux of gastric contents 
can directly irritate the upper respiratory tract, mainly the larynx and the lower 
respiratory tract by micro or macro-aspiration. Reflux of gastric contents into the 
distal oesophagus alone is enough to stimulate cough via the indirect 
oesophageal-bronchial mechanism (Ing et al. 1994; Irwin et al. 2006). 
In the case of direct stimulation of the larynx/airways repeated macro-aspiration 
seems unlikely, as it can result in abscess formation and pneumonia, conditions 
that are not often associated with chronic cough. Micro-aspiration of refluxate 
may however playa role, and our group have previously measured pepsin levels 
in the SAL of a small number of chronic cough patients as a marker of gastric 
aspiration (Stovold et al. 2007). Pepsin levels were comparable to those of 
healthy volunteers, however this could be due to an over-sensitive cough reflex 
preventing the gastric contents reaching the lungs, therefore a logical next step 
would be to investigate pepsin in sputum samples from cough patients. 
1.2.5 Lung transplantation and GOR 
There is evidence to suggest that lung transplant recipients have a number of 
risk factors for GOR. Lung transplant surgery causes significant damage to the 
vagal innervation of the gastro-intestinal (GI) tract, which controls gastric motility. 
Involuntary gastric motility responses are directed to the stomach mainly via 
efferent vagal fibres. There are two types of efferent fibres that control the 
excitation or relaxation of gastric smooth muscle; low threshold cholinergic fibres 
that control contraction of gastric smooth muscle and high threshold non-
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cholinergic, non-adrenergic nerve fibres, responsible for relaxing the body and 
fundus and mediate the efferent link of receptive relaxation and gastric 
accommodation reflexes. These active reflexes are necessary for the prevention 
of excessively high intragastric pressures, and are damaged by vagotomy 
(Stadaas 1975). Truncal vagotomy also results in an initial dis-coordination of 
antral phasic contractions, which results in delayed gastric emptying due to a 
decrease in force of contraction (Victor and Miller 1989). 
Lung allograft patients are also on immunosuppressive therapy, a regimen that 
can include cyclosporine, which has been known to reduce gastric motility. In 
addition to these factors, cough reflexes and mucociliary clearance reflexes are 
attenuated and these would normally play a role in defence against aspiration 
(Veale et al. 1993). 
Even though a high prevalence of GOR has been reported in lung transplant 
recipients it is not entirely clear as to whether it is due to vagotomy resulting from 
surgery, immunosuppressive therapy or if it is a pre-existing condition, as many 
lung diseases, especially idiopathic pulmonary fibrosis (IPF) and cystic fibrosis 
(CF) have already been associated with GOR (Feigelson et al. 1987; Tobin et al. 
1998; Brodzicki et al. 2002; Raghu 2003). 
A paper from Young et al describes a study they performed investigating the 
occurrence of GOR both pre and post lung transplantation (Young et al. 2003). 
They performed 24h pH testing, oesophageal manometry and gastric emptying 
studies on 23 adult patients both before and after transplantation. Pre-transplant 
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studies were performed at a median of 66 days prior to the transplant (range 1 to 
443 days) and at a median of 100 days post-transplant (range 47 to 248 days). 
Their investigation showed that 35% (8 of 23) of patients had an abnormal acid 
contact time before the transplant. This increased to 65% (15 of 23) after 
transplantation. All of the patients who experienced GOR before transplantation 
still had abnormal acid contact times after transplantation, indicating that pre-
transplant GOR is predictive of post-transplant GOR. An additional 7 patients had 
completely normal pH studies prior to transplantation but acquired GOR after 
transplantation. 
There are other references to GOR causing lung allograft dysfunction in the 
literature (Palmer et al. 2000; Benden et al. 2005). One to note is from the Duke 
University group. Their lung transplant program has performed over 450 lung 
transplantations between April 1992 and July 2003, and over that time period 202 
patients have been evaluated for reflux postoperatively by pH probe. Originally, 
pH studies were not performed on patients at all, and then they were performed 
on symptomatic patients, and more recently pH studies are performed on all 
patients as part of their pre and postoperative evaluation. In their studies 63% 
(23 of 36) had abnormal pre-operative pH studies and 76% (127 of 167) had 
abnormal post-operative pH studies. The patients were split into 4 groups; no 
history of reflux, reflux with no fundoplicative surgery, reflux with early 
fundoplicative surgery (median 36 days, with a range of 0 to 87 days) and reflux 
with late fundop/icative surgery (median 447 days, with a range of 106 to 2999 
days). A total of seventy six patients underwent post-transplant fundoplication. 
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At 1 year post-transplantation the patients who had reflux and early surgery 
showed the greatest freedom from BOS (100% free), followed by those with 
reflux and no surgery (92%), then those with no history of reflux (91 %) and finally 
those with reflux and late surgery (90%, figure 1.12). 
After 3 years, freedom from BOS in those with reflux and early surgery was 
significantly higher than all of the other groups (reflux with early surgery, 100%; 
no history of reflux, 62%; reflux and no surgery 60% and reflux with late surgery 
47%). These results show that an improvement in the freedom from BOS can be 
seen with fundoplication, however, the surgery has to be performed early in the 
transplant experience, as this is not the case in patients with more advanced 
stages of BOS, shown by figure 1.12, at 3 years more than 50% of patients with 
reflux and late surgery had developed BOS. 
The paper also makes a point of mentioning that for patients undergoing 
fundoplication, either early or late, there is no in-house or 30 day mortality, 
indicating that the surgery is safe and could delay the onset of BOS, and 
therefore could possibly increase long term survival rates (Cantu et al. 2004). 
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Figure 1.12 Freedom from BOS in the different groups. &-reflux early surgery; 
.-no history of reflux; 0- reflux no surgery and ~- reflux late surgery. This graph 
was taken from the Chamberlain memorial paper, Cantu et al 2004. 
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This data is however, controversial. Cantu et al have identified certain limitations 
in their study, for example, they mention that the retrospective nature and non-
random selection of patients introduces a bias. This becomes most relevant 
when comparing differences in group demographics, mainly age and diagnosis. 
They also point out that the patients in the early fundoplication group are the 
most recent, and therefore benefit from the experience gained throughout the 
program. 
Although these studies give evidence of reflux in lung transplantation, and that 
fundoplicative surgery can improve the outcome of bronchiolitis obliterans 
syndrome, they do not give any evidence of aspiration of gastric content into the 
lung. More recent studies have focussed on measuring biomarkers of gastric 
aspiration in the bronchoalveolar lavage fluid (BAL) of transplant patients. 
D'Ovidio et al have investigated the presence of bile salts in the BAL of their 
patients as a marker of duodenal-gastro-oesophageal reflux (D'Ovidio et al. 
2005). BAL was analysed using a commercially available kit based on a 
spectrophotometric enzymatic assay and bile salts were detected in 66% of 
patients BAL (71 out of 107) and were significantly higher in patients with BOS 
(Op-3) compared to patients without BOS (1.6 and 0.31Jmolll respectively, 
P=0.002). In addition, patients with early onset BOS (within 12 months) had 
significantly higher BAL bile salts compared to patients with late onset (2.6 and 
0.81Jmolil respectively, P=0.02). Patients with high levels of bile in their BAL 
(~8IJmollml) also had higher levels of interleukin-8 (IL-8) and higher neutrophil 
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counts than those with low levels (between 0 and 8lJmol/l) or if no bile was 
detected. Interestingly, IL-8 and alveolar neutrophils have both previously been 
described as possible clinical markers of BOS development (DiGiovine et al. 
1996; Riise et al. 1999; Zheng et al. 2006). 
In addition Blondeau et al have investigated the presence of bile salts and pepsin 
in the BAL of transplant patients, along with performing pH-impedance 
measurements. They found that 46% of lung transplant patients had increased 
gastro-oesophageal reflux, defined as having one or more abnormal reflux 
indices (increased acid exposure, volume exposure or number of reflux events). 
All transplant patients had detectable levels of pepsin in their lavage, measured 
by ELISA, compared to 49% with detectable bile salts, measured using a kit 
based on an enzyme converting bile salts and thio-NAD to 3-keto steroids and 
thio-NADH. The rate of formation of thio-NADH is determined by measuring the 
change in absorbance and therefore allowing quantification (Bioquant, USA). 
Significantly more patients with BOS had detectable bile in their lavage 
compared to patients without BOS. This suggests that while pepsin may be a 
more sensitive marker of aspiration, bile acids may be a more specific marker for 
the development of BOS. 
In their study a small number of patients had increased non-acidic reflux that 
would not have been diagnosed with pH monitoring alone. In addition, patients 
who were on proton pump inhibitor (PPI) therapy had significantly reduced 
oesophageal acid exposure and a reduced number of reflux events; however 
levels of pepsin and bile were comparable in both patients who were on PPls and 
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those that were not. This suggests that while PPI treatment can reduce gastric 
acid secretion, it can not prevent gastric aspiration and therefore is unlikely to 
prove useful in the treatment of allograft damage resulting from such injury 
(Blondeau et al. 2008). 
1.3 Current treatments for lung transplant rejection 
1.3.1 Immunosupress;on 
The modem era of transplantation arose from the discovery of the calcineurin 
inhibitor cyclosporine (Borel et al. 1976). Since then most lung transplant 
recipients have received a triple-immunosupression maintenance regimen 
consisting of a calcineurin inhibitor (most commonly cyclosporine or tacrolimus 
(Trulock et af. 2007), an antimetabolite (azathioprine or mycophenolate mofetil 
(MMF» and corticosteroids. 
The action of activated cytotoxic T cells via an indirect allo-recognition pathway is 
thought to play a major role in the injury to the airway epithelium in lung 
transplant rejection. Cyclosporine is a fungal polypeptide that forms complexes 
with intra-cytoplasmic proteins to inhibit calcineurin, a protein phosphatase that 
stimulates interleukin 2 (IL-2) production and is involved in T cell activation. 
Tacrolimus, also known as FK506, is a macrolide antibiotic and also inhibits the 
production of IL-2 via binding of FK506 binding protein-12 (Schreiber et al. 1991). 
Azathioprine, an antimetabolite, limits T and B cell proliferation through inhibiting 
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DNA, RNA and de novo purine synthesis. MMF also inhibits lymphocyte 
proliferation, but exhibits increased selectivity and decreased toxicity compared 
to azathioprine. MMF is a pro-drug of the active compound mycophenolic acid, 
an inhibitor of inosine monophosphate dehydrogenase, an enzyme involved in 
the de novo synthesis of guanosine monophosphate (Snell and Westall 2007). 
Most lung transplant programmes include a moderate dose of steroids in the 
immunosuppressive regimen comprising of intravenous methylprednisolone (0.5-
1 mg/kg/day) for several days followed by oral prednisolone (0.5mg/kg/day) 
(Knoop et al. 2004). Small studies have shown improved lung function with the 
use of steroids (Takao et al. 1995; Speich et al. 1997), however a larger study 
showed no advantage of inhaled corticosteroids in the treatment of acute or 
chronic rejection (Whitford et al. 2002). In addition there have been some reports 
of successful corticosteroid withdrawal years after transplantation (Knoop et al. 
2004; Borro et al. 2005). 
1.3.2 Total lymphoid irradiation 
One of the major treatment strategies for managing chronic rejection (08/80S) 
is to intensify the patient's immunosuppressive therapy, with the intention of 
removing the alloimmune response to the graft. However in practice, a patient's 
lung function can continue to decline. Irradiation of the lymphoid tissue will act to 
interfere with the alloimmune response to the graft and should provide additional 
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immunosupression to that achieved through conventional drug based therapies 
(Tochner and Siavina 1988). 
Fisher et al have investigated the safety and efficacy of total lymphoid irradiation 
(TLI) in lung transplant patients. 37 lung recipients were treated with TLI for 
progressive BOS, of which 27 completed at least 80% of the full course. Of the 
10 who did not complete, 2 died early as a result of advanced BOS, 2 developed 
severe infections that lead to pneumonia requiring hospitalisation and the 
remaining 6 developed marrow suppression. 
The mean (±SO) pre-TLI FEV1 in the 27 patients that completed at least 80% of 
the treatment was 1.35L (±0.53) and the mean (±SO) post-TLI FEV1 was 1.60L 
(±0.71), P=0.006. In addition, the effect of TLI on the progression of 80S was 
assessed and the rate of decline in FEV1 was 122.7mllmonth pre-TLI vs. 
25.1 ml/month post TLI, P=0.0004 (Fisher et al. 2005). This study provides 
evidence that TLI is well tolerated and could provide additional 
immunosupression in an attempt to slow the rate of progression of 80S. 
1.3.3 Azithromvcin 
Macrolide antibiotics have shown anti-inflammatory properties in some 
respiratory conditions, including asthma, cystic fibrosis and diffuse 
panbronchiolitis (Kudoh et al. 1998; Equi et al. 2002; Gotfried 2004). In addition 
to these lung disorders the macrolide azithromycin has been shown, in a number 
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of small studies, to have a positive effect on the management of BOS in lung 
transplant recipients. 
The first study involved six lung transplant recipients with BOS grade 1 or greater 
that did not respond to augmentation of immunosupression. At the time of the 
last follow-up (up to 6 months after starting azithromycin therapy) five out of the 
six patients showed significant improvement in lung function (FEV1) compared to 
baseline values at the start of the azithromycin therapy. The mean increase in 
absolute FEV1 was 0.5L (range -0.18 to 1.36L), representing an average 
improvement in absolute FEV1 of 46% (Gerhardt et al. 2003). Another study from 
Yates et al including data on 20 patients also shows a significant increase in 
FEV1 with azithromycin therapy that is sustained beyond 3 months of follow up. 
Median improvement was 110ml (range -70 to 730ml) (Yates et al. 2005). 
A recent study from Gottleib et al includes a larger number of patients (n=81) and 
a longer follow-up period (mean 1.3 ± 0.5 years). The mean pre-treatment FEV 1 
in all patients was 1.46L (range 0.46 to 3.04L). A response to azithromycin was 
seen in 30% of patients at 6 months. The average increase in FEV 1 was 17% 
(range -4 to 43%) at 3 months and 16% (range 11 to 32%) at 6 months. 
Interestingly, analysis of SAL (available in 62 out of 81 patients) revealed a 
significantly higher proportion of neutrophils in responders compared to non-
responders, showing a potential predictive value of SAL neutrophilia for 
treatment response in these patients (Gottlieb et al. 2008). 
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The mechanism of action of azithromycin is unknown, however it is of interest 
that macrolides are pro-motility agents and have been shown to decrease gastric 
emptying time (Sifrim et al. 1994; Arts et al. 2005). 
1.3.4 Miscellaneous treatments 
Murphy et al have investigated the effect of the phosphodiesterase type IV 
inhibitor cilomilast on the release of pro-inflammatory cytokines from cultures of 
bronchial epithelial cells taken from lung transplant patients. Previously, 
cilomilast has been shown to reduce inflammatory cells present in biopsies taken 
from capo patients (Gamble et al. 2003). In addition, Murphy et al have shown 
that cilomilast can significantly reduce interleukin 8 (IL-8) and GMCSF 
(granulocyte-macrophage colony-stimulating factor) production from epithelial 
cell cultures (Murphy et al. 2006). IL-8 and GMCSF are associated with 
neutrophilic airway inflammation and airway remodelling seen in obliterative 
bronchiolitis (Hamilton and Anderson 2004; 8elperio et al. 2005), suggesting that 
cilomilast may have effects relevant to the pathophysiology of chronic rejection 
seen in lung transplantation. 
Re-transplantation is also an option for selected transplant patients with 80S, 
however with the limited number of donors available and an increasing number of 
potential recipients it remains controversial. 
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1.4 Airway mucus 
1.4.1 Mucin structure and function 
As well as graft rejection, mucus hypersecretion along with poor airway 
clearance and altered cough have been observed in lung transplant patients 
(Veale et al. 1993). Hypersecretion of mucus has also been observed in several 
respiratory diseases including COPO, CF and asthma (Callaghan-Rose and 
Voynow 2006). 
Mucus is a mixture of water, ions, glycoproteins, proteins and lipids that coats 
epithelial surfaces (including the respiratory, gastrointestinal and reproductive 
tracts). In the airways one of the main functions of mucus is to protect the lungs 
by trapping foreign particles and pathogens and facilitate their removal by ciliary 
transport. As well as providing a physical barrier, mucus also contains a range of 
immunological factors with antibacterial, antiviral and antifungal properties 
(Rogan et al. 2006). 
Mucus glycoproteins (mucins) are the major macromolecular constituent of 
mucus and they are expressed in two main forms; the secreted or gel forming 
mucins and the membrane bound mucins. Mucins are complex glycoproteins 
with a large molecular weight ranging in size from several hundred to several 
thousand kDa. They are characterised by their tandem repeat domain, which is 
composed of tandemly repeating amino acid residues, and is heavily 
glycosylated through 0- or N-glycosyl linkages (figure 1.13). The more widely 
studied O-linkages are made between N-acetylgalactosamine and the hydroxyl 
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groups of serine and threonine residues, while N-linked carbohydrate chains are 
formed through bonds between N-acetylglucosamine and asparagine residues. 
The predominant secreted mucins in the airway appear to be those coded for by 
the MUC5AC and MUC5B genes (Callaghan-Rose and Voynow 2006). MUC5AC 
is mainly produced by the goblet cells present in the surface epithelium and 
MUC5B by the secretory cells of the submucosal glands. However, Chen et al 
have shown that MUC5B can be expressed by surface epithelial cells as well as 
submucosal gland cells in airway tissue sections obtained from patients with 
COPO and asthma, whilst MUC5AC expression was restricted to the surface 
epithelial cells (Chen et al. 2001). 
Normally, in humans goblet cells are present in the large airways and become 
less dense towards the lung periphery, with few or none being present in the 
small airways. This is also true of the submucosal glands, with no glands being 
present in the small non-cartilaginous airways. In chronic airway disease, the 
submucosal glands increase in size and the number of goblet cells also increase 
(goblet cell hyperplasia). Furthermore, goblet cells can appear in the small 
airways via metaplasia of non-goblet cells (Jeffery and Li 1997). The respiratory 
and terminal bronchioles can not be cleared by cough and since the mucociliary 
clearance is reduced compared to the large airways, excess mucus production 
can be a problem, possibly leading to occlusion of the small airways (Aikawa et 
al. 1992). This increase in the number of goblet cells and size of submucosal 
glands in airway disease is associated with an increase in the volume of mucus 
produced in the airways and can have significant clinical effects (Prescott et al. 
1995; Vestbo et al. 1996). 
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Protein Backbone 
Figure 1.13 A schematic diagram of a secreted mucin. A MUC protein backbone 
usually consists of an N terminal domain, a C terminal domain and an area of 
high tandem repeats (shaded) that has O-and N-linked oligosaccharides (0-
glycans, N-glycans respectively) attached. Mucins are classified by their MUC 
protein backbone, which is encoded by a MUG gene. This figure is modified from 
Callaghan-Rose and Voynow 2006. 
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1.4.2 Regulation of mucus secretion 
The regulation of MUC genes has been previously investigated in vitro and a 
number of inflammatory cytokines have been shown to up-regulate MUC5AC 
expression, for example, TNF-a, IL-6 and IL-17 (Chen et al. 2003; Callaghan-
Rose and Voynow 2006). Smirnova et al have also shown that IL-8 can stimulate 
MUC5AC secretion from goblet cells (Smirnova et al. 2002). In addition, the 
group has shown that bacterial LPS up-regulates both IL-8 and MUC5AC mRNA 
expression and secretion from goblet cells, suggesting that the up-regulative 
effect of LPS is partially mediated through an IL-8 dependant mechanism 
(Smirnova et al. 2003). 
Other factors known to stimulate MUC5AC expression in vitro include 
prostaglandins, matrix matallo-proteinases (MMPs), neutrophil elastase, reactive 
oxygen species and also exogenous toxins, such as tobacco smoke and 
environmental pollutants (Voynow et al. 2006). 
Such factors are thought to stimulate the up-regulation of mucins either via direct 
epithelial stimulation, or via leukocyte recruitment and activation (figure 1.14) 
(Jackson 2001). They act by binding to specific surface cell receptors, for 
example, P2Y2 and toll like receptors (Voynow et al. 2006). Additionally, the 
epidermal growth factor (EGF) receptor has been implicated in mucin gene 
regulation through a variety of stimuli (Takeyama et al. 1999). Binding of these 
receptors is then thought to activate mitogen-activated protein kinase (MAPK) 
pathways, which in turn activate the transcription factor, nuclear factor kappa B 
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(NFKB), which will regulate mucin gene expression (Callaghan-Rose and Voynow 
2006). Other transcription factors can also mediate mucin gene expression, for 
example SP1 and AP-1 (Perrais et a!. 2002; Gensch et a!. 2004). 
Few studies have been carried out investigating mucus hypersecretion in lung 
transplantation and therefore further work is required. It is possible that any 
pepsin present in the lung could contribute to the stimulation of epithelial/goblet 
cells causing them to synthesise/secrete mucin, as other diseases that are 
associated with mucus hypersecretion have also been linked to gastro-
oesophageal reflux for example CF, COPD and asthma (Feigelson et al. 1987; 
Havemann et al. 2007; Kempainen et a!. 2007). 
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Figure 1.14 Stimulation of mucus production in goblet cells. Increased mucin 
production can be mediated through either direct stimulation of the epithelial cells 
or via leukocyte recruitment and activation. This figure is taken from Jackson 
2001 . 
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1.5 Outline of study 
As many of the current strategies for treating BOS in lung transplant recipients 
have had little or no impact on the overall progression of the condition it seems 
reasonable to further investigate the effect of gastro-oesophageal reflux as a 
non-alloimmune contributor. As previously mentioned, anti-reflux surgery has 
shown some promising results (chapter 1.2.5), however there is no general 
consensus on when to perform surgery or which patients will benefit the most, 
therefore further investigations are required. 
There are three overall aims of this study. The first is to investigate whether 
aspiration is occurring in lung transplant recipients by measuring levels of the 
gastric protease pepsin, as a biomarker of gastric aspiration, in the 
bronchoalveolar lavage (BAL) from transplant patients. The second is to measure 
pepsin levels in a longitudinal cohort to investigate the variation in levels over 
time and also if high levels of pepsin in the BAL can predispose or predict for 
chronic rejection (OB/BOS). Finally, to investigate the possible links between any 
pepsin present in the lung and damage caused to the epithelium using primary 
bronchial epithelial cell cultures taken from lung transplant patients. 
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2.1 Reagents 
Chapter 2 
Materials and methods 
All reagents used in these experiments were obtained from Sigma UK, Fisher 
Scientific UK or BOH UK unless otherwise stated. All antibody concentrations 
were determined by the manufacturer, unless otherwise stated. 
2.2 Collection of samples 
Ethical approval was received from the relevant local research ethics committees 
for collection of all samples, including bronchoalveolar lavage and gastric juice 
samples. 
2.2.1 Bronchoscopv and BAL col/ection 
Bronchoscopy was performed in accordance with international guidelines (BTS 
Bronchoscopy Guidelines Committee 2001). Patients were pre-medicated with 
intravenous midazolam, and 4% lignocaine was applied topically to the nose, 
pharynx and larynx and below the vocal cords as required, up to a maximum of 
Bmg/kg body weight. 
Bronchoalveolar lavage (BAL) was standardised to a 3 x 60ml procedure, during 
which 02 saturation was routinely measured. The BAL sample was spilt and 
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assessed for clinical microbiology and differential cell counts on Giesma stained 
cytocentrifuge preparations. Cell free SAL supernatants were prepared by 
centrifuging the samples at room temperature and 1500rpm for 10 minutes 
(Centra-3, IEC). Aliquots were then snap frozen by' immersion in liquid nitrogen 
and stored at -80°C prior to experimentation. 
2.2.2 Collection of gastric juice 
Endoscopy was performed for standard indications. After xylocaine throat spray 
or up to 5mg midazolam endoscopy was performed using a fibre-optic 
endoscope. Gastric juice when present was aspirated out of the stomach and 
caught using a trapper (Pen nine Healthcare, UK). 
2.3 Preparation of standards 
2.3.1 Purification of MUC5AC mucin standards 
Media incubated with mucus secreting goblet cell line HT29-MTX (seeded at 
approximately 50000 cells/well) was collected until sufficient volume was 
acquired (approximately 500ml) and frozen at -20°C. The media was then 
defrosted, pooled and concentrated by vacuum dialysis followed by dialysis 
against deionised water to remove low molecular weight material. Once 
concentrated the media was adjusted to a density of 1.42g/ml with caesium 
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chloride and centrifuged at 4°C and 40000rpm for 48h (Centrikon T-1170).The 
resulting density gradient was separated into 8 equal fractions and their densities 
were measured. Each fraction was then exhaustively dialysed against 20 litres of 
deionised water for 3 days with 4-6 changes per day. 
After dialysis the absorbance of each undiluted fraction was measured at 260 
and 280nm on a spectrophotometer to determine the protein/nucleic acid 
concentration. A periodic acid-Schiff's (PAS) assay (Mantle and Allen 1978) was 
also performed on each fraction to determine the glycoprotein concentration. 
Mucin containing fractions were pooled and freeze-dried. 
2.3. 1. 1 Periodic acid-Schiff's assay 
This assay relies on 1 ,2-glycol groups being oxidised to aldehydes, leading to the 
production of a purple/magenta coloured compound that can be read on a 
spectrophotometer at 555nm (Mantle and Allen 1978). 
A standard curve of 0-100l-1g was prepared using 1 mg/ml papain digested pig 
gastric mucus a nd made up to a total volume of 1 ml with deion ised water. 1001-/1 
of periodic acid solution (0.1% periodic acid in 7% acetic acid) was added to 1ml 
of sample or standard and incubated at 37°C for 1 h. After incubation 1001-11 of 
Schiffs solution (0.017g/ml sodium metabisulphate in Schiff's reagent, Biorad 
UK) pre-incubated for 1 h at 37°C was added. Colour was developed for 30 
minutes at room temperature. Samples and standards were then read at 555nm 
on a spectrophotometer. 
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2.3.2 Purification of human gastric juice 
Gastric juice samples from the first 4 patients undergoing endoscopy after ethical 
approval was received were collected and pooled. Samples collected were of an 
abnormal pH (between pH 5.0 and 7.0) due to these patients taking proton pump 
inhibitors. The samples were adjusted to a density of 1.42g/ml with caesium 
chloride and centrifuged at 4°C and 40000rpm for 48h (Centrikon T-1170). The 
resulting density gradient was separated into 8 equal fractions and their densities 
were measured. Each fraction was then exhaustively dialysed against 20 litres of 
deionised water for 3 days with 4-6 changes per day. 
After dialysis the absorbance of each undiluted fraction was measured at 260 
and 280nm on a spectrophotometer to determine the protein/nucleic acid 
concentration. Protein containing fractions 1-3 were freeze dried. Fraction 1 
contained a precipitate so was centrifuged for 5 minutes at 1500rpm (Centra-3, 
IEC) and pellet and supernatant were freeze-dried separately. 
The individual freeze-dried fractions were then run on an SDS-PAGE gel to 
determine whether they contained pepsin (molecular weight approximately 
35000). 
2.3.2.1 SOS-PAGE 
SOS-PAGE was performed using the Pharmacia PHAST gel system. The freeze 
dried fractions and 2 porcine pepsin controls were made up to a concentration of 
2.5mg/ml in reducing buffer (0.0625M Tris buffer at pH 6.8 containing 2% (w/v) 
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SOS, 10% (v/v) glycerol, 0.001 % bromophenol blue and 5% mercaptoethanol). 
Samples and controls were heated for 2 minutes at 1 oooe before 51J1 was applied 
to the gel (PhastGel™ Gradient 4-15%). The gel was run (100V, 10mA, 1W and 
4VH (volt hours)) until the tracking dye had reached the end of the gel. The gel 
was then stained ovemight with a coomassie blue solution (0.05% coomassie 
blue, 25% (v/v) propan-2-01 and 10% (v/v) acetic acid in deionised water), 
followed by de-staining for 24h with a solution containing 25% (v/v) propan-2-01 
and 10% (v/v) acetic acid in deionised water. 
The gel was scanned on a densitometer (GS-BOO, Biorad, UK) and the relative 
mobility of the fractions were determined by calculating the distance moved on 
the gel from the point of application. 
In addition, an ELISA was performed on each fraction to determine pepsin 
concentration (refer to methods 2.4.5). 
2.4 Analytical methods 
2.4. 1 Determination of pepsin concentration by Slot/Blot enzyme linked 
immunosorbent assay (ELISA) 
A nitrocellulose transfer membrane (Whatman, UK) with a pore size of O.21lm 
was supported on blotting paper, wetted with deionised water and inserted into 
the Minifold II 72-well slot/blot apparatus (Whatman Schleicher & Schuell). 
Porcine pepsin standards and 100lli of each SAL sample were added to 
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individual wells in triplicate and the block attached to a vacuum source. Once the 
samples had been absorbed onto the membrane it was removed and incubated 
in phosphate buffered saline (PBS) with 2% bovine serum albumin (BSA) 
overnight at 4°C, or alternatively for 2h at room temperature. This was to prevent 
non-specific binding. After blocking, the membrane was incubated with a primary 
antibody for 1.5h (anti-pepsin, Biodesign International, USA) diluted to 1/2000 
with 1 % BSA in PBS. After incubation the membrane was washed with 2 
changes of 0.5% Tween20 in PBS followed by 3 changes of PBS. The 
membrane was then incubated with a secondary antibody (horseradish 
peroxidase conjugated anti-sheep/goat, Sigma, UK) diluted to 1/10000 with 1 % 
BSA in PBS for 1.5h at room temperature. After incubation, the washing was 
repeated and colour was developed using 0.05% 3, 3'-diaminobenzidine 
tetrahydrochloride (DAB) with 0.03% H202 in PBS for 5 minutes. When the colour 
was sufficiently developed the membrane was rinsed with tap water and then left 
to dry over night before it was read on a Shimadzu scanning densitometer at 
595nm. Negative controls were produced for determination of non-specific 
binding of antibody by omitting samples from the primary antibody incubation; in 
its place they were incubated in 1 % BSA in PBS only. A schematic diagram of 
this method is shown in figure 2.1. 
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2.4.2 Determination of MUC5AC mucin concentration by Slot/blot ELISA 
The slot/blot method using a nitrocellulose transfer membrane of pore size 
0.451Jm was repeated to determine MUC5AC mucin concentration (see 
schematic, figure 2.1). A monoclonal MUC5AC antibody (Vision Biosystems, UK) 
was used to detect MUC5AC mucin concentration and was diluted to 1/75 with 
1 % BSA in PBS, followed by a secondary antibody (horseradish peroxidase 
conjugated anti-mouse, Sigma UK) diluted to 1/5000 with 1 % BSA in PBS. Again, 
negative controls were performed by omitting samples from the primary antibody 
step. 
Mucin standards for this assay were purified from cell media collected from a 
human mucus secreting goblet cell line (HT29-MTX, refer to methods 2.3.1). 
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Figure 2.1: Schematic of the sloUblot ELISA assay. 
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2.4.3 Protease activity assay 
This assay of Hutton et al (a modification of (Lin et al. 1969)) relies on the 
production of new N-terminal amino groups that are formed during proteolytic 
hydrolysis of the substrate succinyl albumin. The new amino groups react with 
trinitrobenzylsulphonic acid (TNBS), generating trinitrophenyl (TNP) derivatives 
which can be estimated spectrophotometrically (Hutton et al. 1986). 
200J!1 of sample or standards (0-2jJg) were added to test tubes in triplicate. 500J!1 
of substrate (8mg/ml succinyl albumin in HCI adjusted to pH 2 using 1 M HCI) was 
added to each tube, the tubes were then mixed, covered and incubated at 37°C 
for 1 h. After incubation the reaction was stopped by adding 500J!1 of 4% (w/v) 
NaHC03 followed by 500J!1 0.05% (w/v) TNBS solution (0.05% 
trinitrobenzylsulphonic acid in deionised water) the tubes were then mixed and 
placed in a water bath at 55°C for 10 minutes to allow the colour to develop. After 
10 minutes 500J!1 of 10% sodium dodecyl sulphate (SDS, w/v) followed by 500J!1 
1 M HCI was added and the tubes were mixed, covered and left to stand at room 
temperature for 1 h. The tubes were then read on a spectrophotometer at 340nm. 
Negative controls were produced by adding substrate to sample immediately 
before the NaHC03 step. 
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2.4.4 Determination of interleukin 8 concentration bv sandwich ELISA 
Interleukin 8 concentration was measured using a DuoSet ELISA kit (R&D 
Systems, USA): 
A 96 well plate (Maxisorp, Nunc) was coated with a capture antibody diluted to a 
working concentration of 4.0tJg/ml in PBS and left overnight at room temperature. 
After incubation the plate was washed with three changes of wash buffer (0.05% 
Tween20 in PBS) and dried by blotting with clean paper towels. 
The plate was blocked for at least 1 h with 1 % BSA in PBS at room temperature 
and the wash step repeated. 100tJI of samples (diluted 1 in 10) or standards (0-
2ng/ml) made up in reagent diluent (0.1 % BSA, 0.05% Tween20 in Tris-buffered 
saline (TBS), pH 7.2-7.4) were added and incubated for 2h at room temperature. 
Again the wash step was repeated followed by the addition of 100tJI of the 
detection antibody (diluted to a working concentration of 20ng/ml with reagent 
diluent) and was left for 2h at room temperature. After washing, 100tJI of 
streptavadin-HRP (diluted to 1/200 with reagent diluent) was added to each well 
and incubated for 20 minutes at room temperature. The wash step was repeated 
and 100tJI of substrate solution (2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic 
acid (ABTS)) was added to each well and colour was developed for 
approximately 20 minutes. The reaction was stopped with 100tJI of 1% SDS and 
the plate was read on a standard plate reader at 405nm. 
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2.4.5 Determination of pepsin concentration bv direct ELISA 
The development of this assay for the measurement of pepsin concentration is 
dealt with in chapter 4. 
1 OOIJI of sample (diluted to 1 in 5) or standards (0-1 Ong/ml) made up in PBS were 
coated onto a 96 well plate (Maxisorp, Nunc) and were incubated overnight at 
room temperature. The plate was then washed with three changes of wash buffer 
(0.05% Tween20 in PBS) and dried by blotting with clean paper towels. 
The plate was blocked for at least 1 h with 1 % BSA in PBS at room temperature 
and the wash step repeated. After washing 100IJI of the primary antibody (anti-
pepsin, Biodesign International, USA) diluted to 1/2000 with reagent diluent 
(0.1% BSA, 0.05% Tween20 in Tris-buffered saline (TBS), pH 7.2-7.4) was 
added and incubated for 2h at room temperature. 
Again the wash step was repeated followed by the addition of 1001J1 of the 
secondary antibody (HRP-conjugated anti sheep/goat, Sigma, UK) diluted to 
1/10000 with reagent diluent and was left for 2h at room temperature. After 
washing, 100IJI of substrate solution (2,2'-Azino-bis(3-ethylbenzothiazoline-6-
sulfonic acid (ABTS)) was added to each well and colour was developed for 
approximately 20 minutes at room temperature. The reaction was stopped with 
1 001-11 of 1 % sodium dodecyl sulphate (SOS) and the plate was read on a 
standard plate reader at 405nm. 
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Negative controls were performed by omitting samples from the primary antibody 
step and incubating with reagent diluent only to determine the degree of non-
specific binding of the secondary antibody. 
2.5 Cell culture methods 
2.5. 1 Primary bronchial epithelial cell culture 
Epithelial cells taken from bronchial brushings were obtained from lung transplant 
patients undergoing routine bronchoscopy and cultured according to the method 
described by Forrest et al (Forrest et al. 2005)(figure 2.2). Cells were used at 
passage 1-3 only: 
Bronchial brushings were obtained from sub-segmented bronchi and were 
dispersed in 5 ml of sterile PBS and 5ml of RPMI and 10% foetal calf serum 
(FCS). The cells were centrifuged at room temperature and 1000 rpm for 5 
minutes (Centra-3, IEC). The supernatant was removed and the cell pellet was 
re-suspended in 2ml of bronchial epithelial basal media (BEBM; Lonza, 
Switzerland) supplemented with bronchial epithelial growth media (BEGM) 
Singlequots (Lonza, Switzerland). penicillin and streptomycin. The cells were 
then transferred to a collagen coated T25 flask (Vitrogen 100; Cohesion, USA) 
and placed in an incubator at 37°C and 5% CO2• Media was changed every 48h 
until the cells reached confluency. 
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Once confluent the cells were passaged using trypsin and neutralised with an 
equal volume of RPMI supplemented with 10% FCS. The cell suspension was 
centrifuged, supernatant removed and the pellet re-suspended with fresh media. 
The cells were then transferred to a T75 flask for expansion followed by a 24 well 
plate for experimentation. All flasks and plates are collagen coated prior to 
addition of the cells. 
Cells were stained with haematoxylin & eosin and for cytokeratin to ensure an 
epithelial phenotype of the cells. 
2.5. 1. 1 Haematoxylin & eosin staining 
Cells were grown on 8 chamber slides until confluent. They were then fixed in 
100% acetone for ten minutes at room temperature and allowed to air dry. The 
cells were stained with Harris Haematoxylin for 1 minute and then were washed 
in running tap water for 2-3 minutes. The slides were then differentiated in 0.1 % 
acid alcohol and washed again with tap water until blue (slides were checked 
under the microscope). The slides were then counter-stained with Eosin Y for 2 
minutes and washed in running tap water, then dehydrated with industrial 
methylated spirits (95% for 30 seconds, 2 x 99% for 30 seconds followed by 
100% xylene). The slides were then mounted in DPX (Distrene-80, Plasticizer, 
Xylene). 
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2.5. 1.2 Cytokeratin staining 
Confluent cells grown in 8-chamber slides were stained for cytokeratin using the 
ImmPRESS ™ detection system (Vector, USA) (figure 2.3). 
Cells were fixed in 1 00% acetone for 1 0 minutes at room temperature and left to 
air dry. Sections on the slide were then ringed with a hydrophobic pen. Each 
section was treated with a Tris buffered saline (TBS)fTween solution (TSS 
adjusted to pH 7.6 and 0.1 % (v/v) Tween20) for 15 minutes. After removing the 
TBS/Tween solution slides were blocked with 2.5% normal horse serum for 30 
minutes. Once blocked the slides were incubated with 100IJI of the primary 
antibodies (a mixture of two anti-cytokeratin antibodies, raised against 
cytokeratin 6 & 8 and 5, 6, 8, 17 & 19, Dako, Denmark) diluted to 1/50 in 3% 
SSArrSS/Tween, or the isotype control also diluted 1/50 in 3% BSA/TBS/Tween 
for 1 h at room temperature. The slides were then washed with TSS for 5 
minutes. Endogenous peroxidases were blocked with 0.3% H202 in methanol for 
30 minutes, followed by washing with running tap water for at least 5 minutes, 
after which slides were rinsed with TSS. 
Excess buffer was removed without drying out the cells on the slides. 1001J1 of 
ImmPRESS™ reagent containing the secondary antibody (horseradish 
peroxidase conjugated anti-mouse/rabbit) was then added for 30 minutes. After 
washing and removing any excess buffer the slides were incubated with DAS for 
5-10 minutes, whilst being checked under the microscope for sufficient colour 
development. The sections were then washed with running tap water and 
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counter-stained with Harris Haematoxylin for 1 minute. Slides were washed 
gently under the tap until blue, and were then dehydrated with industrial 
methylated spirits (95% for 30 seconds, 2 x 99% for 30 seconds followed by 
100% xylene). The slides were then mounted in DPX. (Distrene-80, Plasticizer, 
Xylene). 
2.5.2 Goblet cell culture (HT29-MTX) 
A human goblet cell line HT29-MTX, kindly provided by Dr Thecla Lesuffler 
(INSERM U178, France), was grown at 3rC and 10% CO2 in a T75 flask in 12ml 
of Dulbecco's modified eagles medium (DMEM) supplemented with 10% FCS 
(figure 2.4). Confluent cells were passaged using trypsin and transferred to a 24 
well plate for experimentation. 
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Figure 2.2 Human primary bronchial epithelial cells growing in culture under 
normal conditions (singlequot supplemented BEBM, Lonza, Switzerland, at 37°C 
and 5% C02, cells were seeded at approximately 50000/well). 
Figure 2.3 Human primary bronchial epithelial cells stained for cytokeratin . Cells 
were grown in 8-chamber slides and stained for cytokeratin using antibodies 
against cytokeratin 6 & 8 and 5, 6, 8, 17 & 19. 
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Figure 2.4 Human goblet cells (cell line HT29-MTX) growing in culture under 
normal conditions (FCS supplemented DMEM, Sigma UK, at 37°C and 10% C02; 
cells were seeded at approximately SOOOO/well). 
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2.5.3 Pepsin challenge on epithelial and goblet cells 
Once the goblet cells and epithelial cells reached confluency in 24 well plates 
they were incubated with 5001-11 of media (DMEM, serum free, Sigma UK or 
BEBM, without singlequots, Lonza Switzerland respectively) at pH 7.4 or pH 7.0 
(media adjusted with 1 M Hel) and either with or without pepsin (porcine pepsin at 
a concentration of 10ng/ml, 50ng/ml or 50l-lg/ml). Media was collected at 24,48 
and 72h and frozen for future analysis of mucin and/or interleukin 8. 
2.5.4 Gastric juice challenge on epithelial cells 
Epithelial cells were also challenged with human gastric juice. Confluent cells in 
24 well plates were incubated with 5001-11 of either neat gastric juice or gastric 
juice at one of the following dilutions; 1/4, 1/20, 1/100, 1/1000, 1/5000 or 1/10000 
(diluted with BEBM without singlequots, Lonza, Switzerland). Controls were also 
performed by incubating the cells with media free from gastric juice or serum. 
The media was removed after 24h, after which a viability assay was performed. 
2.5.5 Viabilitv assay 
Viability of both the goblet and epithelial cells was measured using the 
CellTiterblue assay (Promega, USA). 
This assay relies on reduction reactions in the viable cell reducing resazurin, a 
dark blue compound in the TiterBlue reagent, to resorufin which is pink. 
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Resorufin has an absorbance maximum of 573nm compared to that of resazurin, 
which is 605nm. 
Challenge media was removed from the cells and stored at -20°C for further 
analysis. TiterBlue reagent was mixed directly with the goblet and epithelial cell 
media (20\-11 TiterBlue for every 100\-11 DMEM, Sigma UK or BEBM, Lonza 
Switzerland) and the cells were incubated under their standard conditions for 2-
4h. Absorbance was then measured at 560nm on a spectrophotometer and 
values converted to a percentage of the normal contro\. Negative controls were 
also performed by fixing cells for 10 minutes in ice-cold methanol prior to adding 
the TiterBlue reagent. As dead cells have no reducing potential the reagent 
should not change colour, indicating that nothing present in the media alone is 
responsible for the colour change. 
80 
Chapter 3 
Cross-sectional analysis of pepsin present in BAL from 
lung transplant recipients 
3.1 Introduction 
Chronic rejection in the form of obliterative bronchiolitis (08) and it's clinical 
correlate bronchiolitis obliterans syndrome (80S) remains the biggest limitation 
to long term survival in lung transplantation. The pathophysiology is poorly 
understood, but the number and severity of acute rejection episodes are 
consistently linked with the development of 08. In addition non-alloimmune 
mechanisms are becoming increasingly recognised as risk factors for the 
development of post-operative 08 and gastro-oesophageal reflux (GOR) with 
subsequent aspiration has been implicated, not only in the development of 08, 
but in other airway and lung diseases (Feigelson et al. 1987; Tobin et al. 1998; 
Palmer et al. 2000; 8rodzicki et al. 2002; Raghu 2003). 
As a result of this some centres are now assessing their patients for reflux, by pH 
monitoring and/or impedance both pre and post-operatively, and the Duke group 
in particular have taken a very aggressive approach and only feed their patients 
through a G-J tube until GOR-corrective surgery is performed (Cantu et al. 2004). 
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pH monitoring and impedance can diagnose reflux; however they do not tell us 
whether the gastric contents are reaching the lungs. Therefore a biomarker 
approach may be more accurate in detecting gastric aspiration. In 2005 Ward et 
al investigated whether the gastric protease pepsin could be found in the lavage 
of lung transplant patients (Ward et al. 2005). They showed, in a small number of 
patients, that pepsin was present in all of the lung allograft recipients. The study 
was however, small and not powered to look at possible associations between 
acute or chronic rejection and gastric aspiration. 
I have therefore investigated whether pepsin, a marker of gastric aspiration, is 
present in the lungs of transplant recipients and also if high levels are associated 
with the presence of acute rejection and/or DB. 
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3.2 Patient demographics 
Patient demographics are summarised in Table 3.1. Bronchoalveolar lavage 
(BAL) microbiology and transbronchial biopsy pathological rejection assessments 
are summarised only for the lung transplant recipients. 
In the lung transplant recipients twelve patients had stable lung function with no 
evidence of clinically significant acute rejection (6 had AO, 6 A 1) or BOS or 
clinical evidence of infection (stable lung transplant recipients). One patient in 
this group had asymptomatic infection with Pseudomonas aeruginosa. Twelve 
patients had biopsy proven acute rejection (A2 or greater) without BOS and 
twelve patients were diagnosed as having BOS. 
3.2.1 BAL returns 
Median BAL return was 85ml (range 35-115) in the allograft patients, 85ml (range 
60-110) in the normal controls and 67.5ml (range 50-100) in the chronic cough 
disease control group, indicating technically satisfactory BAL procedures. 
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Diagnosis Op. Time Biopsy BOS ant-
Subject post Tx Score Micro- Pepsin acid 
no. Group age sex (weeks) biology ng/ml therapy 
1 a 42 f ipf bit 4 A3B2 * neg 8.5 N 
2 a 35 f pph hit 4 A2B2 * neg 31.2 R 
3 a 50 m emp sit 1 A2B2 * neg 26.5 Oi 
4 a 47 f emp sit 26 A2BO 0 neg 51.7 Oi 
5 a 41 m cf bit 1 A3B2 * neg 5.4 R 
6 a 20 f cf bit 1 A2B2 * neg 10 Oii 
7 a 36 f pph hit 24 A2BO 0 neg 22.3 Oi 
8 a 38 f ob bit 4 A2B1 * neg 9.1 N 
9 a 25 f pph hit 4 A3B2 * neg 10.2 Oi 
10 a 56 f emp sit 12 A2B2 0 neg 10.7 R 
11 a 51 f emp bit 4 A2B1 * neg 11.7 L 
12 a 25 f cf bit 12 A2Bx 0 neg 20.6 Oi 
13 s 61 f lam sit 24 AOBO 0 neg 8.1 Oi 
14 s 43 f lam bit 52 A1BO 0 neg 4.2 L 
15 s 35 m sar sit 24 A1B1 0 neg 1.4 R 
16 s 55 f ipf sit 4 AOB1 * neg 2.5 L 
17 s 37 m emp bit 26 A1B1 0 neg 0 L' 
18 s 48 f ob bit 1 A1BO * neg 2.9 L 
19 s 40 m ipf sit 52 AOBx 0 neg 10.2 L 
20 s 49 m emp bit 12 A1Bx 0 pa 9.9 L 
21 s 59 f emp sit 52 AOBO 0 neg 6.4 L 
22 s 39 m emp bit 24 AOBO 0 neg 7.4 R 
23 s 39 m cf bit 52 A1B1 0 neg 12.6 L 
24 s 22 f cf bit 12 AOBx 0 neg 0 N 
25 b 24 m cf bit 80 AOB1 2 pa 12.8 R 
26 b 54 m ipf sit 230 AuBx 1 neg 19.1 R 
27 b 21 m cf bit 60 A1Bx 3 pa 3.5 N 
28 b 20 f cf bit 54 AOB1 3 pa 7.7 Oi 
29 b 51 f ipf sit 280 AuB1 3 neg 9.3 R 
30 b 16 f cf bit 112 A1Bx 3 neg 0 Oii 
31 b 53 m emp bit 140 AOBx 2 neg 1.3 L 
32 b 28 m cf bit 34 A1Bx 2 pa 5.8 L 
33 b 27 f cf bit 180 A1B1 3 neg 15.6 N 
34 b 57 f emp sit 28 AOBO 1 asp 7.3 Oi 
35 b 17 m cf bit 26 AOBx 2 neg 1.3 N 
36 b 29 m cf hit 160 AuBx 2 pa 0 Oi 
.. Table 3.1. Patient demographics, a- acute rejection (grade A2 or higher), s - stable, b-BOS. Ipf - Idiopathic 
pulmonary fibrosis, lam -Iymphangioleiomyomatosis, cf-cystic fibrosis, sar-sarcoidosis, emp-emphysema, pph-
primary pulmonary hypertension, ob- obliterative bronchiolitis. sit-single lung transplant, blt- bilateral lung transplant, 
hit-heart lung transplant. neg -negative, pa- Pseudomonas aeruginosa, asp-Aspergillus. Au-denotes biopsies that 
are technically un-gradable for acute rejection. * -patients un-grad able for BOS as their biopsies were taken within 
12 weeks of transplantation. N-no acid suppression, R-ranitidine 150mg twice daily, Oi- omeprazole 20mg once 
daily, Oii- omeprazole 20mg twice daily, L-Iansoprazole 30mg once daily, L'-Iansoprazole 15mg once daily 
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3.3 Analysis of SAL Pepsin 
3.3.1 Statistical analvsis of BAL pepsin data 
The statistical analysis of data contained in this chapter was performed with the 
help of a statistician. The median allograft pepsin levels between groups were 
compared using the Kruskal Wallis test (non parametric one-way analysis of 
variance) with a post-hoc Mann Whitney test (two tailed throughout). P-values for 
groups of pair-wise comparisons detailed in 3.3.3 were adjusted using the 
Bonferroni method. Unadjusted P-values are reported, because Bonferroni 
corrections made no difference to the statistical significance using P<O.05 as a 
cut-off. 
Possible confounding variables: 
1. Time post transplantation. 
A rank based Spearmans (non parametric) correlation was used to evaluate a 
possible relationship between time post transplantation and BAL pepsin levels. 
2. A model including demographic variables. 
A model was examined to evaluate possibly confounding, variables for BAL 
pepsin levels which included group, sex, age, operation type and antacid status. 
Time post transplantation could not be assessed in this model because it was 
impossible to dissociate this from group status e.g. BOS patients are further post 
transplantation than other groups. Pair-wise comparisons were performed 
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between the means of the groups and adjusted for all other variables in the 
model, with a Bonferroni correction. 
3.3.2 Comparison of lung transplant recipients and control subjects 
Pepsin levels were analysed in the lavage of 4 normal controls, 17 chronic cough 
disease controls and 36 transplant patients. Pepsin levels from all transplant 
patients (median 8.3, range 0-S1.7ng/ml) were higher than both the control 
groups (normal: median, 1.1, range 0-2.3ng/ml, chronic cough: median 0, range 
0-2.6ng/ml) (all transplant group vs. normal group P =0.02, vs. Chronic cough 
group P < 0.0001) (Figure 3.1). 
Moreover, BAL pepsin levels were significantly raised in lung transplant 
recipients without BOS compared to the control groups, suggesting that gastric 
aspiration is present in lung transplant patients without any significant airflow 
limitation (Figure 3.2). 
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Figure 3.1. BAL Pepsin levels (ng/ml) of all transplant recipients vs. normal and 
chronic cough control groups. Lines represent the median values. Lung TX-Iung 
transplant. Normal n=4, c cough n=17 and lung tx n=36. 
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Figure 3.2. BAL Pepsin levels (ng/ml) of transplant recipients without BOS vs. 
normal and chronic cough control groups. Lines represent the median values. 
Lung TX-Iung transplant, BOS-bronchiolitis obliterans syndrome. Normal n=4, c 
cough n= 17 and lung tx no BOS n=24 
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3.3.3 Comparison of lung transplant recipients with stable lung function, acute 
rejection and 80S 
BAL pepsin levels were elevated in stable lung transplant recipients, subjects 
with acute rejection and subjects with BOS. The highest levels were found in 
recipients with A2 or greater acute rejection (Figure 3.3), with no significant 
difference between stable patients (AO-1) and BOS patients. The statistical 
significance of these results, with a Bonferroni correction for multiple 
comparisons, remained the same after adjustment for age, gender, operation 
type and whether the patients were treated with antacid therapy. 
When compared to normal and chronic cough controls (both GORD and no-
GORD) BAL pepsin levels were significantly raised in the A2 or greater acute 
rejection group (vs. normal P= 0.004 and VS. both chronic cough groups 
P<0.001). 
Pepsin levels were not significantly different in patients treated with a 
maintenance dose of acid suppression therapy (median 8.7, range 0-51.7ng/ml) 
compared to patients who were untreated (median 6.0, range 0-15.6ng/ml, P = 
0.3). 
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Figure 3.3. Values of pepsin (ng/ml) recovered from BAL. Lines represent the 
median values. c. cough-Chronic Cough, GORD-gastro-oesophageal reflux 
disease. AD and A 1 are clinically stable allograft recipients with grade AD or A 1 
acute vascular rejection. The ~A2 group are subjects with A2 or greater acute 
rejection. BOS - allograft recipients diagnosed with Bronchiolitis Obliterans 
Syndrome. Normal n==4, c cough no GORD n==7, GORD n=1D, AD n=6, A1 n=6, 
~A2 n=12 and BOS n=12 
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3.3.4 Airway inflammation 
Grades of airway inflammation were highest in the clinically significant acute 
rejection group (~A2) (median B scores; 0 in AO, 1 in A 1 and 2 in ~A2. P=O.02 AO 
vs. ~A2) (figure 3.4 and table 3.1), showing a possible association between 
gastric reflux, inflammation and acute rejection. 
3.3.5 Potential confounding variables 
1. Time post transplantation. 
There was no relationship between time post transplant in all subjects and BAL 
pepsin level (r=O.144 P=O.4). 
2. A model including demographic variables. 
A model was examined to evaluate possibly confounding variables for BAL 
pepsin levels which included group, sex, age, operation type and antacid status. 
The adequacy of the model fit was examined and found to be reasonable. With 
a Bonferroni correction the conclusions reached in the basic analysis above were 
confirmed (i.e. A2 statistically significantly higher pepsin levels on average than 
the stable (P=O.006) or BOS (P=O.03) patient groups, with no significant 
difference between stable and BOS patient groups (P=O.9). 
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Figure 3.4. Acute rejection status vs. inflammation (8 score). Lines represent 
median values. AO n=7, A 1 n=6 and ~A2 n=11. 
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3.4 Discussion 
Ward et al have previously shown for the first time that pepsin, a marker of 
gastric aspiration, can be found in the airways of lung allograft recipients (Ward 
et al. 2005). This has now been confirmed in a larger group of patients, with more 
control data. It has also been shown that levels of pepsin were highest in lung 
allograft recipients with histologically verified A2 or greater acute rejection. 
Furthermore these patients have the highest grades of airway inflammation, 
suggesting a possible link between aspiration, acute rejection and inflammation. 
Alloimmune mechanisms have been the traditional focus of research and 
therapeutic intervention, however this study adds to the growing evidence that 
supports the role of non-alloimmune mechanisms as risk factors for the 
development of chronic lung rejection. Accumulating clinical evidence suggests 
that gastro-oesophageal reflux (GOR) with sequential aspiration may be an 
important source of injury and this is underlined by a recent paediatric lung 
transplantation study from Great Ormond Street, which showed that all patients 
had evidence of GOR post transplant, except one individual who had received a 
previous fundoplication for confirmed gastro-oesophageal reflux disease (GORO) 
(Senden et al. 2005). Additionally, Senden et al reported that all subjects with 
acute rejection had moderate to severe GORO and that no episodes of acute 
cellular rejection occurred post-Nissen fundoplication (Senden et al. 2005). The 
implication from this, as well as the finding of higher levels of pepsin in adult 
patients with A2 or greater acute rejection, is that non alloimmune injury may 
contribute to a pathology previously attributed solely to alloimmunity. 
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For this study acute rejection was defined as A2 or greater as this is the trigger to 
alter clinical management at the Freeman hospital. However, there has been 
debate on the importance of minimal acute rejection (A 1) as a risk factor for BOS 
(Hopkins et al. 2004; Khalifah et al. 2005). This study indicates that in A 1 
rejection pepsin levels were not raised. This could support the concept that 
aspiration injury is additive to alloimmunity, and where present, results in higher 
grades of injury. This is speculative however, and the suggestion of a possible 
association between acute rejection and gastric aspiration requires further 
studies which may in particular better define the role of A 1 rejection. 
As pepsin levels are elevated in all transplant recipients compared to controls, it 
would appear that aspiration may be an ongoing source of injury. It has 
previously been shown that other non-alloimmune injuries, such as ischemia-
reperfusion may further pre-dispose the transplanted lung to alloimmune injury 
(Serrick et al. 1997) and this study supports the importance of both alloimmune 
and non-alloimmune damage to overall injury in lung transplantation. 
The present findings and previous work indicate that a biomarker approach to 
studying gastric aspiration in lung allografts is informative and practicable. One 
such reason why biomarker approaches may be important is that calcineurin 
inhibitors and other drugs which may be augmented to treat presumed 
alloimmune rejection have adverse effects on gastric motility and may in fact pre-
dispose patients to aspiration. 
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The lack of any pepsin in the BAL samples from chronic cough patients, even 
when 10 patients out of 17 were diagnosed with GORD can be explained by the 
fact that a diagnosis of GORD does not mean that patients are refluxing out of 
the oesophagus and hence aspirating. Even if the refluxate reaches the upper 
airway it is almost certainly cleared by a hyper-active cough reflex (Niimi and 
Chung 2004). In contrast, lung allograft recipients are regarded as being 
especially vulnerable to aspiration since they have gastroparesis, impaired cough 
and an impaired mucociliary clearance (Higenbottam et al. 1989; Laube et al. 
2007). 
Clinical research in human patients is often limited to studies of association 
therefore; the use of animal models can provide important information. Work in a 
rat model of lung transplantation from the Duke group has shown that lung 
allografts challenged with gastric juice demonstrated severe grade 4 acute 
rejection with significant monocyte infiltration, fibrosis, and lung destruction 
(Hartwig et al. 2006). Aspiration was also associated with increases in CD8+ T 
cells and this 'proof of principle' study indicates that aspiration may indeed lead 
to pathological changes previously attributed to T cell, alloimmune based 
mechanisms (Takehisa et al. 2002; Boehler and Estenne 2003). 
This study does not seem to show an association between patients with BOS 
and higher levels of pepsin in the lavage. A potential explanation for this is that 
the study is cross sectional and subjects with BOS tend to be sampled at a later 
time point compared with the other groups, which is important as gastroparesis 
specifically associated with peri-operative vagal damage and early post 
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transplant events would be less marked. Further insights into this would be 
provided through longitudinal assessments of gastric aspiration and its 
relationship with allograft dysfunction. 
There is also increasing evidence to suggest that duodeno-gastro-oesophageal 
reflux may be involved in chronic lung rejection, as bile acids have been 
measured in the lavage of lung transplant recipients (Palmer 2006; Blondeau et 
al. 2008). Unlike pepsin, bile acids seem to show some association with the 
development of BOS. In one study from the Toronto group patients with bile 
acids present in their lavage had a lower freedom from BOS (D'Ovidio et al. 
2005). In a second study they also showed that higher levels of bile acids in the 
lavage fluid was associated with impaired lung allograft innate immunity, 
demonstrated by reduced surfactant collectins and altered phospholipids 
(D'Ovidio et al. 2006). 
This study has shown that patients who are being treated with maintenance 
proton pump inhibitors (PPI) still show evidence of gastric aspiration. On initial 
consideration this may be unexpected, however, approximately 12-20% of 
GORD patients are resistant to acid suppression therapy (Ahlawat et al. 2005) 
and, in addition, it is important to recognise that proton pump inhibitors do not 
prevent reflux per se., but rather act to reduce acidic reflux. Mildly acidic, neutral 
or alkaline reflux, which will still contain pepsin is not the target of PPI therapy but 
may still be an important source of aspiration injury, which requires a biomarker 
approach to monitor more accurately. It is therefore understandable that these 
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allograft patients will continue to reflux and aspirate when on maintenance acid 
suppression therapy. 
Consequently, alternative treatments should be considered. There is evidence 
from the Duke group to suggest that early fundoplicative surgery can provide a 
survival benefit. At 3 years post-transplantation patients that had been diagnosed 
with reflux and had an early fundoplication were 100% free from BOS, compared 
to 62% in patients with no history of reflux, 60% in those with a history of reflux 
and a late fundoplication and 47% in those with a history of reflux and no surgery 
(Cantu et al. 2004). Previously the Duke group did not perform pH studies on 
their patients. Now they assess all patients as part of their pre and post-operative 
evaluation and often fundoplicate within the initial hospitalisation for 
tran splantation. 
The general consensus is that fundoplication is a safe and effective treatment of 
GORD, however, there are some risks and putting patients that have already 
undergone a major surgery through another operation may not always be the 
answer. Assessing which patients will derive clinical benefit of GOR corrective 
surgery is therefore important to minimise unnecessary complications. 
In this study 24 hour oesophageal pH measurements were not taken. As 
mentioned previously such measurements would not tell us whether gastric 
contents have been aspirated into the lung, however, the patient is more likely to 
be aspirating if they are refluxing on a regular basis so future studies may benefit 
from combining traditional methods of monitoring reflux (Le. 24-hour pH 
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monitoring or 24h pH with impedance) with a more novel approach i.e. 
measuring biomarkers to get a more complete picture of what is happening in 
these patients. 
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Chapter 4 
Development of a plate ELISA for the 
measurement of pepsin 
4.1 Introduction 
Gastro-oesophageal reflux with subsequent aspiration is associated with many 
lung diseases as well as lung transplant rejection (Feigelson et al. 1987; Tobin et 
al. 1998; Brodzicki et al. 2002; Raghu 2003). Measuring biomarkers is becoming 
a useful tool in the diagnosis of aspiration. Previous investigations in our 
laboratory have shown that pepsin is present in the bronchoalveolar lavage 
(BAL) of transplant patients using a slot/blot ELISA (Ward et al. 2005; Stovold et 
al. 2007); however the manufacturer of the nitrocellulose membranes required for 
the slot/blot ELISA changed, and as a result the membranes no longer work 
within the assay. In addition, the slot/blot can only process a relatively small 
number of samples at a time. It was therefore decided to change the format of 
the assay to allow a higher through-put of samples. 
The aim was to develop a new ELISA assay that can detect the gastric enzyme 
pepsin in BAL. As well as having a high through-put of samples the assay should 
have a sensitivity range that covers levels of pepsin expected within 
bronchoalveolar lavage, for example, BAL found positive for pepsin using the 
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slot/blot had levels ranging from 1.3 to 51.7ng/ml, therefore the new assay 
should also be able to detect pepsin levels in the range of 1 ng/ml. 
The assay should be reproducible to allow comparisons between patient's 
samples and also between different patients. This can be measured by 
comparing standard curves from different assays and also including an internal 
standard in the assay. The assay should be relatively simple and as well as 
analysing more samples should not take too long to run. 
The assay should be specific for pepsin, therefore antibodies should not cross 
react with any other proteins likely to be present in the lavage, for example 
certain serum proteins (for example albumin or V-globulins) and should also 
measure pepsin in the presence of molecules that may interfere with antibody 
binding, for example mucins. The slot/blot ELISA was initially used as mucus can 
be a problem in plate ELlSAs. 
Currently, there are other centres world-wide using pepsin as a marker of 
aspiration; however, there is a wide variation in levels being reported. For 
example, Siondeau et al report levels over 1000ng/ml in SAL using an ELISA 
based method, whilst Metheney et al are measuring pepsin in tracheal aspirates 
using a gel based immunoassay and give either a positive or negative result with 
no quantitation and also measuring pepsin in tracheal aspirates in children, 
Farhath et al use a proteolytic assay and report levels over 2000ng/mg of protein 
(Metheny et al. 2006; Siondeau et al. 2008; Farhath et al. 2008). In addition, 
there are some groups who use bile salts as a marker of duodenal/gastric 
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aspiration instead of or as well as pepsin, as there is some evidence that bile 
salts correlate with BOS development (D'Ovidio et al. 2005; Blondeau et al. 
2008). 
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4.2 Development of a sandwich ELISA for the determination of pepsin 
concentration 
To improve through-put of samples the assay was changed from a membrane 
based, to a 96-well plate ELISA. Sandwich ELlSAs generally demonstrate good 
sensitivity so this was the preferred format to begin with. To my knowledge there 
were no commercial human pepsin antibodies available at the time (December 
2006), so a human pepsinogen antibody was acquired for use as the capture 
antibody (anti-human pepsinogen I, Europa Bioproducts, UK), along with the 
porcine pepsin antibody used in the previous assay as the detection (anti-porcine 
pepsin, Biodesign Intemational, USA). Pepsinogen is the inactive form of pepsin 
and loses only 44 amino acids to become pepsin below pH 5 (chapter 1.2.2, 
figure 1.9), therefore the pepsinogen antibody should also recognise pepsin in 
our assay, unless it reacts with the 44 amino acids that are lost in the conversion 
process. 
The pepsinogen antibody did not come with any suggested dilutions for use from 
the manufacturer; therefore a range from 1/10 to 1/2000 was investigated using 
standard curves with porcine pepsin (porcine pepsin A, Sigma, UK). However, no 
pepsin was detected, suggesting that the human pepsinogen antibody does not 
bind porcine pepsin. Consequently the porcine pepsin was replaced with human 
pepsinogen (human pepsinogen I, Sigma, UK) as the standard. Different 
concentrations of human pepsinogen were tried with increasing antibody 
concentrations; however there was still no detection. 
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Previous investigations have shown that the pepsin antibody from Biodesign will 
bind porcine pepsinogen; however, it is much less sensitive. At 1IJg/ml of protein 
there is a ten-fold difference in antibody binding between pepsin and pepsinogen 
(Tasker 2003). Therefore the pepsinogen was incubated with hydrochloric acid at 
pH 2.0 for 1 h at room temperature in an attempt to convert it to pepsin, hopefully 
allowing more efficient binding of the antibodies. 
Using activated human pepsinogen as the standard gave a general increase in 
absorbance with increased concentration, showing evidence of some antibody 
binding, however the increase was very small with a poor r2 value (slope=0.0009, 
r2=0.6526 figure 4.1). Consequently the pepsinogen antibody was replaced with 
the anti-porcine pepsin to act as both the capture and detection antibody 
(recommended dilutions were 1/2000 and 1/10000 respectively). The detection 
antibody was conjugated to horseradish peroxidase to allow substrate binding. 
Standard curves were run with porcine pepsin, human pepsinogen and activated 
human pepsinogen. The porcine pepsin standard curve (O-10ng/ml) was 
acceptable (r2=0.9976, slope=0.042 figure 4.2) and was therefore chosen for use 
in future assays. 
4.2. 1 Determination of antibody concentrations 
To ensure nothing in the bronchoalveolar lavage would interfere in the assay 
spiking experiments were performed by adding a known amount of porcine 
pepsin to lavage samples that contained little or no pepsin and measuring the 
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recovery. Three samples were chosen and pepsin was added to give a final 
concentration of 5, 10, 15, 20 and 40ng/ml. Values recovered from the BAL can 
be seen in table 4.1. 
Percentage recovery was lowest in the samples spiked with 40ng/ml pepsin (47-
54 %) and was best at 10ng/ml (74-95%). To try to improve recovery the capture 
antibody concentration was increased to 1/1000 and 1/500. Spiking experiments 
were repeated using one sample made up to give a final concentration of 10, 20 
or 40ng/ml (table 4.2). 
104 
0.025 
E 
t: 0.020 II) 
0 
~ 
@ 0.015 
CI) 
(,) 
t: 0.010 ca 
.c 
... 
0 
fA 
.c 
« 
0.000 
0 1 2 3 4 5 6 7 8 9 10 11 12 
Pepsinogen ng/ml 
Figure 4.1 Standard curve with SEM from a sandwich ELISA with anti-human 
pepsinogen as the capture antibody (1/100), anti-pepsin as the detection 
antibody (1/100) and activated human pepsinogen as the standard. r2=0.6526, 
slope=0.0009. Data is representative of 2 experiments. 
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Figure 4.2 Standard curve with SEM from a sandwich ELISA using anti-porcine 
pepsin as both the capture (1/2000) and detection antibody (peroxidase 
conjugated, 1/10000) with porcine pepsin as the standard. r2=0.9976, 
slope=0.042. Data is representative of 6 experiments. 
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Pepsin ng/ml Neat 5 10 15 20 40 
--* SAL 
Sample 1 
A 0.2 3.1 9.5 11.6 15.8 21.6 
62% 95% 77% 79% 54% 
B 0.9 3.9 8.4 8.6 13.8 18.7 
78% 84% 57% 69% 47% 
C 0.1 3.3 7.4 11.3 14.6 20.0 
66% 74% 75% 73% 50% 
Table 4.1 Values of pepsin in ng/ml and percentage recovery from 
bronchoalveolar lavage spiked with porcine pepsin. Neat values (pepsin 
recovered from SAL with no added pepsin) have been subtracted from the spiked 
samples. The capture antibody was diluted to 1/2000 and the detection 1/10000. 
Data is representative of 3 experiments. 
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Capture antibody 1/2000 1/1000 1/500 
dilution (T aken from table 
---+ above) 
NeatBAL 0.2 0 0 
10ng/ml 9.5 6.9 6.1 
95% 69% 61% 
20ng/ml 15.8 15.3 15.0 
79% 77% 75% 
40ng/ml 21.6 26.6 31.5 
54% 67% 79% 
Table 4.2 Values of pepsin in ng/ml and percentage recovery from 
bronchoalveolar lavage spiked with porcine pepsin. Neat values have been 
subtracted from the spiked samples. Differences in levels recovered from neat 
SAL are due to interassay variation. Detection antibody was diluted t01/1 0000. 
Data is representative of 3 experiments. 
108 
The standard curves (0-20ng/ml) for the different antibody dilutions (1/2000, 
111000 and 1/500) were also compared (~=0.9902, 0.9935 and 0.9921 
respectively). As 1/1000 gave a slightly better r2 value and would use less 
antibody than 1/500, this dilution was used for further assays. 
Spiking experiments were performed in a new SAL sample (made up to either 20 
or 50ng/ml pepsin) with the new capture antibody concentration (1/1000) and 
with dilutions (1/2,114 or 1/8 for 20ng/ml and 1/4 for 50ng/ml) to ensure the levels 
fit within or near to the top end of the standard curve (0-10ng/ml). Samples that 
were previously run using the slot/blot technique were also analysed to compare 
the assays (tables 4.3.1 and 4.3.2). 
4.2.2 Removing interference within the sandwich ELISA 
Pepsin recovery was poor in the spiked SAL at 50ng/ml (68% for neat and 38% 
when diluted 1/4, table 4.3.1) and also in the previously measured lavage. Levels 
were much lower than expected in samples 2, 3 and 4 (13%, 26% and 19% of 
expected based on the slot/blot ELISA respectively, table 4.3.2), suggesting that 
there was some interference within the assay, preventing the pepsin antibody 
binding the pepsin in the lavage. In an attempt to overcome this interference 
wells were saturated with capture antibody in the hope that there would still be 
enough available to capture any pepsin in the SAL despite the interference. 
Capture antibody was diluted 1/100 and the samples previously measured using 
the slot blot were repeated (table 4.3.2). Samples 1, 2 and 4 all measured higher 
levels of pepsin than when using the antibody at a dilution of 1/1000 (table 4.3.2). 
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However, levels were still not as high as previously measured in samples 2, 3 
and 4 (29%, 14% and 41 % of expected levels respectively) and the recovery in 
sample 1 was 263%. 
Spiking experiments were also performed for 1, 5, 10 or 50ng/ml and recovery 
was still varied despite the increase in capture antibody concentration (range 80-
136%, table 4.3.3), suggesting further investigations were required. 
In an attempt to remove any small molecules that may interfere in the assay BAL 
samples were spiked with 5, 10 or 50ng/ml pepsin and then split into two. Half of 
the sample was dialysed against phosphate buffered saline (PBS) overnight at 
4°C. Both dialysed and non-dialysed samples were analysed using the ELISA 
and compared. 
There was an improvement in pepsin recovery from BAL spiked with 10ng/ml 
porcine pepsin after dialysing the samples (table 4.4); however recovery was 
over 200% for 5ng/ml and was not improved for 50ng/ml. This wide variation in 
levels recovered suggests that small molecules within the BAL were not causing 
the interference. To attempt to remove any larger molecules that may cause 
interference spiked BAL samples (5, 10 and 50ng/ml) were centrifuged for 10 
minutes at 14000 rpm and room temperature (Eppendorf microcentrifuge, 
Germany). The recovery of pepsin in the centrifuged samples was improved for 
samples spiked with 5ng/ml (92% vs. 192% in non-centrifuged samples) however 
spiking with other concentrations was not consistent enough even to allow for a 
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correction factor (recovery ranged from 45% to 165%, table 4.4); therefore further 
investigations were still requited. 
The standard curve used to determine the pepsin concentration is linear between 
o and 10ng/ml and is presumed to remain linear above 10ng/ml. However if this 
was not the case any extrapolated values above 10ng/ml could be incorrect. 
Therefore a standard curve using porcine pepsin of between 0 and 1 OOng/ml was 
carried out to ensure that it remained linear above 10ng/ml (figure 4.3). The 
standard curve was linear up to 100ng/ml; therefore, the difference in recovery 
for more concentrated samples can not be explained by non-linearity. 
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Sample Recovered pepsin ng/mll % 
NeatBAL 0.6 
20ng/ml 15.4 
77% 
20ng/ml diluted 1/2 15.5 
78% 
20ng/ml diluted 1/4 18.7 
94% 
20ng/ml diluted 1/8 16.4 
82% 
50ng/ml 34.2 
68% 
50ng/ml diluted 1/4 19.0 
38% 
Table 4.3.1 Values of pepsin in ng/ml and percentage recovery from 
bronchoalveolar lavage spiked with porcine pepsin. Neat values have been 
subtracted from the spiked samples. Capture antibody was diluted to 1/1000 and 
detection to1/10000. Data is representative of 3 experiments. 
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Previously SloUblot Sandwich ELISA Sandwich ELISA 
measured samples results (1/1000 capture) (1/100 capture) 
1 6.4 5.1 16.8 
80% 263% 
2 51.7 6.5 14.8 
13% 29% 
3 8.1 2.1 1.1 
26% 14% 
4 10 1.9 4.1 
19% 41% 
Table 4.3.2 Values of pepsin ng/ml and percentage recovery of expected based 
on the sloUblot from BAL using a sloUblot and a sandwich ELISA. Capture 
antibody dilutions are stated in the table and detection was diluted to 1/10000. 
Data is representative of 2 experiments for the slot/blot and 3 experiments for the 
sandwich ELiSAs. 
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Sample Recovered pepsin ng/ml and % 
Neat SAL 0 
1 ng/ml 0.8 
80% 
5ng/ml 5.4 
108% 
10ng/ml 11.3 
113% 
f- --~~-- -- ------- ----
50ng/ml 68.0 
136% 
50ng/ml diluted 1/10 46.2 
92% 
Figure 4.3.3 Values of pepsin in ng/ml and percentage recovery from 
bronchoalveolar lavage spiked with porcine pepsin. Capture antibody was diluted 
to 1/100 and detection t01/1 0000. Data is representative of 3 experiments. 
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Sample Spiked SAL (no dialysis Dialysed Centrifuged 
or centrifugation) 
SAL spiked with 5ng/ml 9.6 14.6 4.6 
192% 292% 92% 
SAL spiked with 10ng/ml 6.6 9.0 15.4 
66% 90% 154% 
SAL spiked with 50ng/ml 34.1 31.9 82.5 
68% 64% 165% 
SAL spiked with 5ng/ml 9.7 2.2 3.4 
Diluted 1/10 194% 44% 68% 
SAL spiked with 10ng/ml 12.8 2.2 4.5 
Diluted 1/10 128% 22% 45% 
SAL spiked with 50ng/ml 26.4 19.6 38.2 
Diluted 1/10 53% 39% 76% 
-~ 
Table 4.4 Values of pepsin ng/ml and % recovery from spiked SAL, spiked SAL 
that has been dialysed against PBS overnight at 4°C and spiked SAL that has 
been centrifuged at 14000rpm for 10 minutes. Capture antibody was diluted to 
1/100 and detection 1/10000. Data shows the average of 2 experiments. 
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Figure 4.3 Standard curve with SEM from a sandwich ELISA using anti-porcine 
pepsin as both the capture (1/100) and detection antibody (peroxidase 
conjugated, 1/10000) with porcine pepsin as the standard. r2=0.9952, 
slope=0.0222. Data is representative of 2 experiments. 
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With the dialysis and centrifugation steps failing to eliminate the variability in the 
assay, a literature search using Medline was performed to identify other possible 
interfering factors. One search documented the presence of human anti-animal 
antibodies as an interfering factor in immunoassays (Kricka 1999). The most 
common human anti-animal antibody is human anti-mouse, however human anti-
rabbit, -goat, -sheep, -cow,-pig, -rat, and -horse have been identified and they 
can cause both false positive and false negative results within immunoassays 
(figure 4.4). 
The Siodesign pepsin antibody is raised in goat; therefore if the SAL samples 
contained any human anti-goat it is possible that they could bind to the pepsin 
antibody and prevent it from capturing or detecting any pepsin present in the 
sample. The suggested solution to prevent this type of interference is to incubate 
the sample with a blocking agent containing IgG from the animal, in this case 
goat. This seemed like a sensible step to take, as whatever is causing the 
interference, whether it be human anti-goat or not, it could bind to goat IgG 
instead of the anti-pepsin, allowing more antibody to bind pepsin within the 
sample, reducing the possibility of a false negative result. 
Spiking experiments giving a final concentration of 1, 5, 10 or 50ng/ml were 
repeated, this time adding 50ng/ml goat IgG to the reagent buffer used to dilute 
samples and make up the standard curves. The average recovery was 100.2% 
(range 61-126%, excluding recovery for 1 ng/ml as it is an outlier and also the 
lowest level of detection, table 4.5). Although the recovery was not 100% in all 
117 
samples it was improved and the variation was reduced, therefore the goat IgG 
was included in future assays. 
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Figure 4.4 A schematic representation of how human anti-animal antibodies can 
cause interference within immunoassays and how including animal IgG can 
reduce this interference. 
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Spiked sample t Recovered pepsin 
ng/ml and % 
BAL spiked with 1 ng/ml 2.34 
234% 
BAL spiked with 5ng/ml 3.07 
61% 
BAL spiked with 10ng/ml 10.32 
103% 
BAL spiked with 50ng/ml 48.12 
96% 
BAL spiked with 5ng/ml 4.55 
Diluted 1/5 91% 
BAL spiked with 10ng/ml 11.36 
Diluted 1/5 114% 
BAL spiked with 50ng/ml 62.99 
Diluted 1/5 126% 
BAL spiked with 5ng/ml 3.46 
Diluted 1/10 69% 
BAL spiked with 10ng/ml 8.7 
Diluted 1/10 87% 
BAL spiked with 50ng/ml 47.07 
Diluted 1/10 94% 
Table 4.5 Values of pepsin in ng/ml and percentage recovery from 
bronchoalveolar lavage spiked with porcine pepsin. Capture antibody was diluted 
to 1/100 (with buffer containing 50ng/ml goat IgG) and detection t01/10000. Data 
shows the average of 3 experiments. 
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To summarise, the sandwich ELISA was performed using a porcine pepsin 
standard with a porcine pepsin antibody (Biodesign International, USA) as both 
the capture (1/100) and detection (HRP-conjugated, 1/10000). Samples were run 
neat and with a 1 IS dilution to ensure they fit within the standard curve and 
samples and standards were diluted in buffer containing 50nglml goat IgG. 
4.3 Production of a human gastric protein standard 
After ethical approval was granted it was possible to collect gastric juice samples 
from patients undergoing endoscopy. These samples could then be used as 
controls to further validate the assay, as up until this point only porcine pepsin 
had been used in the spiking experiments since human pepsin is not 
commercially available. Four samples were collected and analysed with the 
sandwich ELISA. The basal level of pepsin in the gastric juice is approximately 
200jJg/mi in normal subjects (Pearson et al. 1986), however, this may be an over 
estimation as some of the patients used to collect gastric juice from were on 
proton pump inhibitors, therefore a range of dilutions were performed up to 
1/40000 (to give approximately Sng/ml) to ensure the samples fit within the 
standard curve and did not saturate the plate (table 4.6). 
There was a very large variation in levels measured over the different dilutions. 
This could be a result of either errors being multiplied up when accounting for the 
dilution, i.e. an error of only 0.5ng/ml becomes 20000ng/ml when multiplied up by 
40000, or when diluting the sample it is possible that any interfering factor is also 
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being diluted out allowing the antibodies to bind more pepsin, or it could be a 
combination of both. 
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Dilution of Sample 1 Sample 2 Sample 3 Sample 4 
gastric juice 1 
Neat juice 0 1.56 24.38 0 
1/4 0 2.4 111.98 0.44 
1/20 35.03 4.52 12.57 33.01 
1/100 226.9 3.88 29.78 221.14 
1/1000 1261.78 269.01 556.77 1506.38 
1/10000 6862.63 3121.75 9020.84 12042.32 
1/40000 20544.28 14213.55 29752.61 28601.57 
_.-
Table 4.6 Values of pepsin in ng/ml measured in 4 samples of gastric juice over 
a range of dilutions using the sandwich ELISA (capture antibody diluted 1/100 
and detection diluted 1/10000). Samples have been multiplied by the dilution 
factor. These values are from a single experiment. 
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As detailed previously, human pepsin is not commercially available so the gastric 
juice was purified to produce a human pepsin standard. 
Pooled samples 1-4 were adjusted to a density of 1.42g/ml with caesium chloride 
and fractionated by ultra-centrifugation at 4°C and 40000rpm for 48h (Centrikon 
T-1170). The resulting 8 fractions were separated and weighed to ensure a 
density gradient was present (1.33-1.58g/ml, table 4.7). Each fraction was then 
exhaustively dialysed against deionised water for 3 days with 4-6 changes per 
day. 
After dialysis the absorbance of each fraction was measured at 260 and 280nm 
on a spectrophotometer to determine the location of protein (Le. pepsin 
containing fractions table 4.7). Protein containing fractions 1-3 were freeze dried. 
As fraction 1 contained a precipitate it was centrifuged for 5 minutes at room 
temperature and 1500rpm (Centra-3, lEG) prior to freeze-drying. The pellet and 
supernatant were freeze-dried separately. 
The individual freeze-dried fractions were run on an SDS-PAGE gel using the 
Pharmacia PHAST gel system to determine whether they contained pepsin. The 
freeze dried fractions and two porcine pepsin controls were made up to a 
concentration of 2.5mg/ml in a reducing buffer. 51J1 of each fraction/control was 
loaded onto the gel (chapter 2.3.2.1). Gels were stained for protein using the 
coomassie blue method and were then scanned on a densitometer (GS-800, 
Biorad, UK). The relative mobility of each of the fractions was determined by 
calculating the distance moved into the gel from the point of application (table 
124 
4.8). Fractions 1 (supernatant), 2 and 3 contained just one major band that 
moved a similar distance to the porcine pepsin; therefore it can be presumed that 
they contain a protein with the same molecular weight (approximately 35KOa). 
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Fraction Density g/ml Optical Density 
260nm 280nm 
1 1.33 2.522 Off scale 
2 1.35 1.046 1.304 
3 1.39 0.640 0.720 
4 1.40 0.401 0.414 
5 1.42 0.512 0.503 
6 1.46 0.402 0.448 
7 1.49 0.434 0.455 
8 1.58 0.516 0.456 
Table 4.7 Density in g/ml and optical density at 260 and 280nm of each fraction 
of the pooled gastric juice samples. Fraction 1 contained a dark green precipitate 
resulting in the absorbance being off the top of the scale at 280nm. 
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Sample Relative mobility Protein concentration 
compared to control 
average (mg/ml) 
Control 1 0.59 
Control 2 0.58 
Fraction 1 (pellet) 0.77 8.89 
Fraction 1 (supernatant) 0.60 0.14 
Fraction 2 0.59 1.15 
Fraction 3 0.60 0.04 
Table 4.8 Relative mobility (the distance moved from loading divided by the 
distance moved by the tracking dye) for each protein containing fraction obtained 
from purifying human gastric juice. Protein concentration compared to the 
average of the controls has also been calculated using the optical densities of 
each fraction. 5iJI of a 2.5mg/ml solution of the freeze-dried fraction was used to 
run the gel. 
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Staining the gel with coomassie blue allowed a semi-quantitative value for the 
protein concentration of each fraction (compared to the average of the porcine 
pepsin controls) to be calculated using the optical densities (table 4.8). Each 
fraction was made up to a concentration of 2.5mg/ml; however this was not 
reflected in the levels calculated by the protein assay (lower concentrations were 
seen in fractions 1 (supernatant). 2 and 3). This suggested that the freeze-dried 
fractions 1 (supernatant), 2 and 3 contained other non-protein components. 
Fraction 1 (pellet) had a high relative mobility compared to the porcine pepsin 
and also contained 8.89mg/ml protein, which was not plausible since only 
2.5mg/ml was originally added, suggesting the fraction contained contaminants 
and was consequently discarded. 
4.3.1 Determination of protein concentration of the purified gastric juice by ELISA 
The remainder of the fractions were assayed for pepsin using the sandwich 
ELISA. The fractions were made up to a concentration of 1 mg/ml pepsin, 
assuming that all the protein in the freeze-dried fraction was pepsin (Le. fraction 
2 contained 46% protein; therefore to make a 1 mg/ml pepsin solution 4601-11 of 
reagent buffer should be added to 1 mg of fraction 2). Fractions 1 and 3 came 
back negative and fraction 2 only contained 0.48ng/ml, suggesting that either the 
purification process had not been successful or that the ELISA was not 
recognising human pepsin. 
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To further validate the assay purified human pepsin (pepsin 3A, ion-exchange 
HPLC purified, donated by Technostics, UK) was used to run human pepsin 
standard curves using the sandwich ELISA (0-50ng/ml, figure 4.5). There was an 
increase in absorption with increasing pepsin concentration, however the 
increase was very small (slope=0.0004 compared to 0.0346 for porcine pepsin) 
and therefore could not be used. 
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Figure 4.5 Standard curve with SEM from a sandwich ELISA with anti-porcine 
pepsin as both the capture (diluted to 1/100) and detection (1/10000) with human 
pepsin as the standard (Technostics, UK). r 2 =0.9924, slope=0.0004. This data is 
representative of 2 experiments. 
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4.4 Development of a direct ELISA for the determination of pepsin 
concentration 
Based on the absorbance measured with 50ng/ml pepsin the antibody appears to 
be approximately 50 times less sensitive to human pepsin (Technostics, UK) 
than porcine pepsin (Sigma, UK) in the sandwich format (absorbance for 50ng/ml 
pepsin was 0.021 and 1.099 respectively when the substrate was read at 
405nm). It is possible that the lack of sensitivity is related to the number of 
epitopes that are available for antibody binding, and if so, it would appear that 
there are more on porcine pepsin, allowing increased sensitivity. As the sloUblot 
ELISA appeared to demonstrate a better sensitivity using a single antibody it was 
decided to return to this direct format in a 96 well plate. 
Human and porcine pepsin standards (Technostics and Sigma, UK respectively) 
of between 0-50ng/ml were coated onto a plate overnight at room temperature 
and were then incubated with the pepsin antibody (Biodesign International, USA) 
diluted to 1/2000 according to manufacturer's suggestion, followed by a 
secondary, horseradish peroxidase conjugated, antibody (anti sheep/goat, Sigma 
UK) diluted 1/10000. Once the substrate had been added and colour allowed to 
develop the plate was read at 405nm on a standard plate reader. Both human 
and porcine pepsin showed an increase in absorbance with increasing pepsin 
concentration (~ =0.9838, slope=0.0104 and ~ =0.9871, slope=0.0190 
respectively, figure 4.6). However, the porcine standards gave twice the 
absorbance of the human standards, demonstrating that the antibody is twice as 
sensitive to porcine pepsin as human pepsin. 
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Figure 4.6 Porcine and Human pepsin standard curves with SEM from a direct 
ELISA using anti-pepsin (1/2000) followed by anti sheep/goat (peroxidase 
conjugated 1/10000). Porcine pepsin: ~=0.9877, slope = 0.019, human pepsin: 
~=0.9858, slope = 0.010. The graph demonstrates that the Biodesign antibody is 
twice as sensitive to porcine pepsin than human pepsin (absorbencies at 20,30 
and 40ng/ml are 0.281 vs. 0.164, 0.543 vs. 0.271 and 0.748 vs. 0.383 
respectively). Data is representative of 3 experiments. 
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4.4.1 Differences in antibody reactivity with human and porcine pepsin 
To further understand the relationship between porcine and human pepsin 
antibody binding spiking experiments were performed by making SAL up to a 
concentration of 5, 20 or 50ng/ml using either human or porcine pepsin 
(Technostics UK and Sigma UK respectively). Levels were measured using both 
human and porcine standard curves (table 4.9). 
When analysing SAL spiked with human pepsin, recovery using the human 
pepsin standard curve is approximately twice that of when using the porcine 
pepsin standard curve (average percentage recovery is 14.7% and 6% 
respectively). Again, this data suggests that the antibody is approximately twice 
as sensitive to porcine pepsin as human pepsin. Using this information 
commercially available porcine pepsin can be used as a standard throughout the 
assay; however a correction factor of 2 is required when analysing human 
samples. 
Human and porcine pepsin recovery from the SAL is poor when using either the 
human or porcine pepsin standard curve to analyse the samples (maximum 
recovery is 16% in SAL spiked with human pepsin using the human standard 
curve and 30% in SAL spiked with porcine pepsin using the porcine standard 
curve). As well as demonstrating that the recovery is poor this data also suggests 
that the recovery of human pepsin from SAL is worse than porcine pepsin even 
when using a human pepsin standard, or that the human pepsin standard is not 
quite as pure as the porcine pepsin standard. 
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Sample Recovered pepsin using Recovered pepsin using 
human pepsin standard porcine pepsin standard 
curve ng/ml curve ng/ml 
NeatBAL 3.4 1.5 
.. --- --- -- -- - ----- ~ -- ~----~- --- -- "-- -" - -------- ~~ ----- ---- ---- --- --- - -~ 
BAL spiked with 5ng/ml 2.7 1.2 
porcine pepsin 54% 24% 
BAL spiked with 11.7 4.9 
20ng/ml porcine pepsin 59% 25% 
BAL spiked with 36.7 15.2 
50ng/ml porcine pepsin 73% 30% 
BAL spiked with 5ng/ml 0.8 0.3 
human pepsin 16% 6% 
BAL spiked with 2.7 1.2 
20ng/ml human pepsin 14% 6% 
BAL spiked with 7.2 3.1 
50ng/ml human pepsin 14% 6% 
Table 4.9 Values of pepsin (ng/ml) and percentage recovery from BAL spiked 
with human or porcine pepsin (Technostics, UK and Sigma, UK respectively) 
using either human or porcine standard curves. Neat values have been 
subtracted from the spiked samples. Data shows the average of 2 experiments. 
-
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4.4.2 Improving recovery of pepsin in BAL samples 
To investigate how to improve recovery of pepsin in the BAL spiking experiments 
were performed by adding a known concentration of fraction 2 of the purified 
gastric juice (henceforth termed 'purified gastric protein') to phosphate buffered 
saline (PBS) and BAL to compare recovery rates, since PBS should contain no 
contaminating factors. Recovery of pepsin (using the purified gastric protein) in 
the BAL was poor (table 4.10) so BAL was diluted before a known concentration 
of purified gastric protein was added to investigate whether the interfering factor 
could be diluted out. A solution of purified gastric protein (1.Bmg/ml purified 
gastric protein in deionised water) was used to spike PBS, BAL and diluted BAL 
(1/5 with PBS). Recovery compared to levels measured in PBS was on average 
33% in neat BAL and 112% in diluted BAL (table 4.11), suggesting that the 
recovery can be improved by diluting BAL 1/5. Differences in levels measured 
with each run suggests that the pepsin was not homogenous throughout the 
purified gastric protein, however the purified protein can still be used to 
investigate recovery if the same solution is used to spike the PBS, neat BAL and 
diluted BAl. These results also suggest that not all of the protein in the purified 
gastric protein is pepsin, even though only one band was present on the SDS-
PAGE gel when the gastric juice was purified. This suggests that the other 
protein components have a large molecular weight and therefore stayed at the 
origin, or have a low molecular weight and have run off the end of the gel. 
Spiking experiments were repeated to ensure reproducibility using an alternative 
substrate (tetramethylbenzidine (TMB), R&D systems). Again, a solution of 
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purified gastric protein (1 mg/ml purified gastric protein in deionised water) was 
used to spike PBS, neat BAL and BAL diluted 1/5 in PBS. Interestingly recovery 
was higher in neat BAL than PBS and diluted SAL with the alternative substrate, 
however compared to PSS average recovery was 91 % in diluted BAL and 148% 
in neat SAL which again demonstrates that diluting the SAL gives a more 
accurate measurement of pepsin (table 4.12). 
Previous investigations have shown that the pepsin antibody shows a small 
amount of non-specific reactivity with the serum proteins albumin and y-globulins, 
however antibody binding of only 3.5% and 0.9% of that for 11-1g of porcine pepsin 
was observed for 200l-lg of y-globulins and albumin respectively (Tasker 2003). 
To assess the reproducibility of the assay the coefficient of variation (CV) was 
calculated using an intemal standard by dividing the standard deviation by the 
mean. The mean Intra-assay CV was 6.1 % with a mean inter-assay CV of 9.7%. 
In conclusion, human pepsin can be measured with a direct 96-weJl plate ELISA 
using a porcine pepsin antibody (Siodesign Intemational, USA) and a porcine 
pepsin standard. However a correction factor of 2 must be included to allow for 
human/porcine differences in antibody binding and also, bronchoalveolar lavage 
(SAL) should be diluted 1/5 to remove any factors that may interfere with the 
detection of human pepsin. Negative controls should also be performed for all 
samples to eliminate any background readings by omitting samples from the 
primary antibody incubation. 
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Concentration of purified Recovered pepsin from Recovered pepsin from 
gastric protein PBS ng/ml BAL ng/ml 
250ng/ml 12.6 0.6 
500ng/ml 35.0 0.6 
1000ng/ml 64.0 0.8 
Table 4.10 Values of pepsin recovered from purified gastric protein diluted in 
PBS and BAL. Levels have been multiplied by 2 to correct for human/porcine 
differences in antibody binding. Data is representative of 3 experiments. 
137 
Sample Recovered pepsin 
ng/ml 
1.6mg/ml solution of purified 684.1 
gastric protein diluted 1/10 in 
PBS 
1.6mg/ml solution of purified 224.3 
gastric protein diluted 1/10 in (33% of pepsin 
recovered from PBS) 
neat BAL 
1.6mg/ml solution of purified 765.4 
gastric protein diluted 1/10 in (112% of pepsin 
recovered from PBS) 
BAL diluted 1/5 with deionised 
water 
Table 4.11 Values of pepsin in ng/ml recovered from PBS, neat BAL and diluted 
BAL spiked with purified gastric protein. Values have been multiplied up by the 
dilution factor and have also been corrected for differences in human/porcine 
antibody binding. Data shows the average of 2 experiments. 
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Sample t pepsin recovered ng/ml and % of PBS 
recovery 
PBS 1408.1 
Neat BAL 2083.7 
148% 
BAL diluted 1/5 1285.5 
(in deion ised 91% 
water) 
Table 4.12 Values of pepsin in ng/ml recovered from PBS, neat BAL and diluted 
BAL spiked with purified gastric protein. Values have been multiplied up by the 
dilution factor and have also been corrected for differences in human/porcine 
antibody binding. Data shows the average of 5 experiments. 
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4.5 Discussion 
Gastric aspiration is well documented in many lung diseases as well as lung 
transplant rejection (F eigelson et al. 1987; Tobin et al. 1998; Brodzicki et al. 
2002; Raghu 2003). Measuring biomarkers is becoming increasingly important in 
identifying which patients are aspirating gastric content into the lungs and are 
therefore most likely to benefit from anti-reflux treatment. Previously in our 
laboratory, pepsin levels were measured in the bronchoalveolar lavage (BAL) of 
transplant patients using a sloUblot ELISA (Ward et al. 2005; Stovold et al. 2007). 
This assay was however limited in the number of samples it could process at a 
time, therefore, a new assay was developed based on a 96-well plate format. 
Through a series of investigations I have shown that the new plate ELISA fulfils 
the necessary requirements of the assay set out before development began. 
These investigations have shown that with a correction factor, the assay, based 
on a porcine pepsin antibody can measure human pepsin using porcine pepsin 
as a standard. The assay has a lower limit of detection of 1ng/ml showing it is 
sensitive enough to measure levels of pepsin previously determined using the 
sloUblot ELISA. Finally, the inter-assay coefficient of variance was 9.7% 
indicating that the assay is reproducible. 
Despite sandwich ELiSAs generally demonstrating good sensitivity this was not 
the case for pepsin and therefore a direct format was chosen instead. This lack of 
pepsin detection using the human pepsinogen and the porcine pepsin antibodies 
as a pair could be explained by a number of things; firstly, the capture antibody 
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(anti human pepsinogen) may not be capable of binding human or porcine 
pepsin, as it may recognise part of the 44 amino acid chain that is lost when 
pepsinogen is converted to pepsin. This could be investigated using pepstatin, as 
this is part of the 44 amino acid sequence that is lost during pepsinogen 
conversion. Secondly, it is possible that the capture antibody can bind human 
and porcine pepsin, but when the capture antibody is bound the epitope for the 
detection antibody (anti porcine pepsin) is obstructed, or, finally it is also possible 
that the capture antibody can recognise human pepsin but only poorly. This may 
be the case as when activated human pepsinogen was used as the standard 
there was an increase in absorbance with an increase in concentration, however 
it was a very small increase, suggesting poor antibody binding (figure 4.1). 
The lack of sensitivity of the sandwich ELISA when using the porcine pepsin 
antibody as both the capture and detection could be explained by porcine pepsin 
having two epitopes available for the antibody to recognise and human pepsin 
having only one. If human pepsin only contained one epitope it could be captured 
but not detected. This would also explain the two fold difference in antibody 
reactivity between porcine and human pepsin when using the direct format, as 
there are twice the number of epitopes available on porcine pepsin there is twice 
the antibody binding and therefore twice the detection (figures 4.6 and 4.7). 
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Figure 4.7 A proposed model of porcine pepsin antibody reactivity with porcine 
and human pepsin in a sandwich and a direct ELISA format. 
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The direct ELISA gives a more accurate measurement of pepsin in lavage, 
however, there was some interference that needed to be removed before SAL 
samples could be successfully analysed. The main reason for using the sloUblot 
technique was to avoid any interference caused by mucin and as it is likely that 
the BAL samples would contain some airway mucins; this could provide a 
potential explanation for the interference. Another possible interfering factor could 
be human anti-animal antibodies, as they have been shown to cause interference 
in immunoassays (Kricka 1999) and figure 4.4); however it is unlikely that all the 
patient's samples would contain these antibodies. 
The thorough validation of this assay is important as although measuring 
biomarkers of aspiration is becoming increasingly popular across lung transplant 
centres world-wide the literature is still relatively small and the levels of pepsin 
being reported are reasonably varied. Blondeau et al are reporting levels over 
1000ng/ml using a similar direct ELISA. They are using a porcine pepsin antibody 
as the detection followed by a secondary antibody (goat immunoglobulin G) 
labelled with horseradish peroxidase and tetramethylbenzidine (TMB) as the 
substrate (Blondeau et at. 2008). There is no mention of negative controls in their 
protocols, suggesting they do not perform them. This could help to explain why 
the group document high levels of pepsin, as any non-specific binding is not 
investigated and would therefore not be subtracted from the final concentration of 
pepsin in the SAL sample. In addition, there is also no mention of the BAL being 
diluted before it is analysed, my investigations have shown that neat BAL can 
give an over estimation of pepsin when using TMB as a substrate (table 4.12). 
143 
On the other end of the scale Farrell et al are reporting low levels of pepsin, in 74 
patients the median pepsin level was Ong/ml with an inter-quartile range of 0-
1.5ng/ml (Farrell et al. 2006). The group uses a sandwich ELISA with two porcine 
pepsin antibodies as the capture and detection and the group shows mean 
recovery from spiking experiments to be 88.2%, however, they do not mention if 
the SAL was spiked with human or porcine pepsin. From my investigations I have 
shown it is possible to obtain good recovery of porcine pepsin in spiking 
experiments with a sandwich ELISA; however this is not the case for human 
pepsin. It is possible that the group are underestimating the concentration of 
pepsin in their samples due to human pepsin only having one available epitope 
for the porcine pepsin antibody to bind to; therefore once it is captured it can not 
be detected effectively (figure 4.7). 
The differences in methods used to detect pepsin and the variation in levels 
reported make it impossible to allow direct comparisons across centres. If the 
assay was standardised data could then be shared between centres. This is only 
practical if the assay is sensitive and reproducible, and through a sequence of 
investigations I have shown this to be the case for the plate ELISA outlined in this 
research. 
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Chapter 5 
Longitudinal analysis of pepsin present in BAL from 
lung transplant recipients 
5.1 Introduction 
The biggest limiting factor to long term survival in lung transplantation is the 
onset of bronchiolitis obliterans syndrome (BaS), and despite advances in 
surgical techniques and sophisticated immunosupression there have been no 
significant improvements in long term outcomes. Traditional treatments have 
focussed on the alloimmune mechanisms, however, some non-alloimmune 
mechanisms have now also been implicated in this chronic disease process, 
including the aspiration of gastric contents into the lungs. 
Previous work from our group has shown that pepsin, a marker of gastric 
aspiration, can be measured in the bronchoalveolar lavage (BAL) from transplant 
patients in a cross-sectional cohort (Stovold et al. 2007). This cross-sectional 
study did not show an association between high levels of pepsin and BaS, 
however, it did show an association between acute rejection and high levels of 
pepsin. 
From the above study it was not possible to investigate how pepsin levels in BAL 
vary with time, for example, a patient may experience fewer episodes of gastric 
aspiration the further post transplant they are due to the body adjusting to the 
operation and medication that may cause gastro-oesophageal reflux and 
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subsequent aspiration. It was also not possible to investigate whether high levels 
of pepsin in the lavage can predict for BOS. In order to attempt to address these 
questions a cohort of patients were recruited and longitudinal BAL samples were 
taken at 1 week, 1, 3, 6 and 12 months post-transplant and were analysed for 
pepsin. 
A longitudinal approach allows a broader range of analysis to be performed, 
including a sequential cross sectional analysis (Le. analysing pepsin levels at 1 
week, 1, 3, 6 and 12 months) to investigate if high levels of pepsin are associated 
with different grades of rejection at different time points. Additionally, survival 
analyses can be performed, including whether high levels of pepsin at an early 
time point can predict for BOS. As far as I am aware this is the first longitudinal 
analysis of BAL pepsin levels in lung transplant recipients. 
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5.2 Patient demographics 
Patient demographics are summarised in table 5.1. Forty patients were recruited 
to the study (17 male, age range 19-61 years) and fourteen of those patients 
went on to develop BOS during the follow-up time (last follow up June 2006). 
Between three and eight lavage samples were taken from each patient and were 
analysed for pepsin (table 5.2). In addition, five to seven transbronchial biopsies 
(TBB) were taken at each bronchoscopy to assess acute vascular and airway 
inflammation according to standard criteria (Yousem et al. 1996) by a pathologist. 
An a priori decision was made by a consulting clinician to include an additional 
seven samples taken from stable lung transplant patients as a control group. 
These patients were optimally stable and had no evidence of acute rejection or 
BOS or any other problems commonly experienced by lung transplant recipients 
(table 5.3). 
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Subject no. Age Sex Diagnosis Operation BOS ever Date of BOS 
1 20 m cf BlT n 
2 59 f emp SlT n 
3 61 f lam SlT n 
- - - - -
------- ---1--- ------- - --~-- - ---- --._----
-
4 31 f cf BlT n 
5 50 f emp SlT n 
6 57 m emp SlT n 
7 55 f Ipf SlT Y 07.11.03 
8 36 f emp SlT n 
9 27 m cf BlT n 
10 20 f cf BlT y 26.06.02 
11 26 f ob BlT y 03.09.03 
12 41 f ipf BlT "f 20.10.04 
13 41 f lam SlT n 
14 29 m cf BlT y 03.02.03 
15 19 m cf BlT y 29.01.03 
16 39 m emp BlT n 
17 31 f cf BlT n 
18 31 f cf BlT n 
19 48 f lam SlT n 
20 35 f pph HlT n 
r---------------
21 48 f ob BlT 1 01.10.04 
22 57 f emp SlT y 05.01.04 
23 24 f cf BlT n 
24 41 m cf BlT n 
25 25 f _pj)h HlT n 
26 21 m cf BlT 
.:1 28.08.02 
27 36 f pph HlT n 
28 45 f emp BlT n 
29 47 f emp SlT n 
30 16 f cf BlT 'i. 21.02.03 
31 26 m cf BlT n 
32 28 m cf BlT 'i.. 13.08.04 
33 40 m ipf SlT 'i.. 07.07.04 
34 46 m iQf BlT n 
35 28 m cf BlT 'i.. 19.02.03 
36 52 m cf SlT 
'i.. 12.02.02 
37 37 m cf BlT n 
38 48 m ipf BlT n 
39 20 f cf BlT n 
40 35 m sar SlT n 
, , 
Table 5.1. Patient demographics, Ipf - Idiopathic pulmonary fibrosIs, lam -
Iymphangioleiomyomatosis, cf-cystic fibrosis, sar-sarcoidosis, emp-emphysema, pph- primary 
pulmonary hypertension, ob- obliterative bronchiolitis, sit-single lung transplant, blt- bilateral lung 
transplant, hit-heart lung transplant. 
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Date of Pepsin 
Id DOT Sample (ng/ml) Biopsy BOS Score 
1 01.01.02 11.01.02 23.82 A1 B1/2 
1 28.01.02 130.35 A2B1/2 
1 08.04.02 6.61 A1BO 
1 08.07.02 34.17 A1BO 
1 06.01.03 7.31 AOBX 
2 23.10.02 22.11.02 17.37 AOB1 
2 22.01.03 20.07 A1B1 
2 30.04.03 19.1 A1B1 
r----~-~ .-~ ------~-~--- -- ~-~ 
22.3 
-- --- - - - - - ~ 
2 27.10.03 AOBO 
3 19.05.01 25.05.01 4.34 A1BX 
3 11.06.01 18.53 AOB1 
3 22.08.01 11.11 A1B1 
3 14.11.01 21.7 AOBO 
3 27.05.02 16.61 AOBX 
4 14.10.01 24.10.01 21.92 AOBO 
4 19.11.01 8.89 A2B1 
4 15.04.02 13.66 AOB1 
4 14.10.02 17.46 A1B1 
5 16.06.03 24.06.03 12.8 A2BX 
. ---~------
5 16.07.03 7.4 A2B1 
5 17.09.03 17.4 AO 
5 05.01.04 4.3 A1B1 
-_.- ----
5 14.06.04 15 A1/2B1 
5 08.11.04 18.1 A1B1 
6 18.05.01 25.05.01 16.61 A1 
6 20.06.01 13.8 A1B2 
6 18.07.01 20.46 
6 05.09.01 8.41 A1BO 
6 19.11.01 11.98 A1B1 
6 11.09.02 31.08 A1BO 
7 23.06.03 04.07.03 23.33 A2B1 
7 25.07.03 17.9 AOB1 
7 08.10.03 17.51 A2B2 
7 07.11.03 21.95 A1BX 
7 22.12.03 18.84 A2B3 
8 27.06.02 05.07.02 26.45 A2 
8 24.07.02 25.58 A1B1 
8 21.08.02 14.16 A12 
8 30.09.02 2.41 A1BX 
8 29.04.03 14.86 A1B2 
8 23.06.03 13.13 A1BX 
Table 5.2 Pepsin levels (ng/ml) recovered from sequential BAL samples from 40 
patients. Table also details biopsy and BOS scores associated with each sample. 
AX and BX denotes un-gradable biopsy. DoT-date of transplant. BOS-
bronchiolitis obliterans syndrome. 
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ld 
Date of 
DOT Sample Pepsin ng/ml Biopsy 805 
9 27.12.01 15.01.02 5.59 AXBX 
9 30.01.02 9.90 A1B2 
9 27.03.02 6.16 A1 
9 24.06.02 15.49 A1BO 
9 16.12.02 36.76 A1B1 
9 10.11.04 21.B1 
10 21.09.01 22.10.01 20.65 A2BO 
10 19.12.01 12.39 
10 25.03.02 4.13 AOB1 
10 26.06.02 2.B6 
10 21.10.02 12.20 AOB1 
11 14.05.02 20.05.02 19.75 A2 
11 10.06.02 14.22 AX 
11 20.06.02 332.01 AX 
11 05.0B.02 15.94 A1BX 
11 18.11.02 14.79 AXBO/1 
11 02.06.03 14.79 A1BX 
12 05.01.01 12.02.01 49.90 A2/3BX 
12 26.03.01 27.54 A1B1 
12 09.07.01 2B.12 A1B1 
12 06.01.03 11.42 AOB1 
12 20.10.04 23.43 AOB1 
13 27.06.02 05.07.02 17.53 A2 
13 26.07.02 0 A2 
13 25.09.02 18.17 A1 A2 
13 18.12.02 1.05 AOB1 
13 30.06.03 0 AOB1 
14 12.11.02 19.11.02 33.25 A2B2 
14 09.12.02 5.17 A2B1 
14 03.02.03 22.53 AXBX 
14 04.03.03 19.53 AXB112 
14 22.0B.03 10.29 A1B2 
14 17.11.03 17.71 AOB1/2 
14 05.05.04 1.00 AXBX 
14 22.06.04 B.OO AXBX 
15 16.05.02 05.0B.02 24.00 A2B1 
15 20.11.02 23.29 AOBO/1 
15 29.01.03 15.30 A1BO 
16 01.05.03 09.05.03 5.15 AOB1 
16 23.07.03 20.7B AOBO 
16 03.11.03 2B.60 AOBO 
16 10.05.04 0 A2B1 
16 09.08.04 15.51 
Table 5.2 (continued). Pepsin levels (ng/ml) recovered from sequential BAL 
samples from 40 patients. Table also details biopsy and BOS scores associated 
with each sample. AX and BX denotes un-gradable biopsy. DoT-date of 
transplant. BOS-bronchiolitis obliterans syndrome. 
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Date of 
Id DOT Sample Pepsin ng/ml Biopsy BOS 
17 17.08.02 23.08.02 3.70 A2B1 
17 16.09.02 0 A2B1/2 
17 11.11.02 5.17 AXBO 
17 24.02.03 25.63 A1B1 
17 18.08.03 0 AXBO 
17 26.04.04 11.75 AOBO 
18 06.08.02 14.08.02 14.59 A2B1 
18 06.09.02 12.94 AOBX 
--------- f------------- --- - - - ~-
18 10.02.03 17.65 A1B1 
18 15.08.03 18.59 A1B1 
19 10.09.02 07.10.02 12.44 A2bO 
19 11.12.02 0 
19 12.03.03 0 A2BO 
19 15.09.03 0 A1BO 
20 23.06.01 02.07.01 5.85 A1/2B1 
20 11.07.01 5.54 AXB1 
20 19.09.01 8.26 A1B1 
20 17.12.01 13.34 A2B2 
20 24.06.02 15.20 A1B1 
21 24.08.03 26.11.03 7.03 AOBO 
21 23.02.04 18.84 AOBX 
21 11.08.04 10.71 AxB1 
.. ------.---.~--
21 01.10.04 25.23 A10B 
22 21.03.03 25.04.03 19.41 A2B1 
22 18.06.03 18.48 A1BO 
22 03.09.03 19.04 A2Bx 
22 05.01.04 22.00 AOBO 
23 15.05.03 16.06.03 24.30 A2B2 
23 15.08.03 31.45 A1B1 
23 10.11.03 10.89 A1B1 
23 17.05.04 68.78 A1BX 
24 09.01.02 16.01.02 37.70 A2/3B2 
24 11.02.02 30.03 A2B1 
24 11.03.02 31.37 A2B1 
24 15.04.02 14.86 AXBO 
24 15.07.02 18.35 A2 
24 08.01.03 30.80 A1BO 
25 22.05.02 24.06.02 5.10 A3 
25 05.08.02 11.63 A2/3B1 
25 02.09.02 16.54 A1BO 
25 25.11.02 38.50 A2B1 
25 15.11.04 4.30 
Table 5.2 (continued). Pepsin levels (ng/ml) recovered from sequential BAL 
samples from 40 patients. Table also details biopsy and BOS scores associated 
with each sample. AX and BX denotes un-gradable biopsy. DoT-date of 
transplant. BOS-bronchiolitis obliterans syndrome. 
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Id 
Date of 
DOT Sample Pepsin ng/ml Biopsy BOS 
26 29.06.01 06.07.01 32.40 A2B1 
26 19.07.01 21.60 A2B1 
26 26.09.01 24.14 A1B1 
26 17.12.01 23.82 AOBX 
26 28.08.02 37.70 A1BX 
27 30.10.01 05.11.01 0 A2B1 
27 28.11.01 10.61 A2B2 
27 06.02.02 13.20 A2BO 
27 28.10.02 10.90 A1BO 
27 17.10.03 2.37 AOBX 
28 22.01.02 01.02.02 29.86 A2B2 
28 22.02.02 25.42 A2B2 
28 10.04.02 29.86 AOBO 
28 29.07.02 13.48 AOB1 
28 19.11.02 0 A2B1 
28 02.04.03 25.26 A1BO 
29 26.06.01 04.07.01 0 A1B1 
29 01.10.01 0 A1/2B1 
29 19.12.01 31.70 A2BO 
29 22.07.02 15.20 A1B1 
30 12.04.01 09.05.01 18.82 AOBO 
30 06.06.01 0 AOBO 
30 11.07.01 9.55 A2B2 
30 10.10.01 5.21 A1B1 
30 21.02.03 8.800 A1BX 
31 27.11.01 03.12.01 32.97 A1B1 
31 21.12.01 0 A2BX 
31 20.02.02 17.32 A1 
31 05.06.02 7.26 A1BO 
31 1B.11.02 15.36 A1BO 
32 14.08.02 16.09.02 27.B3 A1B1 
32 13.11.02 19.B9 AOB1 
32 14.02.03 22.65 AOBO 
32 11.0B.03 18.32 AOBO 
32 14.11.03 21.25 AO 
32 13.08.04 20.39 AxBx 
33 10.10.02 16.10.02 17.23 A2B1 
33 1B.11.02 21.47 AxBx 
33 03.03.03 15.29 A1BO 
33 16.07.03 19.07 AOBX 
33 15.10.03 33.30 AOBx 
33 07.07.04 5.17 AOBO 
Table 5.2 (continued). Pepsin levels (ng/ml) recovered from sequential BAL 
samples from 40 patients. Table also details biopsy and BOS scores associated 
with each sample. AX and BX denotes un-gradable biopsy. DoT-date of 
transplant. BOS-bronchiolitis obliterans syndrome. 
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Id 
Date of 
DOT Sample Pepsin ng/ml Biopsy BOS 
34 17.02.03 04.03.03 7.81 AXB112 
34 21.03.03 21.15 AXBX 
34 12.05.03 14.58 A2BO 
34 20.0B.03 13.46 AOB1 
34 1B.02.04 12.03 AOBO 
35 27.11.01 16.12.02 13.17 A1B1 
35 19.02.03 16.70 A1BX 
35 04.03.03 0 A1BX 
35 30.07.03 5.17 A1BX 
36 02.05.01 30.05.01 13.13 A2 
36 23.07.01 12.90 A3 
36 21.11.01 5.70 A2 
36 20.02.02 5.12 
36 01.05.02 0 
37 05.11.01 13.11.01 0 AOBO 
37 14.12.01 0 A1BO 
37 04.02.02 0 AOBO 
37 OB.05.02 0 AOBO 
37 04.11.02 12.01 AXBO 
38 11.08.04 10.09.04 26.00 A1B1 
38 10.11.04 20.80 A2B2 
38 02.02.05 22.10 A1B1 
39 15.01.02 21.01.02 9.40 A2B112 
39 13.02.02 0 A2B1 
39 01.03.02 5.01 A2BO 
39 24.04.02 13.27 A2BX 
39 2B.OB.02 1B.22 AX 
39 13.01.03 16.51 AXBO 
39 07.02.05 22.90 
40 19.07.02 26.07.02 26.35 A2BX 
40 16.0B.02 23.14 A2BX 
40 24.02.03 37.39 A1B1 
40 21.07.03 23.08 A2B1 
40 03.03.04 6.05 A1B1 
Table 5.2 (continued). Pepsin levels (ng/ml) recovered from sequential BAL 
samples from 40 patients. Table also details biopsy and BOS scores associated 
with each sample. AX and BX denotes un-gradable biopsy. DoT-date of 
transplant. BOS-bronchiolitis obliterans syndrome. 
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Stable Age Sex Diagnosis Operation Time Biopsy BOS Pepsin 
Subject post-Tx Score (ng/ml) 
no. (months) 
1 37 m copd bit 6 AOBO 0 10.38 
2 51 f copd bit 6 AOBO 0 0 
3 49 m copd bit 3 AOBO 0 5.21 
4 22 f cf bit 6 AOBO 0 7.40 
---------- f--- --- r- -- - ---- -----::-- -------,-:-- -----------::-- - --
5 34 f cf bit 3 AOBO 0 5.20 
6 37 m ob sit 6 AOBO 0 5.50 
7 28 f cf bit 3 AOBO 0 12.56 
Table 5.3 Demographics and pepsin levels (ng/ml) recovered from lavage of 
stable controls. copd-chronic obstructive pulmonary disease, cf-cystic fibrosis, 
ob-obliterative bronchiolitis. bit-bilateral lung transplant, sit-single lung transplant. 
Tx-transplant. BOS-bronchiolitis obliterans syndrome. 
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5.3 Cross-sectional analysis of BAL pepsin 
Levels of pepsin present in BAL ranged from 0 to 332ng/ml. BAL samples were 
grouped into samples taken at 1 week, 1 month, 3 months, 6 months and 12 
months, and were divided into 5 groups; AO, (no acute rejection), A1 (minimal 
acute rejection), ~A2 (mild-moderate acute rejection), BOS and all transplant 
patients. A control group containing 7 patients who were clinically stable was also 
included for comparisons. For statistical analysis non parametric methods were 
used throughout using GraphPad Prism software. Groups were compared using 
the Kruskal Wallis test (non parametric one-way analysis of variance) with a post 
hoc Mann Whitney test. 
5.3.1. Analysis of BAL pepsin at 1 week 
Pepsin levels from all transplant patients (median 16.9ng/ml, range 0-37.7ng/ml) 
were not significantly higher than the stable controls (median 5.50ng/ml, range 0-
12.56ng/ml, P= 0.055). Pepsin levels from the ~A2 acute rejection group were 
significantly higher than the control group (median 17.5ng/ml range 0-37. 7ng/ml 
p= 0.03, figure 5.1). The pepsin levels from AO and A 1 groups were not 
significantly different than the controls (P>0.05). 
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5.3.2 Analysis of BAL pepsin at 1 month 
Pepsin levels from all transplant patients (median 17.9ng/ml, range 0-332.0ng/ml) 
were significantly higher than the stable controls (median 5.5ng/ml, range 0-
12.56ng/ml, P= 0.02). In addition, pepsin levels from the AO and the A 1 groups 
were significantly higher than the control group (median 17.9 and 13.8ng/ml, 
range 12.9-18.8 and 0-27.8ng/ml, P= 0.003 and P=0.04 respectively, figure 5.2). 
The pepsin levels from '2.A2 group were not significantly different than the 
controls (P>0.05). 
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Figure 5.1 Values of pepsin (ng/ml) recovered from BAL at 1 week post 
transplant. Lines represent median values. Stable controls are patients with no 
evidence of rejection or infection, AO are patients with no evidence of acute 
rejection, A 1 are patients with minimal acute rejection and ~A2 are patients with 
mild to moderate acute rejection. Tx-transplant. Stable controls n=7, AO n=3, A 1 
n=4, ~A2 n=17 and all Tx n=26 
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Figure 5.2 Values of pepsin (ng/ml) recovered from SAL at 1 month post 
transplant. Lines represent median values. Stable controls are patients with no 
evidence of rejection or infection, AD are patients with no evidence of acute 
rejection, A 1 are patients with minimal acute rejection and '?A2 are patients with 
mild to moderate acute rejection. Tx-transplant. Stable controls n=7, AD n=5, A 1 
n=7, '?A2 n=2D and all Tx n=35 
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5.3.3 Analysis of BAL pepsin at 3 months 
Pepsin levels from all transplant patients (median 15.4ng/ml, range 0-31.5ng/ml) 
were significantly higher than the stable controls (median 5.5ng/ml, range 0-0-
12.6ng/ml, P= 0.01). In addition, pepsin levels from the A1 and ~A2 groups were 
significantly higher than the control group (median 16.2 and 13.9ng/ml range 2.4-
31.5 and 0-24.0ng/ml, P= 0.01 and 0.007 respectively, figure 5.3). Pepsin levels 
from the AO group were not significantly different from the controls (P>0.05) and 
there were not enough patients in the BOS group to perform statistical analysis. 
5.3.4 Analysis of BAL pepsin at 6 months 
Pepsin levels from all transplant patients (median 18.2ng/ml, range 0-38.5ng/ml) 
were significantly higher than the stable controls (median 5.5ng/ml, range 0-0-
12.6ng/ml, P= 0.009). In addition, pepsin levels from the A1 group were 
significantly higher than the control group (median 17.7ng/ml, range 4.3-
37.4ng/ml, P= 0.02, figure 5.4). The pepsin levels from AO and ~A2 groups were 
not significantly higher than controls (P>0.05) and again, there were not enough 
patients in the BOS group to perform statistical analysis. 
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Figure 5.3 Values of pepsin (ng/ml) recovered from SAL at 3 months post 
transplant. Lines represent median values. Stable controls are patients with no 
evidence of rejection or infection, AO are patients with no evidence of acute 
rejection, A 1 are patients with minimal acute rejection, ~A2 are patients with mild 
to moderate acute rejection and 80S are patients diagnosed with bronchiolitis 
obliterans syndrome at the time the sample was collected. Tx-transplant. Stable 
controls n=7, AO n=6, A1 n=14, ~A2 n=10 and all Tx n=36 
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Figure 5.4 Values of pepsin (ng/ml) recovered from BAL at 6 months post 
transplant. Lines represent median values. Stable controls are patients with no 
evidence of rejection or infection, AD are patients with no evidence of acute 
rejection, A1 are patients with minimal acute rejection, "2.A2 are patients with mild 
to moderate acute rejection and BOS are patients diagnosed with bronchiolitis 
obliterans syndrome at the time the sample was collected. lx-transplant. Stable 
controls n=7, AD n=12, A1 n=13, "2.A2 n=7, BOS n=1 and all lx n=35 
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5.3.5 Analvsis of BAL pepsin at 12 months 
Pepsin levels from all transplant patients (median 15.0ng/ml, range 0-68.8ng/ml) 
were significantly higher than the stable controls (median 5.5ng/ml, range 0-0-
12.6ng/ml, P= 0.02). In addition, pepsin levels from the A 1 group were 
significantly higher than the control group (median 15.4ng/ml range 0-68.8ng/ml, 
P= 0.006, figure 5.5). Pepsin levels in the AO, ~A2 and 80S groups were not 
significantly higher than the controls. 
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Figure 5,5 Values of pepsin (ng/ml) recovered from BAL at 12 months post 
transplant. Lines represent median values. Stable controls are patients with no 
evidence of rejection or infection, AD are patients with no evidence of acute 
rejection, A 1 are patients with minimal acute rejection, ~A2 are patients with mild 
to moderate acute rejection and BOS are patients diagnosed with bronchiolitis 
obliterans syndrome at the time the sample was collected. Tx-transplant. Stable 
controls n=7, AD n=8, A1 n=11, ~A2 n=4, BOS n=4 and allTx n=31. 
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5.4 Longitudinal analysis of BAL pepsin 
The chosen format of analysis was to decide on a time pOint and investigate 
whether high levels of pepsin at this time point can predict for the development of 
BOS. As there is evidence of gastric aspiration being problematic early post-
transplant (Cantu et a!. 2004) three months was chosen. Three months is still 
relatively early post-transplant, however, patients will be more 'clinically 
stabilised' than they would be at one week or one month. 
There were 36 patients with a BAL sample collected at 3 months (± 2 weeks) that 
were included in the analysis. Patients 4, 18, 33 and 40 were excluded from the 
analysis as they did not have a sample taken at 3 months. Patient 33 did develop 
BOS during the follow up time; therefore the number of patients included in the 
study that went on to develop BOS was 13. 
The statistical analysis of data contained in this chapter was performed with the 
help of a statistician. 
5.4. 1 80S vs. no 80S-pepsin levels at 3 months 
The patients were split into two groups, patients who did not develop BOS in the 
follow up time and those who did develop BOS within the follow up time. The 
descriptive statistics for the two groups can be seen in table 5.4 and a dotplot of 
pepsin levels in figure 5.6. There was a trend for a higher 8AL pepsin level in the 
group who developed 80S, however this was not statistically significant (using 
the Mann Whitney test, P=O.07). 
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n Mean SEM Minimum Median Maximum 
---~.---- .- ------- -- - - ----- - - - -- - - - -
NoBOS 23 12.9 1.8 0 13.3 31.5 
development 
_within foU<:lIJl.l~~ ___ 
-- -~------ ---- --~---- . --. - --------- --- ---
BOS 13 17.9 1.7 7.0 17.5 27.5 
development 
within follow up 
Table 5.4 The mean, standard error of the mean (SEM). median and range of 
pepsin levels (ng/ml) recovered from SAL taken at 3 months post-transplant from 
patients who did not develop BOS and patients who did develop BOS within the 
follow up time of the study. 
• • t- --No 80S within follow up • • • • • • ••• • • • •• • • 
• 
--t 
• 80S within follow up • • • • •• • 
• 
• I I I I I I I 0 5 10 15 20 25 30 35 
Pepsin ng/ml at 3 months 
Figure 5.6 Dotplot of pepsin (ng/ml) recovered from SAL collected at 3 months 
post-transplant from patients at who did not develop 80S (n=23) within the follow 
up time of the study and those who did develop BOS (n=13). Lines represent 
median values. 
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5.4.2 Percentage BOS bv pepsin level 
The general hypothesis is that 'high' values of pepsin in the BAL at around 3 
months post-transplant may be predictive for time to BOS. As there is no general 
consensus of what high levels of pepsin are in bronchoalveolar lavage a number 
of 'cut-ofts' were used based on levels measured in the stable controls. These 
were the median, 5.5ng/ml, the maximum, 12.6ng/ml and the two values between 
the median and the maximum, 7.4 and 10.4ng/ml. 
The percentage of patients with BOS by 'high' or 'low' BAL pepsin at 3 months 
was calculated and the percentage of patients with BOS was higher in patients 
with 'high' levels of pepsin for all the cut of levels (table 5.5). 
In addition to the percentage of patients with BOS, the rate ratios were also 
calculated for the cut off values. The rate ratio estimates the rate the patient is 
likely to develop BOS and the confidence interval indicates the range of possible 
underlying true values for the rate ratio. For example patients with BAL pepsin 
levels above 7.4ng/ml at 3 months are estimated to develop BOS at 4.1 times the 
rate of patients with 7.4ng/ml or below, however, the width of the confidence 
interval suggests that it could be as high as 31.6 times, or conversely twice as 
slow (0.5 times). Patients with levels above 10.4ng/ml are estimated to develop 
BOS at 3.0 times the rate of those with 10.4ng/ml or be/ow (CI 0.7-13.6) and 
patients with levels above 12.6ng/ml are estimated to develop BOS at 2.3 times 
the rate of patients with 12.6ng/ml or below (CI 0.6-8.3) (table 5.6). 
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A rate ratio of 1.0 indicates no difference between the groups and as all the 
confidence intervals include a rate ratio of 1.0, this demonstrates that there are 
no significant differences in the rate of BOS development between the two 
groups. This is also reflected by the P values. 
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Variable Level Number of Number and 
patients percentage with 
(total=36) 80S by level 
Pepsin ~ 5.5 ng/ml 5 0 0.0% 
at 3 months > 5.5 ng/ml 31 13 41.9% 
Pepsin ~ 7.4 ng/ml 8 1 12.5% 
at 3 months > 7.4 ng/ml 28 12 42.9% 
Pepsin ~ 10.4 ng/ml 11 2 18.2% 
at 3 months > 10.4 ng/ml 25 11 44.0% 
Pepsin ~ 12.6 ng/ml 13 3 23.1% 
at 3 months > 12.6 ng/ml 23 10 43.5% 
Table 5.5 Percentage of patients with bronchiolitis obliterans syndrome (80S) 
based on whether they have 'high' or 'low' levels of pepsin present in their 
bronchoalveolar lavage at 3 months. 
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Variable Level Rate ratio 95% CI P-value 
(score test) 
Pepsin S 5.5 ng/ml 
at 3 months > 5.5 ng/ml 0.1 
Pepsin S 7.4 ng/ml 1.0 
at 3 months > 7.4 ng/ml 4.1 0.5-31.6 0.1 
Pepsin S 10.4 ng/ml 1.0 
at 3 months > 10.4 ng/ml 3.0 0.7 -13.6 0.1 
Pepsin s 12.6 ng/ml 1.0 
at 3 months > 12.6 ng/ml 2.3 0.6 -8.3 0.2 
Table 5.6 Rate ratios and 95% confidence intervals for BOS development by 
'high' or 'low' bronchoalveolar lavage pepsin at 3 months. There is no rate ratio 
for 5.5ng/ml as when using Cox proportional hazards, the rate ratio can not be 
calculated if there are 0 events in one of the groups (refer to table 5.5). CI-
confidence interval. 
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5.4.3 Survival analysis of patients with 'high' and 'low' BAL pepsin at 3 months 
Kaplan-Meier estimates of survivor functions (Le. remaining BOS free) were 
plotted using a cut off of 10.4 and 12.6ng/ml. Using a cut off of 10.4ng/ml patients 
with SAL pepsin at 3 months of 10.4ng/ml or below are approximately 80% free 
from 80S at 3 years post-transplant compared to approximately 60% with levels 
above 10.4ng/ml. Using a cut off of 12.6ng/ml patients with SAL pepsin at 3 
months of 12.6ng/ml or below are approximately 75% free from 80S at 3 years 
post-transplant compared to approximately 60% with levels above 12.6ng/ml 
(figures 5.7 and 5.8). 
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Figure 5.7 Kaplan-Meier estimates of survivor functions for patients using a cut 
off of 1 O.4ng/ml at 3 months post transplant to define 'high' pepsin levels. 
Survival function-remaining BOS free. BOS -bronchiolitis obliterans syndrome. 
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5.5 Discussion 
Previous work from our group has investigated the presence of the gastric 
protease pepsin in the bronchoalveolar lavage (BAL) of lung transplant recipients 
in a cross-sectional cohort (Ward et al. 2005; Stovold et al. 2007). These 
investigations confirmed that pepsin, and therefore the gastric refluxate was 
reaching the lungs, however these studies were not designed to determine how 
levels of pepsin in BAL change over time and whether high levels can predict the 
development of bronchiolitis obliterans syndrome (BOS). Therefore, longitudinal 
samples were collected and analysed to investigate these changes, and whether 
pepsin can predict the development of BOS. 
Forty patients were recruited to the study and at least 3 sequential BAL samples 
were taken and analysed for pepsin. Initially, the data was split into 5 cross 
sectional time points: 1 week, 1 month, 3 months, 6 months and 12 months post-
transplant to investigate whether high levels of pepsin are associated with 
different grades of rejection at different time points. Samples were divided into 5 
groups; AO, (no acute rejection), A 1 (minimal acute rejection), ~A2 (mild-
moderate acute rejection), BOS and all transplant patients. In addition, a control 
group containing 7 patients who were clinically stable was also included for 
comparisons. 
Pepsin levels from all transplant patients were significantly higher than the control 
group at 1 month, 3 months, 6 months and 12 months. The samples taken at 1 
week did not contain significantly higher levels of pepsin than the controls, 
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however, this may be explained by the fact that there were a large number of 
patients (n=14) without a BAL sample taken at 1 week. 
The pepsin levels in the AO group were only significantly higher than the controls 
at 1 month post transplant. A difference between the controls and AO group was 
not expected, as the two groups are similar by definition. Both groups have no 
evidence of acute rejection, however the AO group may have evidence of 
infection. In addition, the difference at 1 month may be explained by the AO 
patients not being clinically stabilised, the patients may still be adjusting to the 
transplant itself and also the medication they would be taking, factors which may 
promote gastro-oesophageal reflux and consequent aspiration. The patients in 
the stable control group were at least 3 months post-transplant, therefore will 
have had more time to adjust to these factors. 
The A 1 group showed significantly higher levels of pepsin than the controls at 1, 
3, 6 and 12 months, suggesting a link between minimal acute rejection and 
gastric aspiration. This was not identified in the previous study, however, this 
could be due to the smaller numbers of patients with A 1 rejection in the earlier 
work. In addition, comparisons were made against a normal volunteer control 
group, not stable transplant controls. The decision not to include a normal (non-
transplant) control group in the current analysis was made on the basis that for 
survival analysis lung transplant patients are not comparable to normal healthy 
subjects, therefore deciding what a high level of SAL pepsin is based on normal 
subjects would not be appropriate. In addition, the normal control data has been 
included in two previous studies (Ward et al. 2005; Stovold et al. 2007) and 
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considering no new 'normal' samples were taken it would not be good practice to 
include them in a third study. 
There is some evidence that minimal acute rejection is important in the 
development of obliterative bronchiolitis (08). Studies have shown that multiple 
episodes of histologically graded A 1 acute rejection can be a risk factor for 
08/80S (Hopkins et al. 2004; Khalifah et al. 2005), however, the evidence is not 
as strong as it is for ";!A2 rejection and should therefore be further investigated. 
The A2 or greater acute rejection group was significantly different at 1 week and 
3 months post-transplant, suggesting a link between ~A2 rejection and gastric 
aspiration early post transplant. Acute rejection is consistently linked with the 
development of 08/80S (Sharples et al. 2002; Scott et al. 2005). In addition, the 
Duke University group have published data suggesting that gastric aspiration is a 
problem early post-transplant and needs to be treated early to see any survival 
benefit (Cantu et al. 2004). 
Finally, statistical analysis could only be performed on the 80S group at 12 
months post-transplant, as there were too few numbers at the other time points. 
There was no significant difference between the stable controls and the 80S 
group, however further investigations are required to increase the numbers in this 
group to allow a more detailed analysis. 
For the survival analysis it was decided to look at pepsin levels at 3 months post-
transplant, as this is still an early time point, however patients will have clinically 
stabilised, i.e. adjusted to factors that may promote gastric aspiration for example 
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certain medications and the transplant surgery itself. The patients were divided 
into two groups, one including patients who developed BOS during the follow up 
time and the other group included patients who remained BOS free throughout 
the study. 
For the survival analysis the hypothesis was that 'high' values of pepsin in the 
BAL at three months post-transplant may be predictive of time to BOS. As there 
is no general consensus of what a 'high' level of BAL pepsin is a number of 
possible 'cut-ofts' were used based on values recovered from stable transplant 
controls. These were the median (5.5ng/ml), the maximum (12.6ng/ml) and the 
two values between the median and the maximum (7 A and 10Ang/ml). 
For all cut-off values the percentage of patients with BOS was greater in the high 
BAL pepsin group, suggesting that high levels of pepsin in the BAL at 3 months 
may be associated with the development of BOS. The rate ratios were also 
calculated for the groups using 7.4, 10.4 and 12.6ng/ml as a cut of for high 
pepsin. Using aI/ three values the estimated rate of developing BOS in the high 
pepsin group was at least twice that of the low pepsin group (4.1, 3.0 and 2.3 
times respectively), again suggesting a link between high pepsin levels and the 
development of BOS. However, the confidence intervals (representing the range 
of possible values) are wide and include a value of 1.0, which indicates that there 
is not enough evidence from this data to conclude that there is a statistically 
significant difference in the rate of development of BOS between the two groups. 
However, to demonstrate no difference between the two groups the confidence 
interval should be 'tight' around 1.0, and as this is not the case it would also be 
176 
incorrect to assume no difference between the two groups. In this case it is 
possible that the width of the confidence intervals reflect the small number of 
patients and the small number of BOS events in the two groups. 
Based on the Kaplan-Meier survival curves using a cut off of 10Ang/ml the low 
pepsin group (:510Ang/ml) are approximately 80% BOS free at 3 years, 
compared to approximately 60% in the high pepsin group. This difference in 
survival is also demonstrated when using 12.6ng/ml as a cut off (75% BOS free 
in the low pepsin group and 60% BOS free in the high pepsin group). 
Although all the data outlined in this chapter is suggesting a link between early 
high levels of pepsin in BAL and the development of BOS there is a lack of 
statistical significance, which could be explained by the small numbers of patients 
and the small number of BOS events in the groups. To detect a statistically 
significant difference of 20% in BOS free survival at 3 years post-transplant (i.e. 
80% vs. 60% BOS free for a 10.4ng/ml cut off) using a logrank test would require 
173 patients and 53 'events' (Freedman 1982). This number may be reduced, 
however, with longer follow-up and/or a difference in percentage of BOS free 
survival. These sample-size calculations should be considered in any future 
analysis. 
Gastric aspiration is becoming increasingly recognised as a contributing factor for 
the development of BOS. A study by Li et al has shown that the chronic 
aspiration of gastric fluid can induce the development of DB in a rat model of 
transplantation. Allografts that were instilled with gastric juice once a week for at 
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least 2 months showed evidence of cellular fibro-proliferative tissue, significant 
reduction in the size of the bronchiolar lumens and mild degrees of peri-
bronchiole inflammatory cell infiltrates, consistent with the development of OB. 
This was not seen in allografts and isografts that were not treated with gastric 
juice, showing that gastric aspiration can accelerate the development of OB/BOS 
(Li et al. 2008). 
As previously discussed, Cantu et al have also shown that the treatment of 
gastro-oesophageal reflux can lead to a survival benefit in terms of BOS, 
however any intervention must be carried out early in the transplant process to 
see any improvement (Cantu et al. 2004). Using Kaplan-Meier survival analysis 
Cantu et al showed that patients who received an early fundoplication (up to 87 
days post-transplant) were 100% free from BOS at 3 years post-transplant, 
compared to 60% in patients with a history of reflux and no fundoplication and 
47% in those with a history of reflux and a late fundoplication (106 to 2999 days 
post transplant. 
This is consistent with the work outlined in this chapter, as there is a trend for 
patients with 'high' BAL pepsin (>10.4ng/ml) at 3 months post-transplant to show 
a survival disadvantage compared to those with 'low' BAL pepsin (S10.4ng/ml) at 
3 months post-transplant (60% vs. 80% BOS free at 3 years post-transplant 
respectively). This suggests that treatment is required before this time point to 
reduce the development of BOS. 
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As gastric aspiration is becoming increasingly recognised as a contributing factor 
for the development of BOS measuring biomarkers is becoming ever more 
important in identifying which patients are most likely to benefit from anti-reflux 
treatment. There are two biomarkers currently being utilised by transplant groups 
world wide; pepsin and bile salts (D'Ovidio et al. 2005; Ward et al. 2005; 
Blondeau et al. 2008). However, over the past 3 years many groups have chosen 
to focus on bile salts rather than pepsin. A possible explanation for this is the 
commercial availability of kits designed to measure bile salts, combined with the 
difficulty in setting up an assay to accurately measure pepsin. 
Our group chose to continue measuring pepsin as a biomarker, mainly due to the 
fact that the gastric refluxate will not always contain bile acids, as duodenal-
gastro-oesophageal reflux may occur less frequently than gastro-oesophageal 
reflux, therefore, some aspiration episodes may be overlooked. Pepsin is more 
likely to be consistently present in the gastric refluxate and as a result less 
aspiration episodes would be missed. 
More recently, our group has also investigated the presence of bile salts in the 
BAL of lung transplant patients (1 and 3 months post-transplant) using mass 
spectrometry, with a lower limit of detection of 0.1jJmol/l and found no evidence 
of bile salts. This does not necessarily mean that bile salts are not reaching the 
lungs, it may be that once the saline used to perform the lavage is instilled the 
bile salts become too diluted to measure using these methods. Again, this implies 
that pepsin may be a more sensitive marker of aspiration. 
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Further investigations are required to understand the mechanisms behind this 
injury. Neutrophil levels have also been investigated in this patient cohort by 
another member of the group as they are consistently implicated in the 
pathogenesis of OB/BOS (DiGiovine et al. 1996; Elssner and Vogelmeier 2001). 
Neutrophils are part of the innate immune system and in infection are recruited to 
the lung and activated, mainly by macrophage-derived mediators, such as IL-8, 
TNF-a and GM-CSF. Neutrophils can cause damage to the tissue in their region 
of activity by the reactive oxygen species they produce, chiefly via the action of 
myeloperoxidase (MPO). It is possible that the lung epithelial cells are releasing 
neutrophilic chemokines such as TNF-a and GM-CSF in response to stress or 
damage caused by refluxed pepsin and/or acid. If this was the case there may be 
a correlation between neutrophil and pepsin levels in the SAL and as both have 
been measured in the same patients statistical analysis could be performed. This 
would help to identify if neutrophils are implicated and whether or not they should 
be further investigated as a potential mechanism of damage caused by gastric 
aspiration. 
The investigations outlined in this chapter have confirmed previous work by 
demonstrating that pepsin is present in the SAL of lung transplant patients and 
that there is an association between high pepsin levels and acute rejection 
(minimal to moderate acute rejection). There is also a trend towards high SAL 
pepsin levels at 3 months and the development of SOS, however the difference 
is not statistically significant, which may be reflecting the small number of 
patients and also the small number of BOS 'events', therefore further 
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investigations involving a larger patient cohort are required to confirm these 
results. This is the first longitudinal study investigating SAL pepsin levels and it 
supports the hypothesis that gastric aspiration may be an important injury in lung 
transplantation and that pepsin is potentially a useful biomarker. 
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Chapter 6 
The effect of pepsin on goblet and epithelial cells 
6.1 Introduction 
Extra-oesophageal reflux has been shown to have adverse effects on the upper 
respiratory tract, including the trachea, larynx and pharynx (Vaezi 2003; Farrokhi 
and Vaezi 2007). In addition aspiration of gastric contents into the lungs has 
been associated with the development of chronic rejection in lung transplantation 
(810ndeau et al. 2008; Li et al. 2008). Chronic lung rejection manifests itself 
histologically as obliterative bronchiolitis (08) and Clinically as bronchiolitis 
obliterans syndrome (80S). 
Early 08 is characterised by an influx of inflammatory cells into the lung, 
including T lymphocytes, monocytes and neutrophils (80ehler et al. 1998). 
Chemokines such as interleukin 8 (IL-8) and interleukin 17 (IL-17) have been 
shown to be important in the recruitment of such inflammatory cells, especially 
neutrophils which are repeatedly elevated in the lung lavage of transplant 
patients with 80S. This suggests that IL-8 along with other such chemokines 
plays a crucial role in the pathogenesis of 08. 
IL-8 is an important component of the innate immune system and can be 
produced by immune cells, such as macrophages as well as the epithelium itself 
in response to many pathogens or stimuli present in the lung. The potential for 
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pepsin, an important component of the gastric refluxate, to stimulate IL-8 
production from epithelial cells was therefore investigated. 
In addition, epithelial surfaces (including the respiratory, gastrointestinal and 
reproductive tracts) are coated with mucus, a mixture of water, ions, 
glycoproteins, proteins and lipids, which provides a protective barrier against 
pathogens and toxins. Mucin glycoproteins (mucins) are the major 
macromolecular constituent of mucus and the predominant mucins in the airway 
appear to be those expressed by the MUC5AC and MUC58 genes (Callaghan-
Rose and Voynow 2006). MUC5AC is mainly produced by the goblet cells 
present in the epithelium and MUC58 by the secretory cells of the submucosal 
glands. 
It is possible that airway goblet cells could secrete mucus in response to pepsin 
aspirated into the lung. This could be receptor mediated, as the presence of a 
receptor on laryngeal cells that has the ability to recognise pepsin has been 
suggested (Johnston et al. 2007). Hypersecretion of mucus has been reported in 
some airway diseases for example COPO, CF and asthma (diseases also linked 
with gastro-oesophageal reflux) and has been observed in lung transplant 
patients, along with poor airway clearance and altered cough (Veale et al. 1993). 
Therefore, in addition to analysing media collected from epithelial cells, media 
from goblet cells challenged with pepsin was also collected and assayed for 
mucin (MUC5AC). 
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Pro-inflammatory cytokines have also been shown to stimulate mucus production 
from goblet cells. Studies by Smirnova et al have shown that IL-8 and TNF-a 
both stimulate MUC5AC mucin production from these cells in vitro (Smirnova et 
al. 2000; Smirnova et al. 2002). Pro-inflammatory cytokines, especially IL-8, have 
been consistently implicated in the pathophysiology of BaS. The possible 
stimulation of epithelial cells by pepsin emphasises the potential for complex 
interactions between epithelial and goblet cells. 
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6.2 Stimulation of epithelial cells with porcine pepsin 
Primary bronchial epithelial cells from transplant patients were grown in 24 well 
plates until confluent. Cells were seeded at approximately 50000 per well. The 
cells were then incubated with either 10ng/ml, 50ng/ml or 50l-lg/ml pepsin in 
basal media (serum-free, BEBM at pH 7.4, Lonza, Switzerland) or basal media 
adjusted to pH 7.0 with 1 M He!. Media was collected at 24, 48 and 72h and 
assayed for interleukin-8 (IL-8) with a commercially available kit (R&D systems, 
USA). Data was plotted for each pepsin concentration at either pH 7.4 or 7.0 at 
24, 48 and 72h. 
6.2. 1 Cells challenged with 10ng/ml porcine pepsin 
As the production of IL-8 from the primary cells varied between patients data was 
analysed with the Wilcoxon matched pairs test (non-parametric) using GraphPad 
prism software. IL-8 production was not significantly altered when challenged 
with 10ng/ml pepsin at either pH 7.4 or pH 7.0 over 24,48 or 72h (figures 6.1.1, 
6.1.2 and 6.1.3). Data was also grouped to allow comparisons between pH 7.4 
and pH 7.0 (figure 6.1.4). IL-8 production increased over each 24h time period 
(Le. from 24h to 48h and again from 48h to 72h) for each challenge condition, 
however the increase was not significant (P>0.05). There was also no significant 
difference in IL-8 production between the challenge conditions when analysed 
using a non-parametric one-way analysis of variance with a post-hoc Mann 
Whitney test (median values in pg/ml for 72h; pH 7.4 947, pH 7.4 & pepsin 1191, 
pH 7.0822 and pH 7.0 & pepsin 1545). 
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Figure 6.1.4 Interleukin 8 production from primary bronchial epithelial cells 
challenged with 10ng/ml pepsin at either pH 7.4 or pH 7.0. Bars represent mean 
with SEM and shows the average of 3 experiments. 
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6.2. 1. 1 Cell viability 
The viability of the cells was analysed at 72h using the Cell TiterBlue assay 
(Promega, USA). Negative controls were performed by fixing the cells in 
methanol prior to adding the TiterBlue reagent. Viability remained fairly constant 
over the challenge conditions. Pepsin caused a decrease in viability at pH 7.0 to 
72%, however this was not significant (figure 6.1.5). 
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6.2.2 Cells challenged with 50ng/ml porcine pepsin 
Again, data was analysed with the Wilcoxon matched pairs test (non-parametric) 
using GraphPad prism software. IL-8 production was not significantly different 
when challenged with 50ng/ml pepsin at either pH 7.4 or pH 7.0 over 24, 48 or 
72h (figures 6.2.1, 6.2.2 and 6.2.3). Data was also grouped to allow comparisons 
between pH 7.4 and pH 7.0 (figure 6.2.4). As with the 10ng/ml pepsin challenge 
IL-8 production increased over each 24h time period (Le. from 24h to 48h and 
again from 48h to 72h) for each condition; however the increase was not 
significant (P>0.05). There was still no significant difference in IL-8 production 
when comparing the different challenge conditions when analysed using a non-
parametric one-way analysis of variance with a post-hoc Mann Whitney test 
(median values in pg/ml for 72h; pH 7.4 1608, pH 7.4 & pepsin 2911, pH 7.0 
2348 and pH 7.0 & pepsin 2411). 
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with SEM and show the average of 4 experiments. 
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6.2.2. 1 Cell viability 
The viability of the cells was analysed at 72h using the Cell TiterBlue assay 
(Promega, USA). Negative controls were performed by fixing the cells in 
methanol prior to adding the TiterBlue reagent. The addition of 50ng/ml pepsin 
and the decrease in pH caused an increase in cell viability; however none of the 
changes were significant (figure 6.2.5). 
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Figure 6.2.5 Primary bronchial epithelial cell viability after 72h exposure to 
50ng/ml pepsin at either pH 7.4 or pH 7.0. Data is displayed as a percentage of 
the positive control (pH 7.4). Bars represent mean with SEM and show the 
average of 4 experiments. Negative controls were performed by fixing cells in 
methanol prior to adding the TiterBlue solution. 
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6.2.3 Cells challenged with 50Ug/ml porcine pepsin 
Again data was analysed with the Wilcoxon matched pairs test using GraphPad 
prism software. IL-8 production was still not significantly different when the 
pepsin concentration was increased 1000 fold to 50~g/ml pepsin at either pH 7.4 
or pH 7.0 over 24, 48 or 72h (figures 6.3.1, 6.3.2 and 6.3.3). Data was also 
grouped to allow comparisons between pH 7.4 and pH 7.0 (figure 6.3.4) and at 
pH 7.4, pH 7.4 & pepsin and pH 7.0 & pepsin there was an increase in IL-8 
production over time, which was not significant (P>0.05). At pH 7.0 there was an 
increase from 24 to 48h, however from 48 to 72h IL-8 production remains fairly 
constant. Again, there was no significant difference in IL-8 production between 
the challenge conditions when analysed using a non-parametric one-way 
analysis of variance with a post-hoc Mann Whitney test (median values in pg/ml 
for 72h; pH 7.4 1350, pH 7.4 & pepsin 1153, pH 7.0 1174 and pH 7.0 & pepsin 
1575). 
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Figure 6.3.1 Mean interleukin 8 production from primary human bronchial 
epithelial cells challenged with 50IJg/ml pepsin. Cells were seeded at 
approximately 50000 per well. The 4 lines represent 4 different patients and 
experiments were performed in duplicate. Media was collected at 24h. 
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Figure 6.3.2 Mean interleukin 8 production from primary human bronchial 
epithelial cells challenged with 50~g/ml pepsin. Cells were seeded at 
approximately 50000 per well. The 4 lines represent 4 different patients and 
experiments were performed in duplicate. Media was collected at 48h. 
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Figure 6.3.3 Mean interleukin 8 production from primary human bronchial 
epithelial cells challenged with 50~g/ml pepsin. Cells were seeded at 
approximately 50000 per well. The 4 lines represent 4 different patients and 
experiments were performed in duplicate. Media was collected at 72h. 
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Figure 6.3.4 Interleukin 8 production from primary bronchial epithelial cells 
challenged with 50jJg/mi pepsin at either pH 7.4 or pH 7.0 . Bars represent mean 
with SEM and show the average of 4 experiments. 
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6.2.3. 1 Cell viability 
The viability of the cells was analysed at 72h using the Cell TiterBlue assay 
(Promega, USA). Negative controls were performed by fixing the cells in 
methanol prior to adding the TiterBlue reagent. Neither the addition of pepsin or 
reducing the pH had any significant effect on cell viability (figure 6.3.5). 
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Figure 6.3.5 Primary bronchial epithelial cell viability after 72h exposure to 
50IJg/ml pepsin at either pH 7.4 or pH 7.0. Data is displayed as a percentage of 
the positive control (pH 7.4). Bars represent mean with SEM and show the 
average of 4 experiments. Negative controls were performed by fixing cells in 
methanol prior to adding the TiterBlue solution. 
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6.3 Viability of epithelial cells challenged with gastric juice 
In a preliminary experiment the epithelial cells were also challenged with basal 
human gastric juice collected from patients undergoing endoscopy. The patients 
were taking proton pump inhibitors and as a result the pH of the gastric juice was 
abnormally high (pH 5). 
The epithelial cells were challenged with neat or diluted gastric juice (1/4, 1/20, 
1/100, 1/1000, 1/5000 or 1/10000 diluted in serum free basal epithelial media, 
Lonza, Switzerland). The viability was calculated as a percentage of the control 
(cells grown in serum free basal media) after 24h and was significantly reduced 
in all test conditions when analysed using a one-way analysis of variance with a 
post-hoC Mann Whitney test (P< 0.001 for all dilutions, figure 6.4). 
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Figure 6.4 Viability of epithelial cells challenged with a range of dilutions of 
human gastric juice (diluted in serum free basal epithelial media, Lonza, 
Switzerland). Viability is displayed as a percentage of the normal control and was 
measured after 24h. Bars represent mean & SEM. Negative controls were 
performed by fixing the cells in methanol prior to adding the TiterBlue reagent. 
Viability is significantly reduced with all dilutions of gastric juice (P< 0.001 for all 
conditions). This data represents a single experiment. 
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6.4 Stimulation of goblet cells with porcine pepsin 
Mucus secreting goblet cells (cell line HT29-MTX) were grown until confluent in 
24 well plates. The cells were then incubated with 10ng/ml, 50ng/ml or 50lJg/ml 
pepsin in serum free Dulbecco's modified eagles medium (DMEM) or serum free 
DMEM adjusted to pH 7.0 with 1 M Hel. Media was collected at 24, 48 and 72h 
and assayed for MUC5AC mucin with a slot/blot ELISA. 
6.4. 1 Cells challenged with 10ng/ml pepsin 
Data was analysed using a one-way analysis of variance with a post-hoc Mann 
Whitney test. Mucin production increased over each 12h period and was 
significantly increased from 24 to 72h within each condition (P<0.05). At pH 7.4 
there was a significant increase in mucin production between 48 and 72h (P= 
0.026). In addition at pH 7.0 and 7.0 & pepsin mucus production was also 
increased over 24h to 48h (P= 0.004 and 0.009 respectively). Mucus production 
was not Significantly altered between the challenge conditions (figure 6.5). 
Viability was also measured using the TiterBlue assay (Promega, USA) and was 
not significantly altered by lowering the pH or with the addition of 10ng/ml pepsin 
(figure 6.6). 
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Figure 6.5 MUC5AC mucin production from goblet cell line HT29-MTX 
challenged with 10ng/ml pepsin. Bars represent mean with SEM and show the 
average of 2 experiments. 
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Figure 6.6 Goblet cell viability after 72h challenge with 10ng/ml pepsin at pH 7.4 
and pH 7.0. Data is displayed as a percentage of the pH 7.4 control. Bars 
represent mean with SEM and show the average of 2 experiments .. 
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6.4.2 Cells challenged with 50ng/ml pepsin 
Data was analysed using a one-way analysis of variance with a post-hoc Mann 
Whitney test. At pH 7.4 and pH 7.4 & pepsin there was an increase in mucin 
production over each 24h period. This increase was significant from 24 to 72h at 
pH 7.4 (P=0.004) and from 24 to 48h, 48 to 72h and between 24 and 72h at pH 
7.4 & pepsin (P= 0.015, 0.002 and 0.002 respectively). At pH 7.0 and pH 7.0 & 
pepsin there was an increase in mucin production from 24 to 72h, however this 
was not significant. In addition there was also an unexpected decrease from 24 
to 48h for both pH 7.0 and 7.0 & pepsin (P=0.009 for both conditions). 
Mucin production was also significantly increased at 72h when challenged with 
50ng/ml pepsin at pH 7.4 (medians: pH 7.4 61.4j.Jg/ml and pH 7.4 & pepsin 
92.2j.Jg/ml, P= 0.002 figure 6.7). Mucin production did not increase on exposure 
to pepsin at pH 7.0. 
Viability was also measured using the TiterBlue assay (Promega, USA) and was 
not significantly altered by lowering the pH or with the addition of pepsin (figure 
6.8), showing that the increase in mucin production is not due to increased cell 
numbers. 
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Figure 6.7 MUC5AC mucin production from goblet cell line HT29-MTX 
challenged with 50ng/ml pepsin. Bars represent mean with SEM and show the 
average of 2 experiments. 
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Figure 6.8 Goblet cell viability after 72h challenge with 50ng/ml pepsin at pH 7.4 
and pH 7.0. Data is displayed as a percentage of the pH 7.4 control. Bars 
represent mean with SEM and show the average of 2 experiments. 
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6.4.3 Cells challenged with 50uqlml pepsin 
Data was analysed using a one-way analysis of variance with a post-hoc Mann 
Whitney test. At pH 7.4 & pepsin, pH 7.0 and pH 7.0 & pepsin mucin production 
increased over each 24h time period. At pH 7.4 mucin production remained 
constant between 24 and 48h, however there was a significant increase between 
48 and 72h and 24 and 72h (P=0.0043 and 0.0260 respectively). At pH 7.4 & 
pepsin there was a significant increase between 24 and 48h, 48 and 72h and 24 
and 72h (P=0.0173, 0.0159 and 0.0095 respectively). Again at pH 7.0 there was 
a significant increase between 24 and 48h, 48 and 72h and 24 and 72h 
(P=0.0043 for all time points). Finally, at pH 7.0 & pepsin there was a Significant 
increase in mucin production from 48 to 72h and from 24 to 72h (P=0.0159 and 
0.0043 respectively) (figure 6.9). 
Mucin production was significantly increased at 72h on addition of pepsin at pH 
7.4 (median values pH 7.4; 163.4lJg/ml and pH 7.4 & pepsin; 448.9IJg/ml, 
P=0.038) and at pH 7.0 (median values pH 7.0; 55.31Jg/ml and pH 7.0 & pepsin; 
327.2j.Jg/ml, P=0.016, figure 6.9). 
Again, viability was measured using the TiterSlue assay (Promega, USA) and 
was reduced to 70% on the addition of pepsin at pH 7.4 however this was not 
significant (figure 6.10), showing that the increase in mucin production is not due 
to increased cell numbers. 
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Figure 6.9 MUC5AC mucin production from goblet cell line HT29-MTX 
challenged with 501Jg/ml pepsin . Bars represent mean with SEM and show the 
average of 2 experiments. 
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Figure 6.10 Goblet cell viability after 72h challenge with 50lJg/ml pepsin at pH 
7.4 and pH 7.0. Data is displayed as a percentage of the pH 7.4 control. Bars 
represent mean with SEM and show the average of 2 experiments . 
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6.5 Activity profile of pepsin over pH 5.0-7.0 
The activity of pepsin (2ug) over a pH range of 5.5 to 7.0 was investigated using 
succinyl albumin as a substrate. Activity was compared to the optimum pH, which 
for pepsin working on succinyl albumin is pH 2.2. Pepsin had some residual 
activity up to pH 6.0 (14.5% of optimum) however after pH 6.5 the activity 
decreases to below 1 % (figure 6.11 ). 
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Figure 6.11 Activity profile for pepsin (2I-1g) over a pH range of 5.5 to 7.0. Values 
are displayed as a percentage of optimum (pH 2.2) and bars represent mean with 
SEM and are representative of 3 experiments. 
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6.6 Discussion 
Mucus is an important part of the innate immune system and helps to protect the 
lungs against pathogens and/or toxins. However, mucus hypersecretion can be a 
problem in certain lung diseases, particularly asthma, COPD and CF (Voynow 
2002; Callaghan-Rose and Voynow 2006). Aspiration of gastric contents into the 
lungs has also been associated with these pathologies; therefore the current 
study aimed to investigate the effect of pepsin, an important component of the 
gastric refluxate, on the production of mucus from goblet cells. In addition, 
interleukin 8 (IL-8) has been implicated in the chronic rejection of lung transplants 
and has also been shown to stimulate mucus production from goblet cells, 
therefore the potential for pepsin to stimulate IL-8 release from primary human 
lung epithelial cells has also been investigated. 
The addition of pepsin or the reduction in pH did not significantly reduce the 
viability of the goblet cells over 72h; however, mucus production was significantly 
increased when the cells were exposed to 50ng/ml and 50IJg/mi pepsin at pH 7.4 
and with 50IJg/ml pepsin at pH 7.0. Previous work has shown that pepsin has 
little or no activity above pH 6.5 (Piper and Fenton 1965). This has been 
confirmed by the current investigation (figure 6.11) and suggests that any pepsin 
remaining adhered to the airway tissue could stimulate mucus hypersecretion 
even after it has been neutralised. 
There was also an unexpected decrease in mucin production at 48h when the 
cells were exposed to 50ng/ml pepsin at pH 7.0 and with pH 7.0 alone (figure 
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6.7). This may be explained by low mucin production in one of the experiments, 
reducing the average value. This suggests that the result is an anomalous one 
and that the experiments should be repeated. 
The regulation of MUC genes has been previously investigated in vitro and a 
number of cytokines have been shown to up-regulate MUC5AC expression, for 
example, TNF-a, IL-6 and IL-17 (Chen et al. 2003; Callaghan-Rose and Voynow 
2006). Smirnova et al have also shown that IL-8 can stimulate MUC5AC 
secretion from goblet cells (Smirnova et al. 2002). In addition, the group has 
shown that bacterial LPS up-regulates both IL-8 and MUC5AC mRNA expression 
and secretion from goblet cells, suggesting that the up-regulative effect of LPS is 
partially mediated through an IL-8 dependant mechanism (Smirnova et al. 2003). 
Other factors known to stimulate MUC5AC expression in vitro include 
prostaglandins, matrix matallo-proteinases (MMPs), neutrophil elastase, reactive 
oxygen species and also exogenous toxins, such as tobacco smoke and 
environmental pollutants (Voynow et al. 2006). 
Such factors are thought to stimulate the up-regulation of mucins by binding to 
specific surface cell receptors, for example, P2Y2 and toll like receptors (Voynow 
et al. 2006). Additionally, the epidermal growth factor (EGF) receptor has been 
implicated in mucin gene regulation through a variety of stimuli (Takeyama et al. 
1999). Binding of these receptors is then thought to activate mitogen-activated 
protein kinase (MAPK) pathways, which in tum activate the transcription factor, 
nuclear factor kappa B (NFKB), which will regulate mucin gene expression 
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(Callaghan-Rose and Voynow 2006). Other transcription factors can also mediate 
mucin gene expression, for example SP1 and AP-1 (Perrais et al. 2002; Gensch 
et al. 2004). 
To further understand the link between the presence of pepsin and the increase 
in mucus production the effect of pepsin on interleukin 8 release from epithelial 
cells was also investigated. IL-8 has been shown to playa key role in the 
recruitment of inflammatory cells in obliterative bronchiolitis (OB), the histological 
manifestation of chronic rejection in lung transplantation. IL-8 is a neutrophilic 
chemokine, and neutrophils are repeatedly elevated in transplant patients with 
BOS. Neutrophils may not only damage/kill invading micro-organisms, but also 
the tissue in their region of activity due to the reactive oxygen species they 
produce. IL-8 can be produced by the epithelium itself in response to any 
pathogens or toxins present in the lung, therefore the potential for any aspirated 
pepsin to stimulate IL-8 production by the epithelial cells was investigated. 
Pepsin did not significantly alter IL-8 production at either pH 7.4 or pH 7.0. Levels 
of IL-8 measured in this study compare to levels previously measured from other 
groups, including primary bronchial epithelial cell cultures (Weihler et al 
measured levels of approximately 500pg/ml over 24h under control conditions) 
and also an epithelial cell line (BEAS-2B, Gulliot et al also measured levels of 
approximately 500pg/ml) (Wiehler and Proud 2007; Guillot et al. 2008). 
Additionally the viability of the cells was not altered with the addition of pepsin or 
when the pH was lowered. 
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Studies by Smirnova et al have shown that LPS can stimulate IL-8 and mucus 
production from goblet cells in vitro, and potentially that the mucus production is 
mediated through an IL-8 dependant mechanism (Smimova et al. 2003). The 
potential for pepsin to stimulate IL-8 secretion from the goblet cells themselves 
was also investigated, however IL-8 production was negligible (data not shown). 
Whilst the epithelial or goblet cells did not produce IL-8 in response to pepsin it is 
possible that in vivo other sources could, for example macrophages. 
It is also possible that other cytokines could contribute to the increase in mucin 
production. In a study by Chen et al differentiated human primary 
tracheobronchial epithelial cells in an air liquid interface were treated with a 
variety of cytokines (interleukins-1a&~, 2-13, 15-18 and TNF-a). The group 
showed that a significant increase in MUC5AC and 58 expression was seen with 
the addition of IL-6 and IL-17. As IL-17 is known to stimulate IL-6 production from 
bronchial epithelial cells the group also investigated whether the stimulatory 
effect of IL-17 on mucin expression was mediated through an IL-6 
paracrine/autocrine loop. Using a neutralising IL-6 antibody they showed that IL-
17 mediated MUC58 expression was significantly decreased (Chen et al. 2003). 
IL-6 can also be produced by airway epithelial cells so it is possible that an 
increase in IL-6 production from these epithelial cells (in response to pepsin or IL-
17 from T cells) could cause an additional increase in mucu s production from 
goblet cells causing further airflow obstruction in already injured airways. 
The results from the current investigation provide evidence that the increase in 
mucin production from goblet cells in response to pepsin is not mediated entirely 
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through IL-8. One other potential explanation is the presence of a pepsin receptor 
on the goblet cells. A recent study by Johnston et al has indicated that pepsin 
can be taken up by laryngeal cells through receptor mediated endocytosis 
(Johnston et al. 2007). This could also be the case in goblet cells, and once 
pepsin has bound to a receptor it could stimulate mucus production via a MAPK 
pathway as previously described, or it could be taken up by the cell and stimulate 
mucus production through an alternative pathway. 
It is of interest that mucus production is increased only with 501Jg/ml pepsin at pH 
7.0 when at pH 7.4 both 50IJgmi and 50ng/ml pepsin can stimulate mucus 
production. This could be explained by the reduction in pH causing certain cell 
processes to slow down. This might also explain why the result is only seen after 
72h of simulation. The decrease in pH may be causing an increase in time taken 
for the cells to respond to pepsin i.e. introducing a 'time lag'. 
Another previous study by Johnston et al has shown that although pepsin has 
little or no activity above pH 6.5, it remains stable for at least 24h at pH 7.0 and 
3rC and can retain approximately 79% of its original activity upon reactivation 
(Johnston et al. 2007). This is clinically important as any pepsin remaining in the 
goblet cells after it has been taken-up could be reactivated by a decrease in pH 
that would occur after a subsequent reflux event. This could also be true of the 
lung epithelial cells, meaning that any refluxed pepsin could lay dormant until 
reactivation or it may also be possible that once taken up by the cells inactive 
pepsin could be transported to an intracellular compartment of lower pH and 
once activated could cause further damage. 
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Whether or not this is the case can not be determined from this study, therefore 
further investigation into the mechanisms behind this increase in mucus 
production on exposure to pepsin is required. 
Viability was not significantly reduced with the addition of pepsin at either pH 7.4 
or pH 7.0; however it was significantly reduced with the addition of whole gastric 
juice. This suggests that there are other components of the refluxate with the 
potential to cause epithelial damage, possibly bile salts as duodenal-gastro-
oesophageal reflux has also been implicated in chronic lung rejection. It is likely 
that the gastric juice used to stimulate the cells in this study did contain bile, as 
the pH was abnormally high (approximately pH 5) and appeared green in colour. 
There are certain limitations to this study. The cells were grown in separate 
cultures, meaning that any observations were only associative, for example, if 
pepsin had stimulated the epithelial cells to produce IL-8 it could only be 
assumed that this would then stimulate the goblet cells to produce mucin. IL-8 
was not increased on exposure to pepsin, however other cytokines may have 
been, for example IL-6, and therefore future experiments could include incubating 
the goblet cells with media taken from epithelial cells challenged with pepsin. 
Another approach would be to set up an air-liquid interface of the primary 
epithelial cells. This would allow the cells to differentiate into ciliated epithelial 
cells and goblet cells within the same culture, therefore mucins and cytokines 
could be measured in the same experiment. This technique was not available in 
our laboratory when this study began; however now it is available the 
experiments could be repeated to strengthen the results. 
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To summarise, mucus production was significantly increased when the cells were 
exposed to 50ng/ml and 50\Jg/ml pepsin at pH 7.4 and with 50\Jg/ml pepsin at pH 
7.0. This increase is unlikely to be IL-8 dependant, as pepsin did not alter IL-8 
production from the goblet or epithelial cells. The addition of pepsin at either pH 
7.4 or pH 7.0 did not reduce the viability of the epithelial cells, however the 
addition of whole gastric juice, whether neat or diluted did significantly reduce the 
viability of epithelial cells in vitro. This suggests there are other components 
present in the gastric juice with the potential to cause further damage to the lung 
epithelium. 
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Chapter 7 
General Discussion 
Lung transplantation has become a viable therapeutic option for patients with 
end-stage lung disease, however, despite improvements in surgical techniques 
and post-operative management, long term survival is poor when compared to 
those of other solid organ transplants. The long term success is limited by the 
onset of obliterative bronchiolitis (OB) and its clinical correlate bronchiolitis 
obliterans syndrome (BOS). Obliterative bronchiolitis is thought to occur as a 
response to both immunological and non-immunological mechanisms, and there 
is increasing evidence to suggest that gastro-oesophageal reflux with subsequent 
aspiration is a contributing factor (D'Ovidio and Keshavjee 2006; Li et a/. 2008). 
There were three overall aims of this study. The first was to investigate whether 
aspiration was occurring in lung transplant recipients by measuring levels of 
pepsin, as a biomarker of gastric aspiration, in the bronchoalveolar lavage (BAL) 
of transplant patients. The second was to measure BAL pepsin in a longitudinal 
cohort to investigate the variation in levels over time and also if high levels of 
pepsin in the BAL at a particular, early time pOint can predict for or predispose a 
patient to chronic rejection (OB/BOS). The final aim was to investigate the 
possible links between any pepsin present in the lung and damage caused to the 
epithelium using goblet cells and primary bronchial epithelial cell cultures taken 
from lung transplant patients. 
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When this project began gastro-oesophageal reflux (GOR) had been implicated 
in the development of 80S (Palmer et al. 2000; Davis et al. 2003; Cantu et al. 
2004), however, there were few, if any studies investigating the underlying 
mechanisms. In 2005 Ward et al showed for the first time that pepsin can be 
found in the SAL of lung transplant patients, at levels higher than could be 
accounted for by serum pepsinogen, providing evidence that gastric contents 
could in fact reach the lungs. This has now been confirmed in a larger group of 
patients with more control data. In the cross-sectional study outlined in this thesis 
pepsin levels were higher in all lung transplant patients compared to normal and 
disease controls suggesting that gastric aspiration is an ongoing source of injury 
in this patient population. In addition, pepsin levels were highest in recipients with 
histologically verified A2 or greater acute rejection. Furthermore, these patients 
had the highest grades of airway inflammation, suggesting a possible link 
between aspiration, acute rejection and inflammation (Stovold et al. 2007). 
Another point of interest is that this study has shown that patients who are being 
treated with maintenance proton pump inhibitors (PPI) still show evidence of the 
aspiration of gastric contents into the lung. On initial consideration this may seem 
unexpected, however, approximately 12-20% of gastro-oesophageal reflux 
disease (GORD) patients are resistant to acid suppression therapy (Ahlawat et 
al. 2005). In addition, PPls act to reduce acidic reflux, but will not prevent mildly 
acidic, neutral or alkaline reflux, which may still contain pepsin. Gastric aspiration 
is not the target of PPI therapy, therefore patients may continue to aspirate whilst 
taking this medication. 
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The second aim of the study was to further investigate the role of gastric 
aspiration in lung transplant rejection using longitudinal BAL samples collected at 
1 week, 1, 3, 6 and 12 months post-transplant. Initially, the data was split into 
cross-sectional time points to investigate whether high pepsin levels are 
associated with different grades of rejection at different times. Again, there was 
some evidence that transplant patients with histologically verified A2 or greater 
acute rejection had higher levels of pepsin compared to stable controls, 
confirming earlier work. In this study there were also significantly higher levels of 
BAL pepsin in patients with minimal acute rejection (graded A 1), which was not 
the case in the previous cross-sectional study. This may be due to the smaller 
numbers in the A 1 group used in the earlier investigation where there were only 6 
patients with A 1 acute rejection. 
For the longitudinal assessment of BAL pepsin the chosen format of analysis was 
to decide on a time point and investigate whether high levels of pepsin at this 
time point can predict for the development of BOS. There is evidence of gastric 
aspiration being problematic early post-transplant (Cantu et al. 2004) and so 
three months was prospectively chosen. Three months is still relatively early 
post-transplant, however, patients will be more clinically stabilised than they 
would be at one week or one month. 
As there is no general consensus of what are high levels of pepsin in 
bronchoalveolar lavage a number of 'cut-offs' were used based on levels 
measured in stable transplant controls. Concentrating on the 75th perCentile 
(10.4ng/ml) as a cut off, patients with high levels of SAL pepsin at 3 months (i.e. 
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> 10 .4ng/ml) are estimated to develop BOS at 3 times the rate of those with low 
SAL pepsin ($10.4ng/ml). In addition, using Kaplan-Meier estimates of survival 
patients with BAL pepsin above 1 O.4ng/ml at 3 months are 50% free from BOS at 
4 years post-transplant compared to 80% in patients with BAL pepsin 
:510.4ng/ml. 
Alloimmune mechanisms have been the traditional focus of research and 
therapeutic intervention for lung transplant rejection, however the investigations 
outlined here add to the growing evidence that supports the role of non-
alloimmune mechanisms as risk factors for the development of chronic lung 
rejection. 
Throughout these investigations there is suggestion of a link between acute 
rejection and high levels of SAL pepsin. This has also been shown in a rat model 
of lung transplantation from the Duke group. Allografts challenged with aspiration 
demonstrated severe grade 4 acute rejection with significant monocyte 
infiltration, fibrosis, and lung destruction (Hartwig et al. 2006). Aspiration was also 
associated with increases in CD8+ T cells and this study indicates that gastric 
aspiration may lead to pathological changes previously attributed to T cell, 
alloimmune based mechanisms (Takehisa et al. 2002; Boehler and Estenne 
2003). Acute rejection is consistently linked with the development of BOS 
(Sharples et al. 2002; Scott et al. 2005) so it is possible that gastric aspiration is 
promoting injury (acute rejection) which in tum is accelerating the development of 
BOS. 
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In these investigations there was a trend towards patients with early elevated 
levels of BAL pepsin developing BOS at a greater rate than those with lower 
levels, however this was not significant at 95% confidence levels. Further 
investigations with an increased sample size are required to achieve 
conventional levels of adequate power. 
As a result of this research and other studies, lung transplant patients at the 
Freeman hospital (Newcastle, UK) now have the option to be monitored for reflux 
post-operatively, and if appropriate fundoplicative surgery will be considered. 
During the project it was necessary to develop an ELISA for the measurement of 
pepsin. Although the development process took a Significant amount of time the 
assay has now been shown to be sensitive and reliable, which is important as 
since this work began a number of other centres have started using biomarker 
approaches to monitor aspiration. Many of these centres are using bile salts as a 
marker rather than pepsin, and this may be due to the commercial availability of 
bile acid kits and the time required to develop an assay to measure pepsin. Some 
preliminary work from our group has shown that bile may not be detectable in 
BAL using mass spectrometry, suggesting the kits are not sensitive enough to 
accurately measure levels of bile you may expect to find in BAL. This implies that 
pepsin may be a more suitable biomarker of gastric aspiration and as a result of 
this research our group is one of the few that can accurately measure pepsin in 
BAL from lung transplant patients. 
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The final aim of the project was to investigate the possible links between any 
pepsin present in the lung and damage caused to the epithelium which may lead 
to the development of OB. Early OB is characterised by an influx of inflammatory 
cells into the lung (Boehler et al. 1998) and chemokines such as interleukin 8 (IL-
8) have been shown to be important in the recruitment of such inflammatory cells, 
especially neutrophils which are repeatedly elevated in the lavage of transplant 
patients with BOS (DiGiovine et al. 1996; Elssner and Vogelmeier 2001). This 
suggests that IL-8 along with other such chemokines playa crucial role in the 
pathogenesis of OB. 
IL-8 is an important part of the innate immune system and can be produced by 
the epithelium itself in response to many pathogens or stimuli potentially present 
in the lung. The potential for pepsin to stimulate IL-8 production from epithelial 
cells was therefore investigated. 
Mucus production is also an important part of the innate immune response 
against any pathogens present in the respiratory tract. The cells responsible for 
mucus production in the airways are goblet cells and the secretory cells of the 
submucosal glands and one of their main products is the mucin expressed from 
the MUC5AC gene. 
It is also possible that airway goblet cells could secrete mucus in response to 
pepsin aspirated into the lung, therefore, in addition to looking at the effects of 
pepsin on IL-8 production from epithelial cells, mucus production from goblet 
cells was also investigated. 
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Mucus production was significantly increased when goblet cells were exposed to 
50ng/ml and 50l-lg/ml pepsin at pH 7.4 and with 50l-lg/ml pepsin at pH 7.0. This 
increase is unlikely to be IL-8 dependant, as pepsin did not alter IL-8 production 
from the goblet or epithelial cells. The effect of incubating the epithelial cells with 
whole gastric juice was also investigated and was found to significantly reduce 
cell viability, even when diluted 1/10000, an effect not seen with pepsin alone up 
to a concentration of 50l-lg/ml. This suggests there are other components present 
in the gastric juice with the potential to cause further damage to the lung 
epithelium, for example bile salts or some chemical constituents of food. 
This work has shown that pepsin, a biomarker of gastric aspiration is detectable 
in BAL from lung transplant recipients, and that it is associated with injury (acute 
rejection, a known risk factor for BOS). In addition, it has shown a trend for early 
elevated BAL pepsin to be associated with an increased risk of developing BOS. 
Therefore, this thesis supports the hypothesis that gastric aspiration may be an 
important injury in lung transplantation and that pepsin is a potentially useful 
biomarker that may be associated with chronic allograft damage. Further 
investigations involving a larger patient cohort are required to confirm these 
findings. 
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Future Areas for Research 
Future directions of the project could include setting up an air-liquid interface of 
the primary bronchial epithelial cells, as this would allow the cells to differentiate 
into ciliated epithelial cells and goblet cells within the same culture. The pepsin 
and gastric juice challenges could then be repeated and a number of cytokines 
and mucins could be measured within the same experiment. This could involve 
measuring MUC5B, as well as MUC5AC, seeing as there is some evidence to 
show that goblet cells can produce MUC5B in disease states (Chen et al. 2001). 
It could also involve measuring cytokines, including IL-6 and IL-17 (known to 
stimulate mucin production) as well as TNF-a and GM-CSF (known neutrophilic 
chemokines). 
There is some evidence that pepsin is taken up by laryngeal epithelial cells 
through receptor-mediated endocytosis (Johnston et al. 2007) and this may also 
be occurring in the lung. It may therefore be of interest to stain biopsies and 
epithelial cells taken from lung transplant recipients for pepsin, in an attempt to 
further understand what happens to the pepsin once it has been aspirated into 
the lungs. 
Additionally, neutrophil levels have already been investigated in this patient 
cohort by another member of the group as they are consistently implicated in the 
pathogenesis of OB/BOS (DiGiovine et al. 1996; Elssner and Vogelmeier 2001). 
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It is possible that the lung epithelial cells are releasing neutrophilic chemokines in 
response to stress or damage caused by refluxed pepsin and/or acid. If this was 
the case there may be a correlation between neutrophil and pepsin levels in the 
SAL and as both have been measured in the same patients statistical analysis 
could be performed. This would help to identify if neutrophils are implicated and 
whether or not they should be further investigated as a potential mechanism of 
damage caused by the aspiration of gastric contents into the lungs. 
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Appendix 
The following appendix contains graphs detailing individual patient's pepsin and 
acute rejection scores from chapter 5. 
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